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Abstract  
Background  
Currently, there are a number of disease modifying therapies (DMTs) 
available that can help to reduce the number of attacks experienced in 
relapsing remitting multiple sclerosis (RRMS). However, optimal outcomes are 
not always achieved due to early treatment discontinuation and low levels of 
overall adherence. Other research has found a disconnect between studies 
exploring drivers of adherence behaviour and the body of research that seeks 
to modify this behaviour, whereby the former is doing little to inform or learn 
from the latter. This study sought to understand the drivers of nonadherence 
in people with RRMS from a patient perspective, their potential to be modified 
through behaviour change intervention and the level of congruence between 
these two areas of research.  
Methods  
A two-part scoping review was carried out to determine the drivers of 
adherence in people with MS and to explore how these drivers are currently 
being addressed through adherence interventions. The COM-B model for 
adherence and Behaviour Change Wheel were used to operationalize these 
findings.  Following this review, it was evident that there was a lack of 
qualitative research exploring drivers of adherence from the perspective of the 
patient themselves and exploring the ‘mechanisms of action’ between drivers 
and behaviour. Therefore, a multi-country, qualitative study was conducted. 
Semi-structured interviews, based on constructs from the self-regulatory 
model (SRM) and the COM-B model for adherence were conducted with 24 
(n=12 females) people with RRMS from Germany, Spain and the United 
Kingdom. Framework analysis was used to interpret the data.    
	 3	  
Findings   
The review identified over sixty discrete factors, across thirty-three studies, 
which had been found to potentially influence adherence behaviours in MS. 
Discrepancy between these findings and the COM-B Model for adherence led 
to creation of a COM-B model specifically for adherence to DMTs in people 
with MS, which contained eighteen factors, across five of the six categories. 
The review also identified four successful behaviour change interventions that 
targeted five of these factors, utilising a total of sixteen behaviour change 
techniques (BCTs). The qualitative research determined that control and 
conflict were the overarching themes related to adherence, whereby an 
increased sense of control over MS and limited conflicts with self-
management behaviours and ‘day to day’ life could enhance likelihood and 
ability to adhere to treatment and other self-management tasks, thereby 
leading to potentially better outcomes. These findings also led to revision of 
the MS specific COM-B model from the first review.       
Conclusion   
This research has demonstrated that, at this time, there appears to be little 
congruence between the bodies of research exploring drivers of adherence 
behaviour in people with RRMS and that which is successfully modifying this 
behaviour through intervention. A focus on ‘convenience’ data, in particular 
clinical and demographic factors, has done little to further our understanding 
in terms of how best to support this population and there is an apparent need 
for research exploring drivers of adherence to align more closely with 
intervention research. This is further supported by the qualitative findings that 
demonstrated the complex, multi-layered interplay and between drivers and 
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behavioural outcomes, as well as the influence of individual experiences and 
beliefs.  
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Scoping Review   
Adherence to medication in Multiple Sclerosis: a review of factors 
impacting adherence behaviours and the interventions to change these 
behaviours 
  
Introduction  
 
About Multiple Sclerosis  
Multiple sclerosis (MS) is a chronic, degenerative disease affecting the central 
nervous system, through demyelination and inflammation. The systemic and 
uncontrolled nature of the condition results in a variety of symptoms. These 
symptoms vary in their severity and frequency, both across and within 
individuals. Symptoms include blurred vision, bladder and bowel dysfunction, 
fatigue, difficulty with walking and general coordination, and cognitive 
impairment (Multiple Sclerosis Society UK, 2016).  
Who is affected?   
MS affects approximately 2.5 million people worldwide, with more women 
affected than men (2:1). Onset is typically in young adults, with a peak onset 
age of 30 years, though over the past decade or so there have been an 
increased number of diagnoses of paediatric MS, with up to 5% of people 
experiencing the first clinical attack before the age of 16. There is variance in 
geographical distribution across the world, with prevalence increasing in 
relation to distance from the equator in both directions (World Health  
Organization, 2006).       
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Types of MS  
In terms of disease categorisation, approximately 80% of patients are 
diagnosed with a relapsing-remitting form of the disease (RRMS); 
characterized by recurring episodes of neurological dysfunction (relapses), 
followed by periods of full or partial recovery. Over time, the extent of the 
recovery lessens, leading to progressive disability over the disease course. Of 
these, 50% will develop secondary-progressive MS within 10 years of onset, 
which is characterised by progression without presence of relapses. This will 
increase to 80% of people within 20 years of onset. On average, 10-15% of 
people will present with primary-progressive MS, which does not feature 
attacks but has a steady worsening of symptoms. Most people with MS can 
expect to have a near normal life expectancy (World Health Organization, 
2006).     
Etiology  
There is no definitive etiology known for MS but some of the generally 
accepted features of the disease provide insight into potential causes and 
triggers. As described above, the geographical distribution has been 
investigated to see if there are specific environmental factors involved but no 
specific cause has been identified, though it is posited that climate plays a role 
due to the latitudinal dispersion. It is yet to be determined whether this is a 
direct or indirect cause (World Health Organization, 2006). There are also 
indications of a genetic component as the risk of developing MS increases for 
the children and siblings of people already diagnosed (Bennett, 2011). This 
risk increases in monozygotic twins, further favouring a genetic element, 
though this is limited to an approximate 30% occurrence rate (World Health 
Organization, 2006). At a biological level, it is hypothesised that MS is a result 
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of immune system errors or viral infection. In particular, the presence of the 
chemical gamma-interferon is elevated in people with MS, which may work to 
increase levels of cytotoxic T cells. These cells ‘normally’ work to destroy 
other, damaged, cells. In MS, the T cells seem unable to recognise the myelin 
sheath of nerve cells of the brain and spinal column as ‘part of the self’ and 
therefore seek to destroy them. This may be derived genetically, or there 
could be a genetic disposition that is then triggered by a viral infection or 
environmental factor described above (Faith et al., 2013).   
Psychosocial Impact  
MS has been shown to negatively impact health related quality of life (HRQoL) 
(Klevan et al., 2014; Mitchell et al., 2005). HRQoL considers the impact of 
health status on quality of life, in particular going beyond the physical 
implications to also look at mental, emotional and social functioning (Bullinger, 
1991), though research suggests that the physical and psychological 
components often interact with each other, rather than being separate entities 
(Wilson and Cleary, 1995). For example, some common MS symptoms such 
as fatigue, mobility impairments and cognitive problems, can negatively 
impact many aspects of day-to-day life such as ability to socialise and 
maintain leisure activities. They can also impact the ‘role’ of the patient in 
terms of career and family (Mitchell et al., 2005). These restrictions can then 
lead to emotional problems, as increasing isolation and the frustration of daily 
limitations manifest into depression and anxiety (Feinstein et al., 2014).  
Even when symptoms are relatively well managed or a person is in a stage of 
remission, MS patients may still experience poor quality of life, thus 
demonstrating the need to consider influencing factors beyond the symptom 
experience. For example, in the early stages following diagnosis, many 
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patients experience emotional distress, including anxiety, isolation, anger and 
denial, even though their symptoms and level of disability are relatively mild. 
Research demonstrates that simply having the label of an ‘MS patient’ can 
illustrate a high personal burden (Lysandropoulos and Havrdova, 2015). 
Several studies have further identified that the emotional distress often 
experienced by MS patients across the full course of the disease can become 
so severe that there is a raised risk for long-term psychiatric comorbidities 
(Marrie et al., 2015; Moore et al., 2015).  
  
As described above, the varying degrees of functional decline and the 
unpredictable nature of relapses and remission, have a significant impact on 
the social roles of people with MS and those close to them. In particular, the 
age of onset occurring in young to middle adulthood has far reaching 
implications in terms of productivity. Estimates put levels of unemployment in 
this population as high as 70% (World Health Organization, 2006) with many 
people unable to continue with their careers following diagnosis (Hakim et al., 
2000). In addition, certain health related costs, such as home and transport 
modifications to accommodate physical disability, often add to these financial 
challenges (World Health Organization, 2006).  
  
The level of additional care needed, frequently provided ‘informally’ by family 
members, means that those close to people with MS can also experience a 
reduced quality of life (Hakim et al., 2000). This can be related to both the 
time taken to provide practical support (Buhse, 2008) and the psychological 
burden that is prevalent amongst informal caregivers in general (Adelman et 
al., 2014).   
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Societal Impact  
When combined across the MS population, the economic and social 
implications reach further than the individual and their family and start to 
represent a significant cost to society as a whole (Trisolini et al., 2010).  
The total costs of MS vary across countries for which data are available but 
are substantial in all countries. A comprehensive report published in 2014, 
showed the total average cost per person with MS in 2007 varied from a low 
of $16,400 (US) in France to a high of $54,500 (US) in Norway and Sweden.  
The overall prevalence-weighted average was $41,000 (US) (Trisolini et al., 
2010). Key drivers of this cost can be extrapolated from an analysis 
conducted for the Australian MS Society that estimated their country’s total 
financial cost per year at $450m (US), which is the equivalent of 0.07% of 
their GDP. Some of the key drivers of this cost included informal care, work 
production losses, hospitalisations and disease burden (Multiple Sclerosis 
Australia, 2005).    
 
Treatment and Management of MS  
Presently, there are no curative treatments available for MS, however there 
are a number of disease-modifying therapies (DMTs) available that can help 
to reduce the number of attacks experienced in RRMS. Some therapies are 
also posited to slow disease progression and modify the overall disease 
course (Menzin et al., 2013). However as these are more recent forms of 
DMT, the long-term impact across the lifespan is still to be determined (World 
Health Organization, 2006).  
There are a number of approved DMTs, which vary in their administration 
method and frequency. Interferon beta treatments are delivered both through 
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subcutaneous injection (e.g. Betaseron; Rebif) and intramuscular injection 
(e.g. Avonex). Frequency of administration ranges from once a week to every 
other day. Other forms of treatment, such as natalizumab (Tysabri), 
mitoxantrone (Novantrone) and alemtuzumab (Lemtrada) are delivered 
through infusion, at four-week, three month and yearly intervals respectively.  
Oral medications were introduced approximately 6 years ago, with fingolimod 
(Gilenya) being the first, followed by dimethyl fumarate (Tecfidera) and 
teriflunomide (Aubagio). Dosage is twice a day for dimethyl fumarate and 
once a day for the others (MS Society UK, 2016b; Menzin et al., 2013; World 
Health Organization, 2006). Other medications prescribed for MS are used to 
treat exacerbations or help manage symptoms, such as corticosteroids and 
analgesics. These are primarily acute in their administration, contrary to DMTs 
that are prescribed long-term (Menzin et al., 2013).   
Treatment Efficacy  
The complex nature of MS, including different pathologies, means that 
response to treatment is variable and can be difficult to predict (Rio et al., 
2005; Tomassini et al., 2006; Comi, Radaelli and Sorensen, 2017). Whilst 
there are some indicators for potential treatment success, such as relatively 
higher benefits from treatment in early phases of the disease, it is proposed 
that close monitoring and individualised treatment plans are key to promoting 
optimal outcomes across the disease course (Comi, Radaelli and Sorensen, 
2017). Treatment efficacy can be categorised into 3 overarching outcomes; 
reduction in relapse rates, reduction in disease progression and MRI 
(presence of legions) (Rio et al., 2005). Where treatment is not successful, or 
stops having a therapeutic effect, then people may be prescribed a number of 
different treatments / regimens until a response is noted. Even where 
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treatment is clinically successful, these outcomes can sometimes be difficult 
for the patient themselves to assess. For example, it can be more difficult for 
an individual to evaluate the impact of a reduction in disease progression as 
there is not an immediate effect apparent, potentially leading to uncertainty 
about the efficacy or need for treatment (Pound et al., 2005). 
Treatment Experience   
As with the majority of chronic conditions, treatment of MS requires a long-
term commitment from the patient to adhere to the treatment regimen as 
prescribed (Lugaresi et al., 2012). As described above, DMTs prescribed for 
RRMS work to reduce the number of relapses experienced or to delay the 
progression of disability, rather than providing relief for day-to-day symptoms 
(Menzin et al., 2013). Research has described the low levels of treatment 
satisfaction people with MS experience, related to factors such as the 
inconvenience of methods of delivery (in particular with injection and infusion-
based treatments), difficult dosing schedules and the presence of significant 
side effects (Klauer and Zettl, 2008; Twork et al., 2007). These factors have 
been indicated as contributing to the levels of non-adherence seen in this 
population (Glanz et al., 2014).    
Why adherence is important   
Generally, with long-term treatments for chronic conditions, it is understood 
that sub-optimal adherence rates and levels of premature discontinuation by 
the patient are high, with a figure of approximately 50% being proposed 
across conditions (Sabaté, 2003). The publication of three high-profile reports 
in 2003 demonstrated the increasing level of attention that was being placed 
on the problem of adherence at the time (Carter, Taylor and Levenson, 2003; 
Harrison, 2003; Sabaté, 2003) and which still continues to be a focus of 
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healthcare research and guidance (Hazell and Robson, 2015; Sav et al., 
2015; NICE, 2009). Between them, these reports highlight the far-reaching 
impact of non-adherence. They claim that poor adherence is the biggest 
‘threat’ to the potential clinical benefits of treatment. These are reflected as 
medical and psychosocial complications, and the subsequent impact on an 
individual’s quality of life (Carter, Taylor and Levenson, 2003; Harrison, 2003;  
Sabaté, 2003).   
 
There is also the need to consider the waste of medicines and additional 
utilisation of healthcare resources that could be directed elsewhere (Sabaté, 
2003; Hazell and Robson, 2015). These economic considerations are of 
particular importance as we are in a stage of ever-increasing health costs; 
both in terms of the prevalence of chronic, lifelong conditions and the rising 
prices of prescription treatments (Kesselheim, Avorn and Sarpatwari, 2016; 
Iuga and McGuire, 2014). For example, in the US it is estimated that 
healthcare costs will account for 20% of Gross Domestic Product (GDP) by 
2020, and that 20-30% of this cost will be classified as ‘wasteful’ spend (Iuga 
and McGuire, 2014). Non-adherence is a considerable contributory factor to 
this, with estimate annual costs of $100 – $300 billion in the US (IMS Institute 
for Healthcare Informatics, 2013) and €1.25 billion in the EU (European 
Patients' Forum, 2011). These costs are represented by direct medicine 
value, avoidable hospitalisation, and increased health service utilisation such 
as primary care visits and emergency room admissions (Iuga and McGuire,  
2014).  
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A further consideration is the broader societal impact, caused by absenteeism 
and reduced productivity as a result of poorer health outcomes. Whilst these 
factors are considerations for living with a chronic disease in general, it is 
posited that they are exacerbated further due to inappropriate medicines 
usage (Benjamin, 2012; Loeppke et al., 2009). These ‘costs’ are not factored 
into the estimates given above, demonstrating the ever increasing economic 
and social impact when a condition is not properly managed (Loeppke et al., 
2009).     
Non-adherence in MS – what is happening?  
This impact and cost of non-adherence are also replicated in MS. For 
example, clinical outcomes such as the presence of higher rates of relapse, 
disease progression, and hospital visits and hospital stays increase in MS 
patients who demonstrate less adherence (Girouard and Soucy, 2011; 
Halpern et al., 2011). Similarly, on an economic level, non-adherence is linked 
to higher medical costs (Tan et al., 2011; Steinberg et al., 2010).   
 
Much of the literature on adherence in MS focuses on DMT regimens (Menzin 
et al., 2013) as these are frequently prescribed longer term and represent an 
attempt to positively influence the course of the disease, as opposed to acute, 
symptom management treatments (MS Society UK, 2016a). Therefore, it is 
the non-adherence to this range of treatments that poses the largest threat to 
long-term outcomes for patients and the healthcare system in general (Menzin 
et al., 2013).   
 
Two main types of adherence data have informed the current literature on MS. 
Persistence; defined as the time from treatment initiation to discontinuation or 
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significant gap (e.g. 30 days) and reported as a percentage of patients and 
adherence; defined as the percentage of doses taken as prescribed over a 
period of time by an individual (Menzin et al., 2013).    
  
Risk of treatment discontinuation tends to be greatest in the first 6 months of 
therapy, with studies showing up to 27% of patients stopping in this time. This 
coupled with evidence of discontinuation rates reducing post 6 months, 
suggests that this is a crucial time period for establishing long-term 
persistence (Tremlett and Oger, 2003).   
  
Research also demonstrates that adherence to DMTs is variable, with a 
review conducted in 2013 finding adherence rates ranging from 41% to 88% 
of doses being taken (Menzin et al., 2013). Some of this variation could be 
attributed to disease related factors, such as treatment type and course of 
MS, but it is suggested that study type and the definition of non-adherence 
used also contribute to the level of variation in the data (Menzin et al., 2013;  
Klauer and Zettl, 2008).     
 
Non-adherence in MS – why is it happening?  
Understanding the levels of non-adherence is important but research in this 
area also seeks to understand what the causes of non-adherence are. It is 
recognised that in a healthcare system that needs to support people to better 
self-manage, there needs to be a greater understanding and consideration of 
the needs and preferences of patients (Vermeire et al., 2001).   
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Terminology 
Described above is the type of data used to inform adherence studies, but in 
terms of terminology, there has been much debate about the appropriate 
language to use when talking about medicines use (and in fact, undertaking 
general health / self-management behaviours overall) (Vermeire et al., 2001).  
This is an important debate as it is hypothesised that the language used goes 
beyond simply describing the activity to being representative of the overall 
‘ideology’ surrounding this concept of ‘adherence’ and the suitability of terms 
to appropriately represent the role of the patient themselves (De las Cuevas, 
2011)   
Compliance  
Compliance is a term that is seen currently as ‘unfavourable’ due to the 
implication that the patient ‘role’ in this scenario is a submissive one and that 
non-compliance is actually a failure or unwillingness to do as instructed. In this 
scenario, the fault firmly lies with the patient themselves as it is based on 
assumption of absolute authority and correctness on behalf of the healthcare 
system making the recommendations (De las Cuevas, 2011).   
Concordance  
This term was introduced by the Royal Pharmaceutical Society in response to 
a recognition that a one-dimensional approach to medicine taking was not 
cognizant with an evidently complex and pervasive phenomenon 
(Blenkinsopp, Bond and Britten, 1997). Originally, this term placed the patient 
as a decision maker alongside their healthcare professional and tries to shift 
the focus to the desired outcomes of a treatment regimen for the patient, 
rather than just the ‘best’ clinical decision of the doctor. This terminology 
indicates a partnership, so the role of the physician must also change to one 
	 22	  
of empathy and listening to the outcome goals of the patient (Blenkinsopp, 
Bond and Britten, 1997). Over time, this term has become even broader, 
covering a wide range of topics around general patient support with medicine 
taking (Horne, Weinman, Barber 2005).  
Adherence  
The term adherence is defined as ‘the extent to which the patient’s behaviour 
matches agreed recommendations from the prescriber’ – so once again 
moving away from the patient as a passive entity towards one where their 
agreement is seen as key to the medicines taking process (Horne, Weinman, 
Barber, 2005). 
So, when we seek to understand ‘why’ non-adherence is occurring, insight 
into the implications of the rhetoric surrounding the research in this area is 
important as it provides the lens from which the behaviour is being viewed. 
However, it is also important to consider the way that research is being 
conducted. For example, a study may refer to concordance, but if the 
hypothesis or measures still infer compliance to prescribed regime as the 
goal, without, for example, looking at how involved a patient was in the 
decision-making process, then can it really be said to be exploring 
concordance?  
Across the literature, these terms are often used interchangeably and 
unfortunately not always accurately (De las Cuevas, 2011). To this end, for 
clarity in this thesis the term adherence is used to reflect the overall concept of 
medicine taking, with specific behaviours (e.g. number of doses, 
discontinuation) referred to where applicable to detail the specific behaviour 
being studied.    
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Intentional and unintentional adherence  
Studies across chronic conditions have shown that poor adherence can be the 
result of both deliberate and unintentional behaviour. For example, patients 
may take a lower dose than is recommended following consideration of the 
treatment and making a deliberate (intentional) decision to alter the dosage or 
take a drug holiday (Pound et al., 2005). Alternatively, they may alter their 
medication dosage unintentionally, as a result of misunderstanding the 
instructions they have been given, or forgetting (Horne et al., 2005). 
Identification of and the reasons behind both forms of adherence behaviour 
need to be understood and addressed in order to tackle non-adherence and 
offer effective patient support (Horne et al., 2005).   
Intentional – illness perceptions  
In the general population, it is acknowledged that the beliefs an individual 
holds about their illness and their treatment can have a significant impact 
upon their ability to adjust to and cope with a condition, both in terms of 
appropriate self-management behaviours and emotional wellbeing.  These 
beliefs form the basis of a theoretical model proposed by Leventhal and 
colleagues, the Self-Regulatory Model (SRM) (Leventhal, Meyer and Nerenz, 
1980), also referred to as the Common-Sense Model of Self-Regulation 
(CSM) (Leventhal, Phillips and Burns, 2016). The SRM is a multi-level, 
conceptual framework that examines the perceptual, behavioural and 
cognitive processes that are involved in the self-management of health 
threats. The model proposes that individuals will appraise the potential threat 
posed from an illness and form both cognitive and emotional responses to the 
illness threat. The threat can be somatic sensations (e.g. symptoms), function 
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deviations (e.g. a fall) or can be socially presented (e.g. a doctor’s diagnosis, 
public health campaign).  
These stimuli will then activate both memory structures relating to past illness 
experiences and what ‘normal’ functioning is, and then cognitive 
representations of the threat that are the current appraisal (Leventhal, Phillips 
and Burns, 2016). Evidence from across multiple chronic conditions shows 
that patients form representations relating to five key variables: the cause of 
the illness, its nature or identity, its duration, the personal consequences of 
suffering from it and the extent to which the illness can be controlled or cured 
(Moss-Morris et al., 2002).  
It is these memories and representations that dictate the strategies an 
individual will use to cope with the threat. In this way, the SRM is a framework 
that allows for the categorisation and understanding of the processes 
underlying the initiation and maintenance of health self-management 
behaviours (e.g. adherence, lifestyle change). A key feature of this is the 
recognition that this process is multi-level and dynamic. For example, rather 
than just having dichotomous factors of perceived seriousness and 
vulnerability, such as in the Health Belief Model (Rosenstock, Strecher and 
Becker, 1988), it seeks to break this threat into its component parts (the 
levels). What are the immediate consequences, what are the predicted future 
consequences, how controllable is it, how long will it last? How much does 
this experience replicate / differentiate from previous health threats? What 
coping strategies have worked before, what is within my power to do? It is in 
this way that it is dynamic as it is recognises that different combinations of 
these will elicit different responses. The model also accounts for change 
overtime as different experiences form new memories and appraisals of the 
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effect of coping strategies are assessed for their ability to remove or moderate 
the health threat (see Figure.1).  In this way, the framework provides an 
opportunity to not only predict behaviours but to understand the dynamic 
processes leading to action (or inaction) and therefore can provide targets for 
intervention (Leventhal, Phillips and Burns, 2016; O’Connor, Jardine and 
Millar, 2008; Leventhal, Meyer and Nerenz, 1980).   
There is further evidence of the role of these beliefs in specific relation to 
medicine taking behaviours, which are considered part of the coping response 
within the SRM (Leventhal, Phillips and Burns, 2016). A decision about 
treatment will be rational if it fits with the patient’s own beliefs about the illness 
and the appropriate treatments for it, even when the decision is at odds with 
the professional healthcare advice given (Horne and Weinman, 1999). Studies 
have demonstrated that these beliefs can predict the likelihood of adherence 
behaviours in a number of conditions including asthma, diabetes, heart failure 
and hypertension (Kucukarslan, 2012).  
 
Figure 1 – Self-regulatory model (Leventhal, Meyer and Nerenz, 1980) 
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When considering illness perceptions in MS, it is possible to see how the 
nature of the condition could impact an individual’s illness perceptions, and in 
turn the coping behaviours that someone undertakes. For example, illness 
identity (in terms of symptom experience and attribution) is seen as key 
catalyst for prompting action in both acute and chronic conditions (Moss-
Morris et al., 2002). The fluctuating nature of symptoms in RRMS, means that 
in periods of remission, people may reduce their activity in terms of disease 
management as they perceive it to be dormant or simply don’t have the 
somatic cues to prompt action. The unpredictable course of the condition can 
impair beliefs around how much control an individual has over their MS. Low 
personal control, in turn, can reduce the likelihood of engaging in coping 
behaviours, related to a sense that there is little that can be done (Wallston 
and Wallston,1978).  
Intentional – treatment beliefs  
In addition to illness perceptions, with regards to adherence there is also 
evidence of the role of individual treatment beliefs in determining behaviour. 
These ‘common-sense evaluations’ of prescribed medicines are grouped into 
two categories: perceptions of the need for treatment (necessity beliefs) e.g. 
in the absence of symptoms, and concerns about a range of potential 
undesired outcomes, e.g. side effects, addiction. This is referred to as the 
‘Necessity-Concerns Framework (NCF)’ and it is proposed that patients 
perform a “cost-benefit” analysis, weighing-up possible benefits and risks of 
taking medication (Horne, Weinman and Hankins, 1999). A meta-analysis of 
94 studies exploring the impact of these beliefs on adherence behaviour 
demonstrated a significant impact of both necessity and concerns beliefs on 
adherence, even when controlling for study size, country and the adherence 
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measure used (Horne et al., 2013). Leventhal and colleagues (2016) propose 
that there is a strong interplay between illness and treatment representations 
and incongruence between the two can impact behavioural outcomes. As per 
the earlier example, a lack of or reduction in somatic symptoms experienced 
in a period of remission may reduce the perceived necessity for treatment. A 
representation that DMTs should quickly relieve symptoms (identity, timeline) 
may lead to concerns about treatment efficacy when symptom relief is not 
experienced. Therefore, consideration of both illness and treatment 
representations should be taken when exploring adherence (Leventhal, 
Phillips and Burns, 2016). Figure 2 shows an ‘extended’ self-regulatory model 
to include treatment representations.  
 
 
Unintentional – neuropsychological symptoms  
Cognitive dysfunction is a common problem in people with MS, linked to 
damage caused by MS related lesions on the brain. The manifestation of 
these problems is heterogenous, with symptoms, severity and speed of 
SRM 
Extended SRM
Key:
Threat
Illness reps
TX Reps
EMO Response
to TX 
Coping
procedure
Coping
procedure
EMO
response
Appraisal
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Figure 2 – ‘Extended’ Self-regulatory model (Leventhal, Phillips and Burns, 2016)  
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decline varying greatly between patients (Mohr and Cox, 2001). Problems with 
memory and executive function (e.g. problem solving, sequencing) can 
negatively impact an individual’s ability to adequately adhere to treatment 
regimens. Memory problems may lead to forgetting to take treatment as 
prescribed and reduced executive function may, in turn, reduce the ability for 
the individual to be able to formulate or put in place ways to mitigate memory 
problems, such as setting reminders.  More broadly, if we consider that the 
self-regulatory model is contingent on cognitive processes (i.e. 
representations, action planning, coping appraisals) then we can see how the 
threat itself (MS) can be not only the trigger for self-management behaviours 
but may also be impeding the process of self-regulation.   
Modifying behaviour  
Of particular note with regards to illness and treatment representations is not 
only their utility to predict adherence behaviours but their modifiability also. 
Evidence shows that interventions to address ‘unhelpful’ beliefs can change 
not only the perceptions themselves but that that change can translate into 
health behaviours and outcomes too (Broadbent et al., 2009; Petrie et al., 
2002). For example, an SMS text-based intervention in asthma was 
successful in changing illness perceptions, treatment beliefs and adherence 
behaviours, with the changes sustained after the intervention had ended 
(Petrie et al., 2012). This demonstrates the potential of interventions that are 
designed to change these underlying, belief-based drivers of adherence to be 
relatively short whilst still impacting long-term behaviour (Petrie et al., 2012; 
Broadbent et al., 2009). This is in contrast to other interventions whereby 
taking the support away often leads to a reversion of behaviour, for example 
reminders, contingent rewards and financial support (Nunes et al., 2009). The 
importance of deliberate non-adherence and the contribution of patient beliefs 
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are highlighted in recommendations concerning adherence produced by the 
National Institute for Health and Care Excellence (NICE, 2009).   
COM-B Model 
However, whilst the evidence and the importance of the role of illness and 
treatment beliefs in adherence is undoubtedly strong, these beliefs do not 
occur in isolation and will be impacted by other medicine and illness related 
considerations, as well as varying according to disease type, treatment type 
and individual experiences. To this end, it is important to consider these 
beliefs in the context of the overall treatment and illness experience. One such 
way to do this is through the utilisation of the Capability, Opportunity and 
Motivation model of behaviour (COM-B) (Michie, van Stralen and West, 2011). 
The model proposes that health behaviours are driven or limited by a range of 
factors which can be grouped under three broad categories: a person’s 
Capability (e.g. reduced cognitive function, lack of understanding, mobility 
limitations), Motivation (e.g. illness perceptions and treatment beliefs as 
described above, depression, anxiety) and Opportunity (e.g. social support, 
health care system factors). As well as each component influencing 
adherence directly, opportunity and capability may also affect motivation, thus 
moderating / mediating behaviour this way (Michie, van Stralen and West, 
2011). A review by Jackson and colleagues has applied this model specifically 
to adherence behaviours (Jackson et al., 2014). Figure 3 shows the sub-
components proposed to influence adherence identified from their review. 
As described above, when we examine these sub-components in the context 
of MS, capability factors such as executive function may not only impact 
adherence directly through reducing planning ability, but, if it is interfering with 
the self-regulation process as well, then this may be influencing the illness 
	 30	  
and treatment representations which sit within the category of motivation. 
However, COM-b also starts to help us think about the broader context of the 
MS patient. What level of support are they receiving to manage the impact of 
the disease? How good is their relationship with the healthcare team, and 
what influence is this having on their understanding and trust of self-
management recommendations?     
 
Whilst the SRM helps us to understand the cognitive processes in place, 
COM-B gives a framework to define further what may be influencing these 
processes or where people may experience barriers to ‘action’ (e.g. access to 
medicines (opportunity, physical) or physical ability to self-inject (capability, 
Figure 3 – COM-B Model for adherence (Jackson et al., 2014) 
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physical)). Additionally, whilst it is proposed there is an emotional processing 
response alongside the cognitive one, this is specific to emotions ‘prompted’ 
by the illness and are discreet from more global mood disorders, such as 
depression and anxiety (Moss-Morris et al. 2001). COM-B allows for 
consideration of both, and therefore the different ways they may be impacting 
adherence (Jackson et al., 2014). This differentiation and ‘next layer’ of 
definition is important as not only does it deepen our understanding but also 
helps to form the basis for behavioural intervention (Jackson et al., 2014).  
Designing interventions  
As with the understanding of influencing factors, an important consideration 
for intervention design is the use of theories of behaviour and behaviour 
change. In the UK, the Medical Research Council (MRC) recommends an 
analysis of theories before intervention testing to understand the likely 
processes and drivers of change (Campbell et al., 2007). However, there are 
conflicting results across literature as to how consistent the difference is 
between those using a theoretical underpinning and those not, with positive 
and negative results being found for both types of intervention (Michie, Atkins 
and West, 2014). It is proposed however that this is likely related to 
methodological issues, namely how the theory is understood and applied, and 
also how it is reported in relation to the intervention description, rather than an 
indication of a lack of effectiveness. It is suggested that, if applied and utilised 
appropriately, theory may lead to more effective interventions (Michie, Atkins 
and West, 2014).  
Health related behaviours are complex; as mentioned above they do not occur 
in a vacuum. Psychological, social, cultural, clinical and economic 
relationships and processes can all influence the performance of health-
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related behaviours (Ogden, 2016). It is proposed that a theory can provide a 
systematic framework for identifying not only the antecedents of behaviour 
(Michie, van Stralen and West, 2011) but also provide an opportunity to 
explore these in the context of incidental and mediating factors thereby 
‘shining a light’ on the range of influencers to be considered and / or 
addressed through the intervention (Rothman, Sheeran and Wood, 2009; 
Rothman, 2004).  
The reciprocal relationship between theory and intervention also means that 
the application of theory to intervention design allows for evaluation and, 
where applicable, refinement of that theory through its practical application 
(Abraham and Michie, 2008; Rothman, 2004).  
However, despite these apparent advantages, a review of implementation 
research in 2010 estimated that only about 20% of studies utilised a behaviour 
change theory (Davies, Walker and Grimshaw, 2010). Furthermore, studies, 
which apply the theory systematically, are even more limited, with the majority 
simply referencing a theory as influential rather than detailing how the 
constructs map specifically onto intervention components (Webb et al., 2010).  
Behaviour Change Wheel  
The Behaviour Change Wheel (BCW, see Figure 4) is intended to provide a 
systematic way to design behavioural interventions that allows for theoretical 
underpinnings to be applied in a way that not only explains behaviour but 
allows for consideration of how to change it. The COM-B model (described 
above) provides the centre point but the next layer of the wheel explores ways 
in which the factors identified as influencing behaviour may be targeted, either 
to promote facilitating factors, or remove potential barriers through the 
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identification of appropriate intervention functions, policies to support 
intervention execution, the application of discreet behaviour change 
techniques (BCTs) and selection of mode of delivery (Michie, Atkins and 
West, 2014).  
Figure 4 – Behaviour Change Wheel (Michie, Atkins and West, 2014) 
 
Intervention Functions  
Once the behaviour has been better understood in terms of what needs to be 
changed to influence it through COM-B, the next stage as proposed by the 
BCW is to identify intervention functions, namely the type of intervention that 
can be applied to address specific behavioural categories, that will be effective 
to bring about the desired changes. There are 9 intervention functions 
described in the wheel; education, persuasion, incentivisation, coercion, 
training, restriction, environmental restructuring, modelling and enablement. It 
is proposed that these functions map specifically to particular COM-B 
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categories. For example, educational interventions can influence physical 
capability and reflective motivation, whereas persuasion can influence 
automatic and reflective motivation.   
Policy Categories 
The next layer of the BCW promotes identification and understanding of the 
policies / supporting functions that can be used to deliver intervention 
functions.  For example, communication / marketing can help deliver 
education and incentivise people to take action. To support an intervention 
function of environmental restructuring, environmental / social planning 
policies may need to be deployed. Seven policies are described within the 
BCW; communication / marketing, guidelines, fiscal measures, regulation, 
legislation, environmental /social planning and service provision. As with the 
intervention functions, there is a proposed mapping of these policies to 
functions, to aid intervention design (Michie, Atkins and Gainforth, 2014).  
Behaviour Change Techniques  
Once the appropriate considerations have been mapped out for the 
overarching intervention functions and supporting policies needed to put an 
intervention in place, the specific components of that intervention then need to 
be created. Approaches that have been used to target health behaviours have 
been brought together through review and consensus as part of an 
overarching taxonomy of behaviour change techniques (BCTs) (Michie et al., 
2013; Michie et al., 2011b). Intervention functions may be delivered through 
multiple BCTs. For example, education may consist of ‘information about 
health consequences’ and ‘instruction on how to perform the behaviour’. 
Currently, the taxonomy describes 93 techniques that can be used to attempt 
to change behaviour, grouped into 16 overarching categories (Michie et al., 
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2013). The taxonomy has been applied to understanding and mapping 
effective methods of change for a range of health-related behaviours, 
including healthy eating and physical activity (Michie et al., 2011a) smoking 
cessation (Michie et al., 2011b) and reduced alcohol consumption (Michie et 
al., 2012).  
Mode of Delivery 
The final step is choosing the mode(s) for the execution of the intervention, 
usually informed by practical considerations, such as location, type of 
population and availability of budget and resources. 
Impact of approach  
The BCW has been used in a number of areas, both through utilisation of 
discreet parts of the wheel to increase understanding (COM-B and BCT 
studies as described above) and in full to help turn insights into action, for 
example provision of contraception to adolescents (Rubin, Davis and McKee, 
2013), understanding use of risk assessment strategies in cardiovascular 
practice (Bonner et al., 2013) and implementing evidence-based guidelines for 
premature babies (Crowther et al., 2013).   
However, even with these systematic strategies being put in place and some 
evidence of their feasibility, the relative impact of health behaviour change 
interventions is fairly low and inconsistent, suggesting there may be more to 
be done and / or understood (Bull et al., 2014; Kripalani, Yao and Haynes, 
2007; McDonald, Garg and Haynes, 2002; Haynes, McKibbon and Kanani, 
1996).  
Within the area of adherence, a suggested reason for this is the apparent 
disconnect between the research priorities of those providing healthcare and 
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the needs of those consuming it, particularly the focus on consumption of 
pharmaceutical products (Pound et al., 2005). Whilst ‘professionals’ (including 
physicians, researchers, policy makers) may see medicine taking as 
something that should simply be done ‘as prescribed’, leading to monitoring of 
compliance and related variables in a fairly ‘quantitative’ way (Vermeire et al., 
2001) individuals see medicines as a resource that they use ‘as and when’ to 
support the overall management of their condition (Pound et al., 2005; Blaxter 
and Britten, 1996). As discussed previously, this is writ large in the case of 
describing ‘adherent’ behaviours.    
A further explanation for this apparent ‘lack of success’ (Pound et al., 2005) 
could be the chasm between the research that looks at the ‘why’ of 
nonadherence and the research that seeks to change adherence behaviour 
(Allemann et al., 2016). For example, a recent review on adherence to oral 
antiplatelet therapy in people with Acute Coronary Syndrome, found that 
studies which looked at reasons for non-adherence primarily explored 
demographic, clinical and treatment variables. Yet the handful of successful 
interventions primarily targeted psychosocial variables, such as emotional 
wellbeing, treatment perceptions and relationship with healthcare 
professionals (Johnston et al., 2016).  
 
Turning insights into action  
As described above, the potential of DMTs to improve outcomes for people 
with RRMS and the wider reaching socioeconomic implications of non-
adherence means that understanding how to increase and maintain 
adherence certainly warrants exploration. However, whilst some research has 
sought to identify factors impacting adherence and persistence in MS  
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(Devonshire et al., 2011) and other studies have reviewed behaviour change 
interventions in people with MS (Roche, McCarry and Mellors, 2014) there are 
currently no published reviews in MS looking at the extent to which factors 
identified as influencing adherence to DMTs have also been successfully 
modified through intervention. It is proposed that a greater cohesion between 
these two elements may provide an opportunity to ‘refocus’ research aims 
onto variables that provide the greatest opportunity for change (Allemann et 
al., 2016).   
Therefore, this two-part scoping review will explore this relationship by: 
identifying the most prolific patient-related factors found to be influencing 
adherence to DMTs; reviewing behaviour change interventions in MS to see 
which of these identified factors have been subsequently targeted through 
intervention and, crucially, also demonstrated effectiveness through improved 
adherence outcomes.    
Specifically, the aims of this review are:   
• To determine the factors that have been identified as influencing 
adherence to prescribed DMTs in people with MS  
• To operationalize the identified factors using the COM-B model of 
behaviour change as applied to adherence to allow for comparison 
across studies and understand the applicability of the model for this 
population  
• To determine which of these factors have been successfully modified 
through intervention, and how    
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• To categorise the successful intervention components using the BCW 
to allow for comparison across studies and understand how / if the 
interventions align with suggested links within the BCW    
• To explore the degree of consistency between the factors identified 
through research and those targeted and subsequently modified 
through intervention 
• To understand current gaps in our knowledge relating to adherence in 
MS  
It is hoped that this review will help to rationalise the factors that have been 
shown to influence adherence in MS to those that have demonstrated 
response to behavioural intervention and to highlight the amount of congruence 
or disparity between research exploring adherence drivers and adherence 
interventions in MS.  
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Methods   
A scoping review methodology was chosen to identify and review the 
literature.  A scoping review, whilst still following a ‘systematic’ approach, aims 
to rapidly map the key concepts from a particular research area. A scoping 
review still seeks to understand the breadth of the research available but does 
not go into the depth of detail of a traditional Systematic Review. In practical 
terms this means the data extracted is focussed more explicitly on the 
research questions (as opposed to extracting all the variables) and there is 
less focus on the quality and relative ‘weight’ of the findings (Arksey and  
O'Malley, 2005).  
  
In their case study paper, Arskey and O’Malley (2005) describe four primary 
reasons for selecting a scoping methodology, one of which is to identify 
current gaps in knowledge in a particular research area. In terms of this 
review the primary purpose was to identify to what extent two fields of 
adherence research in MS compare in terms of their findings and focus 
(Arksey and O'Malley, 2005). As described above this methodology is 
systematic, allowing for transparency and replication. A systematic approach 
is also important as it increases the reliability of the findings and including 
clear methodological and data descriptions allows for findings to be viewed 
and understood in context (Petticrew and Roberts, 2008; Mays, Roberts and  
Popay, 2001).   
  
A scoping review follows the same process as a systematic review in terms of 
identifying and selecting studies for inclusion (Petticrew and Roberts, 2008; 
Arksey and O'Malley, 2005) and a description of the process for this review is 
provided below. The key difference is in the charting of the data.  As 
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mentioned, there is no quality assessment and it deliberately seeks to extract 
and present only the data that is the most pertinent to the research question 
and relatively easy to understand. In this respect it mirrors a narrative review 
methodology (Pawson, 2002). To aid the understanding of the data it is 
recommended that a common and ‘logical’ framework is applied to how the 
findings are presented (Arksey and O'Malley, 2005; Pawson, 2002). The 
framework for this review is also described below.  
  
Review 1: Factors impacting adherence in MS   
  
Systematic literature searches were conducted using CINAHL, Medline,  
PsychArticles, PsychINFO (via EBSCOHost) and the Cochrane Register for 
Controlled Trials and Systematic Reviews. The search terms used across all 
databases are summarised in Table 1. Subsequently, the reference lists of 
articles that were included at data extraction stage were examined to identify 
any relevant articles that may have not been returned in the database search.  
  
Table 1: Factors impacting adherence to treatment in MS - Search Terms   
1  (adherence* OR complian* OR initiat* OR persist*) AND (“M.S.” OR  
“multiple sclerosis”)  
2  (adherence* OR complian* OR initiat* OR persist*) AND (“M.S.” OR  
“multiple sclerosis”) AND (relaps* OR remit*)  
3  (adherence* OR compliance* OR initiat* OR persist*) AND (“M.S.” OR  
“multiple sclerosis”) AND inject*AND oral*  
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Literature was limited to those written in the English language and published 
after January 1st, 1994. This date was chosen as the first licensed DMT for 
RRMS was approved in 1993 and therefore only clinical trial, as opposed to 
real world, data would have been available prior to this. Additional inclusion 
criteria required that studies involved people diagnosed with MS who were 
prescribed medicines for the management of MS and described patient 
provided reasons for non-adherence / discontinuation or patient related 
correlational data between factors and non-adherence / discontinuation. 
Studies were excluded if they only examined physician led clinical decisions 
for discontinuation, as the focus of this research was patient related factors.       
As appropriate for a scoping review, no limits were put on the type of study 
design as the purpose was to understand the range of factors impacting 
adherence, including those related to the patients’ lived experiences and their 
own commentary, not necessarily the most frequent or strongest predictors 
(Arksey and O'Malley, 2005).  Review and commentary papers were 
excluded, as it was preferential to examine the original studies to extract the 
data specific for the research question.    
Similarly, as this was not a systematic review, a formal quality assessment 
was not conducted to determine inclusion / exclusion, but overarching quality 
and design implications and observations were noted as part of the review 
process and are included in the discussion to provide context.        
A total of 4,874 abstracts were identified through the search methodology of 
which 4,804 were eliminated through a title search, leaving 70 abstracts to be 
checked. At this stage, a further 19 were excluded, leaving 51 full texts to be 
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read. Full text review eliminated a further 20 studies, leaving 31 papers for 
data extraction. These papers also had their reference lists checked.  The 
reference list check identified 5 possible additional papers, 2 of which were 
subsequently included, resulting in 33 papers included in the main review. The 
complete process flow for study selection, including reasons for exclusion can 
be found in appendix i.   
For each study included in the final review the following data were extracted: 
study type, collection methods, sample size, type and definition of ‘adherence’ 
measured and statistically significant or patient elicited factors impacting 
nonadherence. These data were believed to be sufficient to give context to the 
primary findings.  
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Review 2: MS Adherence factors successfully modified through intervention   
  
A relevant scoping review was identified early on in the research process that 
had explored interventions and their components to support self-management 
behaviours in MS; this included the specific identification of interventions for 
medication adherence (Plow, Finlayson and Rezac, 2011). To this end, the 
systematic search strategy was modified to identify studies published post the 
review timeframe (2008 onwards). The same databases were searched as for 
the factors review above and the search terms used are summarised in Table  
2.  
 
For consistency, inclusion / exclusion criteria were followed in line with the 
factors review above and those applied to intervention definition from the 
scoping review (Plow, Finlayson and Rezac, 2011). To this end, literature was 
limited to those written in the English language and involved people 
diagnosed with MS who were prescribed medicines for the management of 
MS. Studies needed to describe the intervention in a way that allowed for 
specific intervention components to be identified and evaluation of the 
outcomes of the intervention. Studies were excluded if they were case studies 
or single-subject design as an objective of the research was to help rationalise 
the research to aid intervention focus and therefore interventions that had 
been applied at a population level were deemed more relevant to this aim. 
Studies were also excluded if they described education only interventions (see 
Plow, 2011 for a definition) as whilst information provision and providing core 
education are a key part of enabling self-management, it is widely recognised 
that education alone is not enough to change behaviour (Haynes et al., 1996).  
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Non-impactful studies were also excluded to aid rationalisation of findings into 
those which could help inform future research and intervention design focus.    
  
Table 2: MS Adherence factors successfully modified through intervention - 
Search Terms   
1  (intervention*) AND (multiple sclerosis* OR M.S.*) AND (self-manag* OR 
adher*)  
2  (intervention*) AND (multiple sclerosis* OR M.S.*) AND (relaps* OR 
remit*)  
3  (intervention*) AND (multiple sclerosis* OR M.S.*) AND (self-manag* OR 
adher*) AND (digital OR technolog* OR mobil* OR web* OR internet* 
OR online* OR app*)  
  
A total of 361 abstracts were identified through the search methodology of 
which 315 were eliminated through a title search, leaving forty-six abstracts to 
be checked. At this stage, a further thirty were excluded, leaving sixteen full 
texts to be read. Full text review eliminated a further fourteen studies, leaving 
two papers for data extraction. These papers also had their reference lists 
checked but no additional studies were found. Of the twenty-seven that were 
included in the scoping review by Plow et al. (2008), two met the inclusion 
criteria and were included in the final review papers. The complete process 
flow for study selection, including reasons for exclusion can been seen in 
appendix ii.   
For each study included in the final review the following data were extracted: 
study type, collection methods, sample size, type and definition of ‘adherence’ 
measured, adherence factors targeted, BCTs applied and significant 
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adherence outcomes1. As with the first review these data were believed to be 
sufficient to give context to the primary findings.        
Findings    
 
Review 1: Factors impacting adherence to treatment in MS  
Overview   
The total sample size across the studies was 20,162 (range 30 - 4,111; mean 
610). Of the thirty-three studies included in this review, twenty-three were 
prospective studies  (Jongen, Wim and Boringa, 2016; Turner et al., 2016; 
Warrender-Sparkes et al., 2016; Wicks et al., 2016; Glanz et al., 2014;  
Hupperts et al., 2014; Lulu et al., 2014; de Seze, Borgel and Brudon, 2012;  
Koudriavtseva et al., 2012; Lugaresi et al., 2012; Beer et al., 2011; Hancock, 
Bruce and Lynch, 2011; Bruce et al., 2010; Treadaway et al., 2009; Turner et 
al., 2009; Siegel, Turner and Haselkorn, 2008; Tremlett et al., 2008; Turner et 
al., 2007; Daugherty et al., 2005; Rio et al., 2005; Fraser et al., 2004; Mohr et 
al., 2001) and ten were retrospective  (Fernández et al., 2016; He et al., 2015; 
Zhornitsky et al., 2015; Bergvall et al., 2014; Salter et al., 2014; Agashivala et 
al., 2013; Fernández et al., 2012; Devonshire et al., 2011; Fraser,  
Hadjimichael and Vollmer, 2003; Fraser, Hadjimichael and Vollmer, 2001); all 
were observational as opposed to experimental and there were no qualitative 
studies found, though a minority of surveys did include free response options  
(Wicks et al., 2016; Hupperts et al., 2014; Devonshire et al., 2011; Treadaway 
et al., 2009). Thirteen were cross-sectional in design  (Jongen, Wim and  
Boringa, 2016; Wicks et al., 2016; Lulu et al., 2014; Salter et al., 2014;  
                                            
1 The categorisations used in these two data points were specifically labelled by me to align 
with the COM-B sub-components shown in Figure 1 and to map to the BCT taxonomy 
definitions, they were not necessarily explicitly stated this way in the paper itself 
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Koudriavtseva et al., 2012; Lugaresi et al., 2012; de Seze, Borgel and Brudon, 
2012; Fernández et al., 2012; Devonshire et al., 2011; Daugherty et al., 2005; 
Fraser, Hadjimichael and Vollmer, 2003; Fraser, Hadjimichael and Vollmer, 
2001; Mohr et al., 2001), with the other twenty being cohort studies  
(Fernández et al., 2016; Turner et al., 2016; Warrender-Sparkes et al., 2016; 
He et al., 2015; Zhornitsky et al., 2015; Bergvall et al., 2014; Glanz et al., 
2014; Hupperts et al., 2014; Agashivala et al., 2013; Beer et al., 2011; 
Hancock, Bruce and Lynch, 2011; Bruce et al., 2010; Treadaway et al., 2009; 
Turner et al., 2009; Siegel, Turner and Haselkorn, 2008; Tremlett et al., 2008; 
Turner et al., 2007; Rio et al., 2005; Berger, Hudmon and Liang, 2004; Fraser 
et al., 2004).   
In twenty-five studies, data on potential factors relating to adherence were 
gathered through surveys or structured interviews (Jongen, Wim and  
Boringa, 2016; Turner et al., 2016; Wicks et al., 2016; Glanz et al., 2014; 
Hupperts et al., 2014; Lulu et al., 2014; Salter et al., 2014; de Seze, Borgel 
and Brudon, 2012; Fernández et al., 2012; Koudriavtseva et al., 2012;  
Lugaresi et al., 2012; Beer et al., 2011; Devonshire et al., 2011; Bruce et al.,  
2010; Treadaway et al., 2009; Turner et al., 2009; Siegel, Turner and  
Haselkorn, 2008; Tremlett et al., 2008; Turner et al., 2007; Daugherty et al.,  
2005; Berger, Hudmon and Liang, 2004; Fraser et al., 2004; Fraser,  
Hadjimichael and Vollmer, 2003; Mohr et al., 2001; Fraser, Hadjimichael and  
Vollmer, 2001), whilst eleven used prescriptions or clinical database data   
(Warrender-Sparkes et al., 2016; He et al., 2015; Zhornitsky et al., 2015;  
Bergvall et al., 2014; Fernández et al., 2012; Hancock, Bruce and Lynch,  
2011; Tremlett et al., 2008; Rio et al., 2005; Fraser, Hadjimichael and Vollmer,  
2003; Fraser, Hadjimichael and Vollmer, 2001; Mohr et al., 2001). Five  
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studies combined these methods (Fernández et al., 2012; Hancock, Bruce 
and Lynch, 2011; Fraser, Hadjimichael and Vollmer, 2003; Fraser, 
Hadjimichael and Vollmer, 2001; Mohr et al., 2001).   
Adherence outcome data was collected via self-report in twenty-one studies   
(Jongen, Wim and Boringa, 2016; Turner et al., 2016; Wicks et al., 2016; 
Glanz et al., 2014; Hupperts et al., 2014; Lulu et al., 2014; Salter et al., 2014; 
de Seze, Borgel and Brudon, 2012; Fernández et al., 2012; Koudriavtseva et 
al., 2012; Lugaresi et al., 2012; Beer et al., 2011; Devonshire et al., 2011;  
Bruce et al., 2010; Treadaway et al., 2009; Turner et al., 2009; Tremlett et al.,  
2008; Turner et al., 2007; Daugherty et al., 2005; Berger, Hudmon and Liang,  
2004; Fraser et al., 2004; Fraser, Hadjimichael and Vollmer, 2003; Fraser, 
Hadjimichael and Vollmer, 2001; Mohr et al., 2001), prescriptions or clinical 
records in eleven studies (Warrender-Sparkes et al., 2016; He et al., 2015; 
Zhornitsky et al., 2015; Bergvall et al., 2014; Agashivala et al., 2013;  
Fernández et al., 2012; Hancock, Bruce and Lynch, 2011; Tremlett et al.,  
2008; Rio et al., 2005; Fraser, Hadjimichael and Vollmer, 2003; Mohr et al.,  
2001) and via electronic monitoring in three (Fernández et al., 2016; Hancock, 
Bruce and Lynch, 2011; Bruce et al., 2010). Six studies featured a 
combination of collection methods (Fernández et al., 2012; Hancock, Bruce 
and Lynch, 2011; Bruce et al., 2010; Fraser, Hadjimichael and Vollmer, 2003; 
Fraser, Hadjimichael and Vollmer, 2001; Mohr et al., 2001). Twenty studies 
looked at treatment discontinuation or switching as an outcome (Fernández et 
al., 2016; Jongen, Wim and Boringa, 2016; Warrender-Sparkes et al., 2016;  
Wicks et al., 2016; He et al., 2015; Zhornitsky et al., 2015; Bergvall et al.,  
2014; Salter et al., 2014; Agashivala et al., 2013; de Seze, Borgel and  
Brudon, 2012; Koudriavtseva et al., 2012; Beer et al., 2011; Tremlett et al.,  
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2008; Daugherty et al., 2005; Rio et al., 2005; Berger, Hudmon and Liang,  
2004; Fraser et al., 2004; Fraser, Hadjimichael and Vollmer, 2003; Fraser, 
Hadjimichael and Vollmer, 2001; Mohr et al., 2001), nineteen focussed on 
dosing adherence (Fernández et al., 2016; Jongen, Wim and Boringa, 2016; 
Turner et al., 2016; Bergvall et al., 2014; Glanz et al., 2014; Hupperts et al.,  
2014; Lulu et al., 2014; Agashivala et al., 2013; de Seze, Borgel and Brudon,  
2012; Fernández et al., 2012; Koudriavtseva et al., 2012; Lugaresi et al.,  
2012; Devonshire et al., 2011; Hancock, Bruce and Lynch, 2011; Bruce et al.,  
2010; Treadaway et al., 2009; Turner et al., 2009; Siegel, Turner and  
Haselkorn, 2008; Turner et al., 2007) and six looked at both together   
(Fernández et al., 2016; Jongen, Wim and Boringa, 2016; Bergvall et al.,  
2014; Agashivala et al., 2013; de Seze, Borgel and Brudon, 2012; 
Koudriavtseva et al., 2012). One study (Tremlett et al., 2008) explored the 
relationship between dosing adherence and persistence.   
There were a range of measures used to determine dosing adherence; 
including Medicines Possession Ratio (MPR) (n=11) (Fernández et al., 2016; 
Jongen, Wim and Boringa, 2016; Turner et al., 2016; Bergvall et al., 2014; 
Lulu et al., 2014; Agashivala et al., 2013; Lugaresi et al., 2012; Devonshire et 
al., 2011; Turner et al., 2009; Siegel, Turner and Haselkorn, 2008; Turner et 
al., 2007), Proportion of Days Covered (PDC) (n=2)  (Bergvall et al., 2014; 
Agashivala et al., 2013), percentage of doses missed (n=4) (Glanz et al.,  
2014; Hupperts et al., 2014; Hancock, Bruce and Lynch, 2011; Bruce et al.,  
2010) and number of doses missed (n=4) (de Seze, Borgel and Brudon,  
2012; Fernández et al., 2012; Koudriavtseva et al., 2012; Treadaway et al., 
2009) Two studies looked at both MPR and PDC (Bergvall et al., 2014; 
Agashivala et al., 2013). Of the eleven studies that reported MPR, nine used a 
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cut-off rate of <80% to define non-adherence (Fernández et al., 2016; Turner 
et al., 2016; Bergvall et al., 2014; Lulu et al., 2014; Agashivala et al., 2013;  
Lugaresi et al., 2012; Turner et al., 2009; Siegel, Turner and Haselkorn, 2008;  
Turner et al., 2007), one study (Jongen, Wim and Boringa, 2016) defined it as  
<95% and another single study defined it as <100% (Devonshire et al., 2011).   
Factors impacting adherence   
A summary of factors influencing adherence is given below and, due to the 
volume of factors which appear only once, this section has been limited to 
describing only those which appeared in more than one study as significantly 
correlated with non-adherence or elicited directly from patients through survey 
responses. Whilst this review is not about relative impact per se, its purpose is 
to determine the extent to which the two research areas of drivers of 
nonadherence and adherence interventions complement each other. The 
large number of single factors meant that there was a risk of the research 
question being unduly biased towards the negative (e.g. little cohesion) and 
therefore it was felt that some prioritisation was required.   
To further aid grouping and classification, I give ‘equivalent’ names in the 
descriptions below. For example, adverse events were classified with side 
effects and cognitive benefit classified with perceived treatment efficacy. 
However, for transparency, original descriptions from the studies remain in  
Table 3. Where applicable the direction of the relationship between a factor 
and non-adherence is positive unless otherwise stated. Category factors are 
labelled with the influencing component (e.g. Gender [female]).    
Overall, twenty-nine different factors, which appeared more than once, were 
identified across the studies and have been clustered into the following five 
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groups of variables: clinical, demographic, opportunity, psychosocial and 
treatment.  
They were not mapped to COM-B at this stage to allow for the findings to be 
initially presented in categories that were salient with the way research to date 
has been described.   
Clinical variables  
Relapse features were found to be the most prevalent clinical factor, including 
shorter length of time since last relapse  (Warrender-Sparkes et al., 2016; 
Hancock, Bruce and Lynch, 2011; Tremlett et al., 2008), the number of 
relapses whilst on treatment (Lulu et al., 2014; Treadaway et al., 2009) and 
total number of relapses across the study period, though this was positively 
correlated in one  (Bergvall et al., 2014) and negatively correlated in another  
(Fernández et al., 2016). Two studies found a significant impact of greater 
levels of disability (Zhornitsky et al., 2015; Rio et al., 2005), whilst one found 
that a lower level of disability was predictive on non-adherence (Berger, 
Hudmon & Liang et al., 2004). Three reported longer duration of disease 
(Devonshire et al., 2011; Treadaway et al., 2009; Turner et al., 2007). Two 
studies found a relationship between the presence of comorbidities and non-
adherence (Fernández et al., 2012; Treadaway et al., 2009).     
  
Demographic variables   
Age related variables were the most prolific in this category with older age 
related to non-adherence in two studies (Bergvall et al., 2014; Fernández et 
al., 2012) and younger age in another two (de Seze, Borgel and Brudon, 
2012, Turner et al., 2007). Younger age at treatment initiation was a factor in 
two studies (Warrender-Sparkes et al., 2016; Zhornitsky et al., 2015). Five 
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studies found a significant impact of gender, three demonstrated that non-
adherence was correlated with being female (Warrender-Sparkes et al., 2016; 
Bergvall et al., 2014; Beer et al., 2011) and two with being male (Jongen, Wim 
and Boringa, 2016; Devonshire et al., 2011). A lower level of education was 
found to be significant in one study (Tremlett et al., 2008), and higher level of 
education in two others (Devonshire et al., 2011; Berger, Hudmon & Liang et 
al., 2004).   
Opportunity variables   
Three studies demonstrated that cost related issues (e.g. less co-pay, higher 
value drugs) were a factor in non-adherence (Bergvall et al., 2014; Treadaway 
et al., 2009; Daugherty et al., 2005). A negative impact of travelling was 
proposed in two studies, whereby people found it more difficult to be adherent 
when travelling (de Seze, Borgel and Brudon, 2012; Treadaway et al., 2009). 
Physician support of treatment was found to have a positive impact on 
adherence in two studies (Fraser, Hadjimichael and Vollmer, 2003; Fraser, 
Hadjimichael and Vollmer, 2001). Three studies reported patients having a 
lack of ongoing support with injections as contributing to non-adherence 
(Devonshire et al., 2011; Treadaway et al., 2009; Mohr et al., 2001). Similarly, 
a lack of caregiver support and / or congruence in treatment beliefs was 
evident from three studies (Salter et al., 2014; Devonshire et al., 2011; Fraser, 
Hadjimichael and Vollmer, 2003). 
Psychosocial variables   
Forgetting was stated as a reason for non-adherence in seven studies   
(Hupperts et al., 2014; Lulu et al., 2014; de Seze, Borgel and Brudon, 2012;  
Fernández et al., 2012; Lugaresi et al., 2012; Devonshire et al., 2011;  
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Treadaway et al., 2009). Lower self-efficacy was correlated with non-
adherence in four (Fraser et al., 2004; Fraser, Hadjimichael and Vollmer, 
2003; Fraser, Hadjimichael and Vollmer, 2001; Mohr et al., 2001). The 
presence of an emotional disorder or higher emotional impact was identified in 
two studies (Bruce et al., 2010; Treadaway et al., 2009) and a lower degree of 
hope was a factor in two studies (Treadaway et al., 2009; Fraser, 
Hadjimichael and Vollmer, 2001). Perception of quality of life was positively 
correlated with adherence in two papers (Devonshire et al., 2011; Treadaway 
et al., 2009).     
Treatment variables  
Treatment variables were the most prolific in these studies. The two most 
prominent factors were the experience of side effects (n=12) (Fernández et 
al., 2016; Jongen, Wim and Boringa, 2016; Warrender-Sparkes et al., 2016;  
Wicks et al., 2016; Hupperts et al., 2014; de Seze, Borgel and Brudon, 2012; 
Fernández et al., 2012; Lugaresi et al., 2012; Beer et al., 2011; Devonshire et 
al., 2011; Treadaway et al., 2009; Daugherty et al., 2005) and perceptions of 
treatment efficacy (n=10)  (Fernández et al., 2016; Jongen, Wim and Boringa, 
2016; Warrender-Sparkes et al., 2016; Wicks et al., 2016; Salter et al., 2014; 
de Seze, Borgel and Brudon, 2012; Koudriavtseva et al., 2012; Beer et al., 
2011; Treadaway et al., 2009; Daugherty et al., 2005), with greater efficacy 
perceptions linked to greater adherence. Method of treatment administration 
was a factor in five studies, with injection treatments leading to greater levels 
of non-adherence when compared to oral formulations (Wicks et al., 2016; 
Zhornitsky et al., 2015; Bergvall et al., 2014; Agashivala et al., 2013; Beer et 
al., 2011). Similarly, a number of injection related factors were also found to 
impact adherence. They included injection anxiety (Hupperts et al., 2014; 
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Devonshire et al., 2011; Treadaway et al., 2009; Turner et al., 2009; Mohr et 
al., 2001), injection fatigue (Wicks et al., 2016; de Seze, Borgel and  
Brudon, 2012; Fernández et al., 2012; Beer et al., 2011; Devonshire et al.,  
2011; Treadaway et al., 2009) and pain at the site of injection  (Hupperts et 
al., 2014; Fernández et al., 2012; Lugaresi et al., 2012; Devonshire et al., 
2011). Four studies found an impact of dosing frequency (Glanz et al., 2014; 
Devonshire et al., 2011; Treadaway et al., 2009; Tremlett et al., 2008) with 
more doses increasing chances of non-adherence and prior treatment status 
was significantly related to non-adherence in three; prior use of a different 
treatment in two (Bergvall et al., 2014; Treadaway et al., 2009) and prior use 
of the same treatment in the other (Fraser, Hadjimichael and Vollmer, 2001). 
Treatment concerns were cited in two studies (Wicks et al., 2016; Berger, 
Hudmon and Liang, 2004), as was a longer duration on treatment 
(Koudriavtseva et al., 2012; Devonshire et al., 2011).        
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Table 3: Overview of adherence factor studies, including study design and significant 
outcomes   
#  Author; year; 
country   
Study type;  
collection 
methods; sample 
size; type and 
definition of 
adherence 
measured   
Significant or patient elicited factors impacting 
non-adherence  
#1   (Agashivala et  
al., 2013)       
USA   
Retrospective, 
observational, 
cohort; prescription 
database; n=1891; 
persistence => 60 
day gap, adherence  
MPR / PDC  
Significant factors:   
Treatment  
 •  Method of administration (injection)   
#2   (Beer et al.,  
2011)  
Switzerland  
Prospective, 
observational; 
cohort; skin 
examination and 
self-report; n=412, 
treatment 
discontinuation or 
switch at 12-month 
follow-up   
Patient elicited factors:   
Treatment   
• Perceived efficacy*   
• Side effects (experienced)  
• Injection fatigue   
Clinical   
• Flu like symptoms  
• Abnormal liver function  
Significant factors:   
Demographic  
• Gender (female)  
Treatment  
• Method of administration (injection)   
#3   (Bergvall et  
al., 2014)  
USA   
Retrospective, 
observational, 
cohort; prescription 
database; n=3750; 
persistence => 60 
day gap, MPR /  
PDC <80%  
Significant factors:   
Clinical   
• Greater no. of relapses  
• Headache   
• Numbness  
Demographic   
• Age   
• Gender (female)   
Opportunity   
• Higher cost   
Treatment   
• Prior use of other treatment   
• Method of administration (injection)  
#4   (Bruce et al.,  
2010)  
USA   
Prospective, 
observational, 
cohort; self-report,  
MEMS, survey; 
n=55; <10% of 
doses missed  
Significant factors:   
Psychosocial  
• Cognition (‘comparative reduced capacity’ 
in memory, list recall, list learning)  
• Emotional disorder (presence of)    
• Personality (neuroticism, openness, 
conscientiousness*)  
#5   (Lugaresi et 
al., 2012)  
Italy   
Prospective, 
observational, 
crosssectional; 
survey; n=  
109; MPR =>80%   
  
Patient elicited factors:   
Psychosocial  
• Forgetting   
Treatment   
• Adverse events  
• Injection site pain   
• Device problems   
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#  Author; year; 
country   
Study type;  
collection 
methods; sample 
size; type and  
definition of 
adherence 
measured   
Significant or patient elicited factors impacting 
non-adherence  
#6   (He et al.,  
2015)  
Multi-country 
sample   
Retrospective, 
observational, 
cohort; registry 
database; n=527; 
treatment 
discontinuation at 
follow-up (13.1 
month median)   
No significant findings   
#7   (Hupperts et 
al., 2014) Multi-
country sample   
Prospective, 
observational, 
cohort; survey; n= 
251; % of doses 
taken   
Patient elicited factors:  
Psychosocial  
• Forgetting   
• Fatigue  
Treatment   
• Adverse events   
• Injection site pain   
• Injection anxiety  
#8   
(Koudriavtseva 
et al., 2012)  
Italy   
Prospective, 
observational, cross 
sectional; structured 
interview; n-97; ‘very 
good’ = no doses  
missed, ‘other’ = 
some doses missed, 
discontinuation >1 
month   
Significant factors:   
Opportunity   
• No choice in physician   
Treatment   
• Perceived efficacy*   
• Duration  
#9   (Lulu et al.,  
2014)  
USA  
Prospective, 
observational, cross 
sectional; surveys; 
n=30; MPR=<80   
Patient elicited factors:   
Psychosocial   
• Forgetting  
• Interferes with activities   
• Want to forget condition   
• Do not think it is needed  
Treatment  
• Injection pain / bruising   
• Side effects   
Opportunity   
• Cost   
• Ran out of medication   
Significant factors:   
Clinical   
• Relapsed when on treatment  
#10   (Mohr et al.,  
2001)  
USA   
Prospective, 
observational, 
crosssectional; 
prescription data 
and psychosocial 
assessment; n=101;  
treatment  
discontinuation   
  
Significant factors:   
Treatment  
• Injection anxiety   
Opportunity 
• Injection administrator (other person 
needed)  
Psychosocial  
• Self-efficacy*   
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#  Author; year; 
country   
Study type;  
collection 
methods; sample 
size; type and  
definition of 
adherence 
measured   
Significant or patient elicited factors impacting 
non-adherence  
#11   (Salter et al.,  
2014)  
USA   
Retrospective, 
observational, 
crosssectional; 
patient survey; 
n=308; switching 
treatment   
Patient elicited factors:   
Treatment  
 •  Perceived efficacy*   
#12  (Siegel, Turner 
and 
Haselkorn,  
2008)  
USA   
Prospective, 
observational,  
cohort; self-report; 
n=54; MPR=>80%  
Patient elicited factors:   
Opportunity 
 •  Supportive qualities of caregiver   
#13   (Rio et al.,  
2005)  
Spain   
Prospective, 
observational, 
cohort; clinical 
database; n=622; 
treatment 
discontinuation  
Significant factors:   
Clinical  
• Type of MS (SPMS)  
• Greater disability   
#14   (Treadaway et 
al., 2009)  
USA   
Prospective, 
observational, 
cohort; survey; 
n=798; missing any 
injection in a 4-week 
period  
Patient elicited factors:   
Clinical  
• Headache   
• Weakness   
• Flu like symptoms     
• Fatigue   
• Comorbidity present   
• Relapse   
Psychosocial  
• Injection anxiety  
• Forgetting   
• Depression    
• Didn’t feel like it   
Treatment   
• Perception of efficacy*   
• Injection fatigue   
• Injection pain   
• Skin reactions   
• Inconvenient dosing   
Opportunity   
• Emergency   
• No support with injection   
• Cost  
• Ran out of medication   
• Travelling   
• Pharmacy delivery issues  
Significant factors:   
Demographic  
• Diagnosis age*  
• Disease duration*  
• Not on first treatment   
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#  Author; year; 
country   
Study type;  
collection 
methods; sample 
size; type and  
definition of 
adherence 
measured   
Significant or patient elicited factors impacting 
non-adherence  
   Psychosocial   
• Reduced cognitive function   
• Role limitations (physical)   
• Emotional problems   
• Emotional wellbeing*   
• Depression   
• Treatment satisfaction*   
• QoL perceptions*  
• Hope*   
• Social function* 
Clinical  
• Energy   
• Physical composite   
• Mental composite   
• Change in health   
• Pain  
#15   (Wicks et al.,  
2016)  
USA   
Prospective, 
observational, cross 
sectional; survey; 
n=281; treatment 
discontinuation or 
switch  
Patient elicited factors:   
Treatment  
• Side effects (experienced)   
• Oral preference   
• Struggling to administer / take   
• Concerns   
• Lack of efficacy   
#16   (Turner et al.,  
2009)  
USA   
Prospective, 
observational, 
cohort; structured 
interviews; n=89;  
MPR =>80%  
Significant factors:   
Treatment 
•  Injection anxiet 
#17   (Turner et al.,  
2007)  
USA   
Prospective, 
observational, 
cohort; structured  
interviews; n=89;  
MPR =>80%   
Significant factors:   
Demographic   
• Age*   
Clinical   
• Years since diagnosis   
Psychosocial  
• HBM Severity   
• HBM Benefits*  
#18   (Tremlett et 
al., 2008) 
Tasmania   
Prospective, 
observational, 
cohort; survey and 
clinical assessment; 
n=97; treatment 
discontinuation  
Significant factors:   
Demographic  
• Lower education   
Treatment   
• Prior missed doses   
• More frequent administration   
Clinical   
• Time since last relapse*  
Psychosocial   
• Alcohol consumption   
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#  Author; year; 
country   
Study type;  
collection 
methods; sample 
size; type and  
definition of 
adherence 
measured   
Significant or patient elicited factors impacting 
non-adherence  
#19   (Warrender 
Sparkes et al.,  
2016)  
Multi-country   
Prospective, 
observational,  
cohort; clinical 
database; n=4,111; 
treatment 
discontinuation   
Significant factors:   
Demographic   
• Gender (female)   
• Country (Australian)   
• Age at start of treatment* 
Clinical   
• <6 months since last relapse  
Treatment  
• Adverse events   
• Tolerance*   
• Efficacy*   
#20   (Turner et al.,  
2016)  
USA  
Prospective, 
observational, 
cohort; structured  
interviews; n=89;  
MPR =>80%   
Significant predictors  
Psychosocial   
 •  Adherence expectations*  
#21   (Fernández et 
al., 2012) 
Spain   
Retrospective, 
observational, cross 
sectional; self-
report, prescription 
data; n=120; 
Moriskey-Green  
test, prescriptions 
dispensed; no of 
doses missed  
Significant predictors  
Demographic   
• Age 
Patient elicited reasons  
Treatment   
• Side effects   
• Injection site pain   
Clinical   
• Infection  
• Comorbidities  
• Fatigue   
Psychosocial   
• Forgetting   
• Social commitments   
#22   (Zhornitsky et  
al., 2015)  
Canada   
Retrospective, 
observational,  
cohort; clinical 
database; n=1,471; 
treatment 
discontinuation   
Significant predictors  
Treatment  
• Type   
Demographic   
• Age (starting treatment before age 30)   
Clinical   
• Disability at treatment initiation   
#23  (Jongen, Wim 
and Boringa, 
2016)  
Netherlands   
Prospective, 
observational, 
crosssectional; 
survey; n=200; 
treatment 
discontinuation and  
MPR =<95%  
Patient elicited factors:   
System  
• Time with psychological care*  
• Time with other medical specialists*  
• Time receiving home care*    
• Time receiving informal care*  
Treatment  
• Side effects   
• Efficacy*   
Demographic   
• Gender (male)  
  
	 59	  
 
#  Author; year; 
country   
Study type;  
collection methods; 
sample size; type 
and  
definition of 
adherence 
measured   
Significant or patient elicited factors impacting 
non-adherence  
#24  (Hancock,  
Bruce and  
Lynch, 2011)  
USA   
Prospective, 
observational, 
cohort; clinical  
records, MEMS, self-
report; n=75; % of 
missed doses   
Significant predictors:   
Clinical   
• Time since last relapse*   
• Steroid use*  
• Adherence to medical appointments*  
#25   (Glanz et al.,  
2014)  
USA   
Prospective, 
observational cohort; 
survey; n=226; % of 
missed doses   
Significant predictors:   
Treatment   
• No. of doses   
Psychosocial   
• Inconvenience   
#26   (Fernández et 
al., 2016) 
Spain   
Retrospective, 
observational, 
cohort; electronic 
device; n=258; MPR 
=<80%; treatment 
discontinuation  
Significant predictors:   
Treatment  
• Adverse events   
• Efficacy   
Clinical   
• No. of relapses*   
#27   (Fraser et al.,  
2004)  
USA   
Prospective, 
observational, 
cohort; survey; 
n=104; treatment 
discontinuation   
Significant predictors:   
Psychosocial  
 •  Self-efficacy*    
#28  (Fraser, 
Hadjimichael 
and Vollmer,  
2003)  
USA  
Retrospective, 
observational, 
crosssectional; 
survey and registry; 
n= 199; treatment 
discontinuation   
Significant predictors:   
Psychosocial  
• Self-efficacy*   
• Less physician support of treatment 
• Less spousal support of treatment  
  
#29  (Fraser, 
Hadjimichael 
and Vollmer,  
2001)  
USA   
Retrospective, 
observational, 
crosssectional; 
survey and registry; 
n= 341; treatment 
discontinuation   
Significant predictors:   
Psychosocial  
• Self-efficacy*  
• Hope* 
• Less physician support of treatment   
Treatment   
• Previous use of treatment class  
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# Author; year; 
country   
Study type;  
collection 
methods; sample 
size; type and  
definition of 
adherence 
measured   
Significant or patient elicited factors impacting 
non-adherence  
#30   (Devonshire et 
al., 2011) Multi 
country   
Retrospective, 
observational, 
crosssectional; 
survey;  
n=2,566;  
MPR<100%   
Significant predictors:   
Treatment  
• Dose frequency  
• Time on treatment   
• Difficulty of injection 
Clinical  
• Disease duration   
• Neuropsychological impairment    
Opportunity    
• Physician not discuss adherence at initiation   
• Not treated at a dedicated MS centre   
• Frequency of neurologist appointments*  
• Less support from spouse / partner   
Demographic   
• Gender (male)   
• Education level  
Psychosocial   
• Satisfaction with treatment*   
• Quality of life*   
Patient elicited factors:(min. 10% of ppt)   
Treatment   
• Injection fatigue   
• Injection site pain   
• Injection anxiety   
• Side effects   
Psychosocial   
• Treatment necessity   
• Forgetting   
Opportunity 
• No-one to support with injections   
Clinical  
• Symptoms   
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# Author; year; 
country   
Study type;  
collection 
methods; sample 
size; type and  
definition of 
adherence 
measured   
Significant or patient elicited factors impacting 
non-adherence  
#31  (de Seze,  
Borgel and  
Brudon, 2012)  
France   
Prospective, 
observational, 
crosssectional; 
survey; n = 202; 
treatment 
discontinuation, 
switch, missing 
doses   
Significant predictors:   
Demographic   
• Age*   
Psychosocial   
• Disease understanding*  
• Forgetting   
• Wanting to forget illness   
• Perceived efficacy*  
Treatment   
• Injection fatigue   
• Side effects   
Opportunity   
• Travel / Holiday  
#32  (Berger,  
Hudmon and  
Liang, 2004)  
USA   
Prospective, 
observational, 
cohort; interview and 
survey; n=531; 
treatment 
discontinuation   
Significant predictors:   
Demographic   
• Level of education  
• Level of disability* 
Treatment   
• Perceived pros of treatment*   
• Perceived cons of treatment  
#33   (Daugherty et  
al., 2005)  
USA   
Prospective, 
observational, 
crosssectional; 
survey; n=108; 
treatment 
discontinuation   
Significant predictors:   
Treatment   
• Side effects   
• Perceptions of efficacy*   
Opportunity   
• Cost   
  
*Signifies a negative correlation or association   
  
 
Comparison of findings to the COM-B model of adherence   
Firstly, where possible, the factors identified from the scoping review (that 
appeared more than once) were mapped against and categorised as per the 
COM-B model for adherence (Jackson et al., 2014). The aim of this, in line 
with the original research objectives, was to help to rationalise (further) the 
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disparate descriptions of adherence drivers / barriers against an evidence-
based adherence model. Fourteen factors (48%) mapped directly; cognitive 
function (forgetting) beliefs about treatment (concerns [includes side effects], 
efficacy), self-efficacy, mood state / disorder, cost, caregiver support 
(general and specific help with injections), dosing, packaging considerations 
of medicine (oral preference, injection fatigue, injection anxiety, injection site 
pain), HCP relationship / communication (physician support of treatment).  
Fourteen factors (52%) remained that could not be mapped directly; clinical 
factors were, relapse features (time since last relapse, number of relapses on 
treatment, number of relapses during study timeframe), increased disability, 
time since diagnosis and comorbidities. Demographic factors included age, 
gender and education level. Psychosocial elements that couldn’t be directly 
mapped were hope and quality of life; patients in two studies cited travelling 
as an adherence barrier. Treatment variables included prior treatment status, 
both being on a different treatment and the same treatment previously as well 
as duration on treatment.    
From the original COM-B model for adherence, ten factors did not appear in 
the rationalised list from the literature: comprehension of disease / treatment, 
executive functioning, physical capability to adapt to lifestyle changes, 
dexterity, perceptions of illness, outcome expectancies, stimuli / cues for 
action, access to treatment, stigma and religious / cultural beliefs. 
Table 4 shows how the findings from the literature review did and did not match 
the COM-B model of adherence as proposed by Jackson and colleagues 
(2014).  
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Of those factors from the review that could not be mapped directly, it was 
possible to align four of them to the COM-B categories, based on the category 
descriptions, namely: increased disability within physical capability, hope and 
quality of life within reflective motivation and travelling within physical 
opportunity. This alignment is shown in Table 5.  
From these insights it was possible to propose a revised COM-B model 
specifically for adherence to DMTs in MS, shown in Figure 5. This model was 
used as the basis for the second part of the review; MS adherence factors 
successfully modified through intervention.  
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Table 4 – Comparison of findings from the factors review to the COM-b model of adherence   
Category   Factors from the original model 
identified* in the review  
Factors from the original 
model not identified * in the 
review  
Capability 
(psychological) 
Cognitive functioning  
• Forgetting  
 
Comprehension of disease 
and treatment  
 
Executive function (e.g. 
capacity to plan) 
Capability  
(physical) 
 n/a Physical capability to adapt to 
lifestyle changes  
 
Dexterity 
Motivation 
(reflective) 
Beliefs about treatment  
• Concerns / side effects  
• Efficacy   
Self-efficacy  
Perceptions of illness  
 
Outcome expectancies  
Motivation 
(automatic) 
Mood state / emotional disorder   
 
Stimuli or cues for action  
Opportunity 
(physical) 
Cost   
Social support  
• Caregiver help to administer 
injection 
• Caregiver ‘general’ support 
Regimen complexity 
• Dosing  
Packaging characteristics of 
medicine   
• Oral preference   
• Injection fatigue   
• Injection anxiety   
• Injection site pain   
HCP-patient 
relationship/communication 
• Physician support of 
treatment 
Access (e.g. availability of 
medication) 
  
Opportunity 
(social) 
n/a Stigma of disease, fear of 
disclosure  
 
Religious / cultural beliefs 
 
*needs to have appeared more than once to ‘qualify’ as per description above 
 Table 5 – Factors from the review that could be mapped to COM-B categories, but do not 
appear in the original adherence model    
Category  Factors identified in the review that were not in the original 
model which could be mapped to the COM-B categories   
Capability 
(psychological) 
n/a 
Capability  
(physical) 
Increased disability 
Motivation 
(reflective) 
Hope  
Quality of life   
Motivation 
(automatic) 
n/a 
 
Opportunity 
(physical) 
Travelling  
 
Opportunity (social) n/a 
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Figure 5 – Revised COM-B for adherence to DMTs in people with MS 
S 
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Review 2: MS Adherence factors successfully modified through intervention  
 
Overview   
The total sample size across the studies was 750 (range 12-367; mean  
187.5). Of the four studies that met the inclusion criteria, three were RCTs  
(Turner et al., 2014; Berger, Liang and Hudmon, 2005; Mohr et al., 2000) and 
one was a prospective, observational, cohort study  (Zettl et al., 2016).  All 
were single country studies from Germany (Zettl et al., 2016) and the USA 
(Turner et al., 2014; Berger, Liang and Hudmon, 2005; Mohr et al., 2000). An 
overview of these studies is shown in Table 6 
Table 6: Overview of successful intervention studies, including study design, factors targeted, 
behaviour change techniques applied and the significant outcomes   
 
  
# Author; 
year; 
country   
Study type;  
collection 
methods; 
sample size; 
type and 
definition of 
adherence 
measured; 
intervention 
approach   
Adherence 
Factors 
targeted 
(identified in 
part 1 of the 
review)   
BCTs applied   Significant 
outcomes   
#1  (Mohr et 
al., 
2000);  
USA  
RCT, Telephone 
survey and 
prescription data; 
n= 32; 
persistence at 4 
months; Weekly, 
50-minute 
telephone 
Cognitive  
Behavioural 
Therapy 
approach, 
delivered over 8 
weeks.    
Mood state / 
emotional 
disorder 
Goal setting 
(behaviour and 
outcome)   
Discrepancy 
between current 
behaviour and 
goal Action 
planning   
Review 
behavioural goals   
Framing / 
reframing   
Self-monitoring of 
behaviour   
Prompts/cues  
Social support  
(unspecified)  
Post 
intervention 
depression 
scores lower in 
treatment group 
compared to 
usual care (p = 
.02); depression 
scores 
decreased 
postintervention 
in treatment 
group (p = 
.0004) but not in 
usual care (p = 
.69).   
Significant 
relationship 
between 
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# Author; 
year; 
country   
Study type;  
collection 
methods; 
sample size; 
type and 
definition of 
adherence 
measured; 
intervention 
approach   
Adherence 
Factors 
targeted 
(identified in 
part 1 of the 
review)   
BCTs applied   Significant 
outcomes   
intervention and 
persistence (p = 
.03).   
#2 (Berger,  
Liang 
and  
Hudmon,  
2005); 
USA  
RCT; telephone 
and web survey; 
n=367; 
persistence at 3 
months;  
Transtheoretical 
Model of Change 
and motivational 
interviewing, 
delivered by 
telephone, using 
a software 
algorithm, at 
fortnightly or 
4weekly intervals 
for 3 months;  
educational 
leaflets 
Beliefs about 
treatment  
Efficacy   
Concerns / 
side effects  
 
Self-efficacy   
Packaging 
characteristics 
of medicine  
Injection site 
pain 
Instruction on how 
to perform the 
behaviour  
Information about 
health 
consequences   
Social support 
(unspecified)  
Pros and Cons   
Framing/reframing 
Positive impact 
of intervention 
on model stage 
(p = <.01)  
Perceived 
importance of 
treatment  
(necessity) 
significantly 
higher in 
intervention 
group (p = <.05)  
Significant 
relationship 
between 
intervention and 
persistence 
(1.2% stopped 
in intervention 
group compared 
to 8.7% 
stopping in 
standard care; p 
= .001). 
#3 (Zettl et 
al., 
2016);  
Germany   
Prospective, 
observational, 
cohort; physician 
provided data, 
patient diary data  
(PDA and 
Paper); n=339; 
persistence at 24 
months, no. of 
injections 
recorded (=>6 
missed every six 
months 
Cognitive 
function   
Forgetting  
Packaging 
characteristics 
of medicine  
Injection site 
pain   
   
Prompts/cues   
Self-monitoring of 
behaviour  
Instruction on how 
to perform the 
behaviour  
   
Significant 
impact on 
adherence (no. 
of injections) of 
PDA plus 
reminders 
compared to  
PDA without 
reminders (OR 
0.57 [95% CI 
0.321-1.018]).   
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# Author; 
year; 
country   
Study type;  
collection 
methods; 
sample size; 
type and 
definition of 
adherence 
measured; 
intervention 
approach   
Adherence 
Factors 
targeted 
(identified in 
part 1 of the 
review)   
BCTs applied   Significant 
outcomes   
nonadherent); 
reminders and 
monitoring, 
education on 
treatment 
administration 
and adverse 
events  
#4 (Turner 
et  
al., 
2014);  
USA  
RCT; self-report; 
n=19; no. of 
injections 
recorded at 1,3,6 
months; 
motivational 
interviewing 
telephone 
counselling (3 
sessions in 
month 1) and 
mailed graphic 
feedback on 
benefits of 
treatment, home 
telehealth 
monitoring 
including tailored 
reminders and 
positive 
reinforcement 
messaging, 
tracking and 
telephone 
followup for 
nonadherence.   
Beliefs about 
treatment  
Efficacy   
Concerns / 
side effects 
 
Self-efficacy   
  
Cognitive 
function   
Forgetting  
Packaging 
characteristics 
of medicine  
Injection site 
pain  
  
Prompts/cues   
Action planning   
Problem solving   
Feedback on 
behaviour   
Self-monitoring of 
behaviour  
Information about 
health 
consequences  
Salience of 
consequences   
Commitment   
Goal setting 
(behaviour and 
outcome)  
Discrepancy 
between current 
behaviour and 
goal Pros and 
Cons   
Instruction on how 
to perform the 
behaviour  
 
Social support 
(unspecified)  
Significant 
impact of 
intervention on 
no. of injections 
recorded at  
6 months only 
(p =  
<.05)  
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Intervention type and delivery   
Three of the interventions used telephone counselling, with two of these 
utilising principles of motivational interviewing (Turner et al., 2014; Berger, 
Liang and Hudmon, 2005) and one using a Cognitive Behavioural Therapy 
(CBT) approach (Mohr et al., 2000).   
Of these three, two used therapists selected and trained specifically for the 
study (Turner et al., 2014; Mohr et al., 2000) and one trained existing call 
centre staff and provided a digital intervention algorithm to guide discussions 
(Berger, Liang and Hudmon, 2005).   
Call times and frequency ranged between the interventions. The CBT based 
study provided weekly, 50 minute calls over the course of eight weeks  (Mohr 
et al., 2000), one of the MI based interventions delivered calls over three 
months at either two or four weekly intervals dependent on patient likelihood 
to adhere (no call length data provided) (Berger, Liang and Hudmon, 2005) 
and the other MI intervention provided three telephone sessions in month 1 
(ranging from 45 – 75 mins each) plus follow-up calls during months two to six 
in response to non-adherence data being received. These averaged 9.3 
minutes in length and across the intervention sample there was an average of 
four follow-up calls executed (range 1-9) (Turner et al., 2014).        
All three telephone counselling interventions also included additional ‘paper 
based’ materials. These took the form of a workbook to support the CBT 
intervention (Mohr et al., 2000), tailored educational leaflets (Berger, Liang 
and Hudmon, 2005) and tailored graphical information on the benefits of 
treatment (Turner et al., 2014).   
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The intervention provided by Turner and colleagues (2014) also provided 
participants with a home telehealth monitoring system with optional treatment 
reminders, prompts to record when medicine was taken, positive 
reinforcement messaging and notifications to the study therapist when 
injections were not recorded which prompted a follow-up call.   
Zettl and colleagues (2016) allowed people to choose between a paper patient 
diary or personal digital assistant (PDA). Those who selected a PDA were 
then randomly allocated one with or without an additional reminder function. 
All diaries included options to record when and where on the body injections 
were administered plus any skin reactions. The PDA also included a help 
function with information on self-injection and managing AEs. It is not clear 
from the intervention description whether any supplementary information was 
provided in the paper diary (Zettl et al., 2016).   
Intervention timeframes varied for each study; eight weeks (Mohr et al., 2000), 
three months (Berger, Liang and Hudmon, 2005), six months (Turner et al., 
2014) and two years (Zettl et al., 2016).   
Behaviour change theories and models   
Two interventions (Turner et al., 2014; Berger, Liang and Hudmon, 2005), 
were delivered using principles of Motivational Interviewing which has been 
defined as a ‘counselling style’ (Rollnick and Miller, 1995) but it is proposed to 
be effective through theory-based mechanisms of action (see Miller and Rose, 
2009 for a discussion on this). Berger and colleagues (2004), also cited the 
Transtheoretical Model of Change as a core basis for their intervention 
design. One used cognitive behavioural therapy (Mohr et al., 2000), which 
again can be classified as an intervention style, but does draw on a theoretical 
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approach (Clak and Beck, 1999). One cited no theoretical basis for the design 
(Zettl et al., 2016).   
Describing the interventions using components of the Behaviour Change Wheel  
As well as utilising the BCW to structure intervention design, its authors also 
propose that it can be used to evaluate and synthesize evidence from 
behaviour change interventions (Michie, Atkins and West, 2014). As a key aim 
of this review is evidence synthesis, the components of the intervention 
studies have been described using policy categories, intervention functions 
and behaviour change techniques, based on my interpretation of the 
intervention description, utilising guidelines outlined in (Michie, Atkins and 
West, 2014). How these intervention elements map to factors identified in the 
COM-B model for adherence to DMTs in MS and alignment to recommended 
links between components, functions and techniques are explored in the 
integrated findings section.  
Policy categories  
As all of these were short-term interventions designed for the purposes of 
research, the primary policy category applicable to all studies was Service 
Provision as each one delivered services / support over and above standard 
care as opposed to implementing a comprehensive ‘new’ model of care.   
Additionally, all studies created and shared Guidelines to help facilitate the 
delivery of the intervention as per the study protocol. Finally, Communication 
was a key component of each of the interventions, including telephone, print 
and electronic information and support.  
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Intervention functions and Behaviour Change Techniques applied   
Across all the studies, a total of five intervention functions were applied; 
Education, Enablement, Environmental Restructuring, Persuasion and 
Training. Sixteen BCTs were identified through a review of the intervention 
descriptions and are listed in Table 7 including their relevant taxonomy 
categories and codes and the functions they were aligned to in these studies.  
 
 
 
 
 
 
 
 
 
Table 7: BCTs and their relevant intervention functions utilised in successful behaviour 
change interventions for people with MS 
BCT Category  BCTs Intervention 
functions 
Studies  
(1) Goals and 
planning  
1.1 Goal setting (behaviour)  
1.2 Problem solving  
1.3 Goal setting (outcome)  
1.4 Action Planning  
1.5 Reviewing behavioural 
goals  
1.6 Discrepancy between 
current behaviour and 
goals  
1.9 Commitment  
Enablement 
 
Turner et al., 
2014; Mohr 
et al., 2000; 
(2) Feedback and 
monitoring  
2.2 Feedback on behaviour  
2.3. Self-monitoring of 
behaviour  
Education  
Enablement  
Persuasion 
Zettl et al., 
2016; Turner 
et al., 2014; 
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Training  Mohr et al., 
2000  
(3) Social support  3.1 Social support 
(unspecified) 
Enablement  
Persuasion 
  
Turner et al., 
2014; Berger, 
Liang and 
Hudmon, 
2005; Mohr 
et al., 2000 
(4) Shaping 
knowledge  
4.1 Instruction on how to 
perform the behaviour  
Training Zettl et al., 
2016; Turner 
et al., 2014; 
Berger, Liang 
and Hudmon, 
2005;  
(5) Natural 
consequences  
5.1. Information about health 
consequences  
5.2 Salience of 
consequences  
Education  
Persuasion  
Turner et al., 
2014; Berger, 
Liang and 
Hudmon, 
2005 
(7) Associations  7. 1 Prompts / cues  Education  
Environmental 
Restructuring  
Zettl et al., 
2016; Turner 
et al., 2014; 
Mohr et al., 
2000 
(9) Comparison of 
outcomes  
9.2 Pros and Cons  Enablement  Berger, Liang 
and Hudmon, 
2005 
(13) Identity  13.2 Framing / reframing  Enablement  Berger, Liang 
and Hudmon, 
2005; Mohr 
et al., 2000 
 
Goals and planning  
Goals and planning oriented BCTs were used in two interventions, including 
goal setting (behaviour and outcome)  (Turner et al., 2014; Mohr et al., 2000), 
reviewing behavioural goals  (Mohr et al., 2000), action planning  (Turner et 
al., 2014; Mohr et al., 2000), problem solving  (Turner et al., 2014) helping 
people identify discrepancy between current behaviour and goal  (Turner et 
al., 2014; Mohr et al., 2000) and commitment (Turner et al. 2014). In the 
context of these studies, goals and planning techniques aligned primarily with 
the intervention function of Enablement.  
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Associations 
Three interventions used prompts/cues, (Zettl et al., 2016; Turner et al., 2014 ; 
Mohr et al., 2000). Two of these studies provided explicit reminders or 
prompts to take medicine (Zettl et al., 2016; Turner et al., 2014) which aligns 
with the intervention function of Environmental Restructuring. Mohr and 
colleagues used prompts/cues in a more educational way through the 
provision of patient workbooks to facilitate homework between telephone 
sessions, therefore aligning more closely to the Education function.   
Feedback and monitoring  
 Self-monitoring of behaviour was applied in three interventions (Zettl et al., 
2016; Turner et al., 2014; Mohr et al., 2000). Feedback on behaviour was a 
feature of one intervention (Turner et al., 2014). Self-monitoring and feedback 
techniques align to a number of functions according to the published guidance 
(Michie, Atkins and West, 2014). For Mohr and colleagues (2000) self-
monitoring was a tool to enable better understanding of cognitive behaviours 
(e.g. thought monitoring) and activity levels for those people receiving support 
with fatigue. To this end the key intervention functions appear to be 
Education, Training and Enablement. The use of a PDA / paper diary in the 
study by Zettl and colleagues (2016) facilitated self-monitoring of adherence 
and any adverse events, plus a help function / direction on how to reduce and 
manage AEs. In this context the most aligned intervention functions are 
Training and Education. In their MI / home monitoring study, Turner and 
colleagues (2014) prompted self-monitoring to identify potential non-
adherence and to adapt the intervention accordingly. They also explored with 
patients any incongruence between their adherence behaviours and their 
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desired health outcomes, suggesting that Persuasion was the key intervention 
function.  
Natural consequences  
Two of the study interventions included BCTs from the natural consequences 
category. These were information about health consequences (Turner et al., 
2014; Berger, Liang and Hudmon, 2005) which maps to the Education 
function and salience of consequences (Turner et al., 2014) which maps to 
the function of Persuasion.   
Shaping knowledge  
Three studies included the BCT, instruction on how to perform the behaviour 
(Zettl et al., 2016; Turner et al., 2014; Berger, Liang and Hudmon, 2005), 
aligned with the intervention function of Training.  
Identity  
Two studies utilised framing/ reframing techniques, drawn from cognitive 
behavioural therapy (Berger, Liang and Hudmon, 2005; Mohr et al., 2000). In 
the context of these interventions, the technique aligned with the function of 
Enablement as it was a specific technique to support cognitive behavioural 
change, therefore “increasing means / reducing barriers to increase capability 
(beyond education and training)” (Michie et al., 2014, pg. 113).    
Comparison of outcomes 
Also from principles of cognitive behavioural therapy, supporting people to 
consider the pros and cons of adherence was featured in one study (Berger, 
Liang and Hudmon, 2005). As with framing / reframing, the use of this 
technique was supporting cognitive changes beyond just providing information 
and therefore sits within the function of Enablement also.    
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Social support  
Social support (unspecified) was a feature of three interventions through the 
provision of telephone counselling (Turner et al., 2014; Mohr et al., 2000; 
Berger, Liang and Hudmon, 2005). Turner and colleagues (2014) also 
encouraged the identification of social support as part of their intervention. In 
this context, social support fits within the function of Enablement as it aims to 
increase capability beyond just providing education or training. In addition, the 
two MI based interventions (Turner et al., 2014; Berger, Liang and Hudmon, 
2005) would have, by the nature of MI techniques themselves, also have 
aligned with the function of Persuasion.    
Adherence measures   
Two studies measured persistence only (Berger, Liang and Hudmon, 2005; 
Mohr et al., 2000) one examined dosing adherence only (Turner et al., 2014) 
and one looked at both persistence and dosing adherence (Zettl et al., 2016).   
Persistence endpoints were different in the three relevant studies, 3 months  
(Berger, Liang and Hudmon, 2005), 6 months (Mohr et al., 2000) and 24 
months (Zettl et al., 2016). Dosing adherence was defined as total no. of 
injections recorded in both studies (Zettl et al., 2016; Turner et al., 2014).    
Adherence outcome data was collected via self-report in three studies (Zettl et 
al., 2016; Turner et al., 2014; Berger, Liang and Hudmon, 2005) and 
prescription data in one (Mohr et al., 2000). The self-report measures used 
were an adapted single item question asking how many doses missed in the 
previous month asked via telephone survey  (Turner et al., 2014), single item 
on persistency at three months asked via telephone survey (Berger, Liang and 
Hudmon, 2005) and reporting treatment continuation and missed doses to 
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physician during study visits as well as data recorded on the PDA  (Zettl et al., 
2016).       
Adherence outcomes    
The 8-week CBT based intervention had a significant impact on 4-month 
persistence rates compared to standard care (2 discontinued compared to 9; 
p = .03) (Mohr et al., 2000).    
The MI based interventions had a significant impact on both persistence at 
three months (1.2% of people stopped in the intervention group compared to 
8.7% stopping in the standard care; p = .001) (Berger, Liang and Hudmon, 
2005) and total number of injections recorded at 6 months (M [SD] = 1.3 [2.1] 
vs 8.2 [12.3] past month missed doses; p <.05)  (Turner et al., 2014).   
The PDA intervention demonstrated an impact on number of injections for 
those who had the additional reminder function, with a mean of  
24.5 more injections over 24 months compared to PDA use with no reminder. 
Comparison data were not available for the paper diary and there was no 
significant impact on persistence (Zettl et al., 2016).    
Other outcomes     
The CBT based intervention demonstrated significantly improved depression 
scores, as measured by the POMS Depression – Dejection scale (McNair, 
Lorr & Droppleman, 1981). Post intervention depression scores were lower in 
the intervention group compared to usual care (p = .02), in addition, there was 
a significant reduction in pre-post intervention depression scores in the 
intervention group (p = .0004) but not in the usual care group (p = .69) (Mohr 
et al., 2000).   
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One of the MI based interventions (Berger, Liang and Hudmon, 2005), 
demonstrated a significant, positive impact on patient ‘stage of readiness’ to 
discontinue treatment (p = <.01) and perceived importance of treatment 
(measured by response to a single item question) was significantly higher in 
the intervention group compared to standard care (p = <.05). In the discussion 
section, Berger and colleagues (2005) reported that there was a significant, 
positive impact on self-efficacy, but the data was not presented in the results 
section to support this finding and was therefore omitted from Table 6. 
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Integrated Findings   
This section integrates the findings from the two reviews and describes which 
factors influencing adherence in MS (based on the revised COM-B for 
adherence in MS, Figure 5) were targeted by the interventions identified in the 
second review, and how.    
Adherence factors targeted by the interventions – COM-B    
One study targeted a single factor from the first part of the review (Mohr et al., 
2000) whilst the other three targeted multiple factors (Zettl et al., 2016; Turner 
et al., 2014; Berger, Liang and Hudmon, 2005). In total, five factors from the 
revised COM-B were addressed, leaving eleven not targeted.  
Capability factors  
Two capability factors were included in the revised COM-B model and one of 
these was addressed by two of the interventions reviewed, namely cognitive 
functioning (forgetting), (Zettl et al., 2016; Turner et al., 2014). Increased 
disability was not a factor described in the interventions.  
Motivational factors 
One intervention explicitly and exclusively targeted mood state / emotional 
disorder (Mohr et al., 2000) and two interventions targeted self-efficacy 
(Turner et al., 2014; Berger, Liang and Hudmon, 2005).  Beliefs about 
treatment were the focus of two interventions (Turner et al., 2014; Berger, 
Liang and Hudmon, 2005) with both attempting to address beliefs about 
efficacy and concerns / side effects. Hope and quality of life from the revised 
COM-B were not targeted.  
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Opportunity factors 
Opportunity (physical) factors were the most prolific from the review, yet only 
one was explicitly described as being supported, physical characteristics of 
medicine (injection site pain). This was a feature of the three of the 
interventions (Zettl et al., 2016; Turner et al., 2014; Berger, Liang and 
Hudmon, 2005). Cost, social support (caregiver general and help with 
injection), regimen complexity (dosing), HCP-patient 
relationship/communication (physician support of treatment) and the 
remaining medicine characteristic factors, oral preference, injection fatigue 
and injection anxiety were not addressed.     
Mapping of Intervention Functions and BCTs to factors  
Guidance for use of the BCW includes recommendations for which functions 
are most appropriate for each of the COM-B categories, referred to as a 
matrix of links (e.g. Psychological capability maps to the intervention functions 
of Education, Training and Enablement). In turn, whilst in their guidance 
Michie and colleagues (2014) acknowledge that, at this time, there are not 
specific BCT taxonomies for each intervention function, they do provide 
consensus guidance as to the most appropriate BCTs by intervention function, 
including prioritisation by frequency of use. The next section describes how 
the BCTs and factors aligned according to the aims and intervention 
description of each study and, in turn how whether these alignments matched 
guidance from Michie and colleagues (2014). Table 6 shows the high-level 
mapping as part of the data extraction. Table 8 shows how the intervention 
functions from the previous section (see Table 7) map to the intervention 
targets.  
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Table 8 Mapping of intervention functions to intervention targets  
COM-B 
category 
Factors Intervention functions Studies  
Automatic 
motivation 
Mood state / 
emotional 
disorder 
Education* 
Enablement 
Training  
Mohr et al., 2000 
Reflective 
motivation  
Beliefs about 
treatment  
 
Self-efficacy  
Education  
Enablement*  
Persuasion 
Training*  
Berger, Liang and 
Hudmon, 2005; 
Turner et al., 2014 
Psychological 
capability  
Cognitive 
functioning  
Education 
Enablement  
Environmental Restructuring*  
Persuasion*  
Training  
Berger, Liang and 
Hudmon, 2005; 
Turner et al., 
2014; Zettl et al., 
2016 
Physical 
opportunity  
Packaging 
characteristics 
of medicine  
Education* 
Enablement  
Persuasion*  
Training 
Berger, Liang and 
Hudmon, 2005; 
Turner et al., 
2014; Zettl et al., 
2016 
 
*denotes where the mapping does not align with recommendations from the BCW 
(Michie, Atkins and West, 2014).  
 
Mapping of intervention functions to intervention targets 
There was an almost even split between which functions and intervention 
targets aligned, as defined in recommendations from Michie and colleagues 
(2014) and which didn’t, as shown Table 8. Education met recommendations 
where it was aligned with reflective motivation and psychological capability; 
however, education was also included in interventions targeting automatic 
motivation and physical opportunity, which do not match the guidance. 
Enablement was congruent with recommendations as it aligned with automatic 
motivation, psychological capability and physical opportunity, however, it’s 
mapping to reflective motivation was not. Training was aligned to all four 
categories, with only its alignment to reflective motivation being incongruent 
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with the recommendations. Persuasion was mapped to three categories, one 
matched recommendations (reflective motivation) but two did not 
(psychological capability, physical opportunity). The remaining intervention 
function, environmental restructuring was only mapped to one COM-B 
category, psychological capability, but this does not align with 
recommendations from the BCW.   
Mapping of BCTs to intervention functions  
Whilst there was some discrepancy between the intervention functions and 
their category targets compared to recommendations from the BCW, specific 
BCTs were all congruent with the guidance with relation to the relevant 
intervention functions they align with (see Table 7). Though it is worth noting 
that whilst there is guidance, the range of BCTs aligned to each function within 
this guidance is very broad (Michie, Atkins and West, 2014).  
Mapping of BCTs to factors  
BCW guidance does not, at this time, directly align to BCTs to specific target 
factors, only to the intervention function level (above) which in turn can then 
be mapped to COM-B categories. To this end, the mappings described in this 
section cannot not be reviewed against recommendations in any greater detail 
than has already been described above,   
Mood state / emotional disorder  
As described above, the intervention from Mohr and colleagues (2000), whilst 
it measured adherence as an outcome, was primarily targeting mood state / 
emotional disorder in MS. A CBT approach was taken, adapted to address 
some specific factors associated with MS and / or living with a chronic 
condition that can impact mood. The specific BCTs it was possible to 
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determine from the intervention description were: Goal setting (behaviour and 
outcome), discrepancy between current behaviour and goal, action planning, 
review behavioural goals, framing / reframing, self-monitoring of behaviour, 
prompts / cues, social support (unspecified).  
Beliefs about treatment and self-efficacy  
Motivational interviewing techniques were used in both the interventions that 
sought to address beliefs about treatment and self-efficacy, both of which sit 
within the COM-B category of Motivation - reflective (Turner et al., 2014; 
Berger, Liang and Hudmon, 2005). BCTs that were used in both interventions 
were: instruction on how to perform the behaviour, information about health 
consequences, pros and cons and social support (unspecified). Berger and 
colleagues (2005) also included framing / reframing. Turner et al. (2004) 
included an additional nine BCTs: prompts / cues, self-monitoring of 
behaviour, action planning, problem solving, feedback on behaviour, salience 
of consequences, commitment and goal setting (behaviour and outcome). 
Cognitive functioning (forgetting)  
Two interventions sought to address forgetting through the use of 
prompts/cues, namely reminders delivered electronically (Zettl et al., 2016) or 
follow-up calls when potential non-adherence was evident (Turner et al., 
2004). Both interventions also included self-monitoring of behaviour and 
instruction on how to perform the behaviour. In addition, action planning, 
problem solving feedback on behaviour, information about health 
consequences, salience of consequences, commitment, goal setting 
(behaviour and outcome), discrepancy between current behaviour and goals, 
pros and cons and social support (unspecified) featured in the Turner et al. 
(2004) intervention.  
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Packaging characteristics of medicine (injection site pain) 
Three of the interventions offered support to reduce / manage injection site 
pain (Zettl et al., 2016; Turner et al., 2014; Berger, Liang and Hudmon, 2005). 
There was only one consistent BCT that featured in all of them which was 
instruction on how to perform the behaviour. Information about health 
consequences, social support (unspecified) and pros and cons featured in 
both the MI based interventions (Turner et al., 2014; Berger, Liang and 
Hudmon, 2005). As described above, prompts and cues and self-monitoring of 
behaviour were also features of the PDA intervention (Zettl et al., 2016) as 
well as Turner and colleagues (2014) MI based support. Action planning, 
problem solving, feedback on behaviour, salience of consequences, 
commitment, goal setting (behaviour and outcome) and discrepancy between 
current behaviour and goal were also included in the Turner and colleagues 
(2014) intervention. Framing / reframing was featured in one intervention 
targeting injection site pain (Berger, Liang and Hudmon, 2005).  
Mechanisms of action - link between positive impact on addressed factors and 
adherence outcomes   
As outlined in the BCW, successful behaviour change is more likely to occur 
when interventions are designed specifically to address identified facilitators or 
barriers to the desired behaviour (Michie, Atkins and West, 2014). With 
reference to factors appearing in the COM-B for adherence to DMTs in people 
with MS, only mood state / emotional disorder and self-efficacy were explicitly 
measured (Turner et al., 2014; Mohr et al., 2000), with a positive change only 
evident in mood state / emotional disorder. Mohr and colleagues did not 
explore whether there was a statistically measurable moderation or mediation 
effect of the factor on intervention outcomes.  
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Discussion   
The overarching aim of this two-part scoping review was to understand the 
level of congruence between research exploring factors related to adherence 
to DMTs in people with MS and behaviour change intervention research to 
address these factors. As it is widely acknowledged that adherence research 
methods, terminology and intervention design / implementation can be fairly 
heterogeneous (Michie, Atkins and West, 2014; Pound et al,, 2005; Vermiere 
et al., 2001) the findings were operationalised using the BCW to aid 
comparison across studies and to help explore the applicability of current 
models of health behaviours and adherence (i.e. SRM, COM-B for adherence) 
for people with MS.  
This discussion comprises the following sections: discussion of findings 
aligned to the research questions; reliability, rigour and trustworthiness of the 
data, review of methods and models applied; summary and implications for 
future research.  
Discussion of findings  
 
Factors influencing adherence to prescribed DMTs in people with MS  
During data extraction from the studies looking at reasons for non-adherence, 
sixty-nine discrete factors were identified across thirty-three studies. Twenty-
nine of these were reported more than once and could be grouped into five 
descriptive categories: clinical; demographic; opportunity; treatment; and 
psychosocial. This high number of discrete factors found across the studies 
supports the position of Vermeire and colleagues (2001) that much of the 
research into drivers of adherence is doing little to advance our knowledge, 
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despite the relatively high number of studies. They describe how over 200 
different factors have been studied, yet there is a definite lack of consistency 
in terms of predicting outcomes, partly due to reductive and inconsistent 
methodologies, but also, it is proposed, due to the ideology that frames 
adherence research in general (Vermeire et al., 2001). As described earlier, 
whilst efforts have been made to change the terminology relating to 
adherence research (from notions of passive compliance to healthcare 
professionals and systems, to language that is more conducive to shared 
decision making and the active role of the patient in their not only their 
healthcare behaviours but also what constitutes desirable, meaningful 
outcomes for them) it is proposed that research into adherence does not 
appear to have adapted to this change (i.e. shifted its ideology) (Pound et al., 
2005; Vermierre et al., 2001) other than to edit the terminology used. Findings 
from this review support this position as, whilst many researchers described 
their studies as exploring adherence (a term used to imply that a level of prior 
agreement has been reached between a patient and their healthcare 
provider), the majority of methodologies used fundamentally failed to seek to 
understand how involved the patient had been in treatment decision making 
processes. Furthermore, out of the thirty-three publications that were 
reviewed, only a small minority (n = 2) provided any opportunity for people 
with MS to provide their own reasons for not wishing to take treatment, and 
even these opportunities were limited to one or two open field responses 
within survey questionnaires. The rest of the factors were pre-determined, 
either through data that was available in clinical notes / databases or by the 
use of closed surveys and structured interviews. The relatively high number of 
factors that encompassed ‘unmodifiable’ clinical or demographic variables, 
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also suggests a lack of consideration of the lived experience of MS and the 
complex nature of self-regulation of health (Leventhal et al., 2016). Research 
such as this can be considered useful for highlighting people more ‘at risk’ of 
nonadherence but does little to help grow our understanding of cognitive and 
perceptual processes or any practical barriers that may be mediating these 
outcomes (Allemann et al., 2016). As these are the components which are 
potentially modifiable through appropriate intervention and support, it is 
possible to see how many of the current approaches to understanding non-
adherence in people with MS may not be cognizant with research that seeks 
to modify behavioural outcomes.  
The large number of study variables also suggest that much adherence 
research in MS has not been built on prior findings (as it would be 
hypothesised that this would reduce the number of variables over time) and 
therefore there has been apparently little advancement in understanding since 
the launch of DMTs in 1993.  
Operationalisation of MS adherence research factors to COM-B  
To aid comparison across studies, synthesis of results, and potential for future 
replication of findings, prevalent (appearing more than once) adherence 
factors were operationalised using the COM-B for adherence (Jackson et al., 
2014) as a reference point. When operationalised to the COM-B model of 
adherence, less that 50% of variables could be mapped. Those that couldn’t 
be mapped directly were primarily demographic and clinical factors 
(referencing the original data extraction categories), such relapse features, 
level of disability, age and gender. This also meant that there were ten factors 
from the COM-B model for adherence (Jackson, et al., 2014) that did not 
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appear in this research, across all category domains. These findings are 
discussed in line with COM-B categories below.  
Capability (psychological)  
One factor from the review mapped to psychological capability, forgetting, 
aligned with cognitive functioning. In their model, Jackson and colleagues 
(2014) actually exclude forgetting as a variant of cognitive functioning as they 
posit that there is more of an interplay between perceptions of treatment 
necessity (where not enough importance is placed on ‘remembering’) and 
forgetting than the category suggests. This is further supported by literature 
examining the interplay between intentional and unintentional adherence, 
which proposes that they are not two distinct domains but are often related to 
each other. In particular demonstrating a positive relationship between 
motivation to adhere and remembering to do so (Gadkari and McHorney, 
2012). An element of social desirability, whereby it can be perceived as more 
acceptable to say you have forgotten rather than admit to ‘not wanting to’ is 
also believed to undermine the validity of this factor (DiMatteo and DiNicola, 
1982). However due to the cognitive limitations that are often experienced as 
a direct result of MS I felt it was not only feasible but also important to include 
this as an explicit factor within Capability. In addition, the structure of COM-B 
acknowledges the interplay between categories, so this element is not lost 
from its inclusion as an explicit factor within cognitive functioning.   
Interestingly, considering the often significant impact on cognition and 
executive functioning of MS, there was not significant evidence from these 
studies of the role of diminished cognitive functioning on adherence. 
Increased disability did feature, but this appeared to be primarily related to 
physical decline rather than mental. As described earlier, reduced capacity 
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can not only increase chances of forgetting but can also impair ability to put 
plans in place to mitigate it. Furthermore, if we look at the proposed tenets of 
the process of self-regulation, whereby coping procedures are driven by 
cognitive process, such as memories, coherence and forming mental 
representation, then reduced cognitive capacity may not only be impacting 
adherence ‘directly’ but also through impeding the general processes of self-
regulation as well.   
Comprehension of disease and treatment, a factor included in the Jackson 
and colleagues (2014) model was not evident from this research, though it 
should be noted that this was rarely explicitly explored rather than being a 
‘negative’ finding. Whilst it is widely acknowledged that education alone is not 
enough to change behaviour (Haynes, 1996) it is recognised that having a 
core understanding of your illness and treatment is a fundamental 
underpinning to self-management (Moss-Morris et al., 2002), so as mentioned 
above, it’s omission is likely to be related to it not being examined, as 
opposed to it not being applicable to people with MS.  
Capability (physical)  
Through the direct mapping process, no factors appeared in this category as 
explicitly reported in the review studies. Due to the potentially comprehensive 
nature of physical limitations in MS, as with cognitive limitations, this was a 
surprising finding. The extent of findings relating to physical characteristics of 
medicine, such as oral preference and injection site pain mean that dexterity, 
as featured in the original COM-B for adherence is ‘likely’ to be factor 
influencing this, but the evidence does not explicitly support this. Increased 
level of disability did feature in the review findings and was therefore mapped 
to this category in the MS specific COM-B. Whilst this would certainly 
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encompass ‘physical capability to adapt to lifestyle change’ from the original 
model, the measures used in the studies were not explicit enough to bring this 
across. Instead, due to the variability of the measures used it features at a 
more holistic level, acknowledging the role of disease progression on general 
ability to self-manage.   
Motivation (reflective)  
Considering the wealth of research demonstrating not only the relevance of 
illness perceptions on adherence behaviours (Kucukarslan, 2012), but also 
their potential for modification to influence adherence outcomes (Broadbent et 
al., 2009; Petrie et al., 2002), it was surprising to see that illness perceptions 
did not feature. However, as with comprehension, they were not really 
explored in the research, despite being operationalised for quantitative 
research through measures such as the illness perception questionnaire (IPQ, 
Moss-Morris et al., 2002).  
Treatment perceptions, however, were evident from the review and treatment 
variables in general were extensively explored. Concerns (including side-
effects) and perceptions of efficacy were the two factors from the original 
model that could be mapped directly. Due to the quantitative nature of the 
research it is difficult to determine the extent to which the findings that 
mapped to concerns were experienced (e.g. adverse events) versus 
perceptual (e.g. long-term impact on body). However, evidence relating to the 
utility of the ‘Necessity-Concerns framework’ (Horne et al., 2013; Horne, 
Weinman and Hankins, 1999) in predicting adherence and the ‘logic’ of 
coming off treatment when experiencing adverse reactions suggest that it is 
likely a combination of both. Conversely, the other ‘side’ of the framework, 
necessity, did not explicitly feature in this research as a driver of adherence. 
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Berger and colleagues (2004) did explore ‘pros and cons’ of treatment, but 
conceptually it is difficult to confidently map this to necessity, as needing a 
treatment may not be perceived as a positive thing. Pros of treatment is more 
likely to incorporate perceptions of efficacy, which did feature as an explicit 
factor. Interestingly, whilst perceptions of efficacy were an apparent driver in 
this research, a closely related factor, outcome expectancies, was not. These 
are important to consider together as perception of efficacy is contingent on 
having appropriate expectations about what the treatment can do (Mohr et al., 
1996). This also relates to the comprehension of treatment from the capability 
category.  
Self-efficacy was another factor from the original model that was cognizant 
with findings from this review. Self-efficacy is a key tenet of chronic disease 
self-management research and support, built on a strong foundation of 
behavioural research into the role of confidence and the execution of health 
behaviours (Lorig et al., 1999; Bandura, 1982). Whilst self-efficacy is a 
discreet concept, it is seen as one of the underpinning ‘dynamic’ mechanisms 
within the SRM. So, as well as low self-efficacy being a ‘flag’ for potential risk 
of non-adherence, trying to understand in what way it influences behaviour 
(e.g. what skills do highly self-efficacious people employ? What prevents 
people from feeling confident to execute behaviours?) can also help to 
understand how best to address it (Leventhal, Phillips and Burns, 2016).  
Hope was an additional factor that mapped to this category, whereby a greater 
sense of hope for the future with MS resulted in better adherence outcomes. 
Hope is not a specific illness perception with the SRM but may tie into beliefs 
about future consequences and sense of personal control over the illness and 
has been shown to have a close association with both motivation and positive 
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coping, underpinned by mental representations of health (Lloyd et al., 2009; 
Maikranz et al., 2007). 
Finally, quality of life (QoL) was another factor that was added to reflective 
motivation based on the findings of the review. Frequently, quality of life is 
used as an outcome measure to determine illness impact as opposed to a 
driver of illness related behaviours (Rabin and de Charro, 2001). However, 
common QoL domains include physical functioning, social functioning and 
mood, so it is possible to see how this is potentially aligning with other 
variables within the COM-B model.  
Motivation (automatic)  
This review did demonstrate the role of mood state / emotional disorder on 
adherence. This is in line with research which has demonstrated that 
depression and low mood are consistent drivers of non-adherence (DiMatteo, 
Lepper and Croghan, 2000). Additionally, further research has shown that 
reducing emotional affect often translates into better self-management 
outcomes, including adherence (Lorig et al., 1999). With relation to self-
regulation, it is recognised that the emotional response to an illness threat will 
also influence coping procedures as well as cognitions (Moss-Morris et al., 
2002). Stimuli / cues for action did not feature as an explicit factor. 
Opportunity (physical)  
This was the most prevalent category in terms of number of individual factors 
and is likely related to the high number of studies that explored treatment 
variables. In particular studies sought to explore oral versus injection 
administration as a driver of adherence and this is evident from the number of 
factors sitting within the sub-category of ‘packaging characteristics of 
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medicine’. Injection-based treatments do have considerations that are not 
applicable in oral treatments, such as injection pain, injection site reactions, 
and greater inconvenience. As described earlier, in MS, some of these 
features are likely compounded by motor-function difficulties (Jopson and 
Moss-Morris, 2003) making self-injection more burdensome through dexterity 
issues, enhancing the likelihood of factors such as injection fatigue, anxiety 
and pain (from incorrect use). Whilst the majority of factors that were 
categorised in this review as treatment related could be mapped to the COM-
B model for adherence, the broad range of potential variables and as 
proposed by the general tenets of the COM-B model (Michie, Atkins and 
West, 2014) changing the treatment administration method may have an 
impact for some people but will not address other potential issues, in 
particular motivational factors that are not related to the treatment type. 
Interestingly, one study did demonstrate that it is possible to increase 
perceptions about the pros of treatment, leading to better adherence, without 
necessarily reducing perceptions about the cons (Berger, Liang and Hudmon, 
2004). Therefore, removing potential barriers (such as method of 
administration) may only be effective if the perceived benefits are strong 
enough to motivate treatment use in the first place. Dosing was another 
treatment factor that appeared across a number of studies, with 
overwhelmingly greater frequency of dosing leading to greater likelihood on 
non-adherence, though some studies simply referred to ‘inconvenient dosing’ 
rather than relative frequency. In general, the literature on impact of dosing is 
cognizant with this finding (e.g. Weeda et al., 2016) but as with administration 
features, reduction in dosing alone may not be enough to drive adherence for 
all people if other factors, such as perceived benefit, are not in place.    
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Other physical opportunity factors were, cost of treatment, physician support 
of treatment choice and caregiver support and congruence with choice. 
Considering the comparatively consistent evidence of the impact of the 
therapeutic relationship on acceptance of and adherence to treatment 
(Fuertes et al., 2015), this relationship was infrequently explored in the studies 
identified and the questionnaires focussed on physician support of the 
treatment as opposed to congruence between patient and doctor, 
communication or satisfaction with relationship. In terms of social support, 
practical elements, in particular administration of injections from ‘caregivers’ 
were prevalent, reinforcing the idea that increasing physical disability may 
impact adherence through dexterity issues. In addition, general caregiver 
support, in terms of agreement with treatment and the provision of general 
support was also evident, in line with other research in MS (Siegel, Turner and 
Haselkorn, 2008).  
Cost was also a factor from the original COM-B that featured in these studies. 
Cost, from a patient choice perspective, is market specific. It has been shown 
to be an important consideration both from a practical perspective in terms of 
real affordability and from a perceptual perspective in terms of relative value 
placed on medicines over and above other expenditure (Eaddy et al., 2012).  
Travelling was a factor that some patients referenced as a barrier to 
adherence but does not feature in the general adherence COM-B. As 
mentioned earlier, cognition problems may make putting alternative plans in 
place to mitigate risk factors or travelling (such as being away from their 
standard environment reducing cues for action) as well as the loss of stimuli 
directly increasing likelihood of non-adherence. Access (availability of 
medicine) did not feature as a discreet factor in this research.  
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Opportunity (social)  
There were no factors from this review that could be mapped to the category 
of social opportunity. Whilst social elements appeared in the form of the 
caregiver and HCP variables featured in physical opportunity, this category 
refers to the broader social ‘landscape’ that may influence behaviours or 
motivation. Specifically, within the COM-B model for adherence this includes 
‘stigma of disease, fear of disclosure’ and ‘religious / cultural beliefs’. As with 
many of these factors, it may be more related to the lack of exploration of 
these factors than it not being relevant to this population. The role of stigma to 
negatively influence adherence has been investigated and demonstrated 
across chronic conditions, in particular areas such as HIV (Katz et al., 2013) 
and mental illness (Corrigan, 2004) where the social stigma is seen as 
relatively pervasive in society. With relation to MS, stigma has been shown to 
negatively influence adjustment and acceptance (Dennison et al., 2010) and   
the use of injection-based treatments, particularly for adolescents has been 
shown to be perceived as stigmatising (Thannhauser, Mah and Metz, 2009). 
Similarly, there is a body of evidence relating to the impact of cultural and / or 
religious beliefs to self-management and adherence. This can be through its 
direct influence on perceptions of illness (Borras et al., 2007) or the impact 
that cultural structures have on availability of social support (Hatah et al., 
2015). Leventhal and colleagues state in their relatively recent paper that, 
“The relationship of social factors to the formation of prototypes of diseases 
and specific treatment procedures is an open area for study” (Leventhal, 
Phillips and Burns, 2016, pp. 941), supporting the assertion that this may be a 
relatively un-explored area in specific relation to impact on illness and 
treatment representations and self-management behaviours.     
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Factors from the review that could not be mapped to COM-B categories  
From the original data extraction, a range of factors could not be mapped, 
these were from the clinical and demographic categories. With regards to 
clinical features, such as number of relapses, it could be argued however that 
these will be part of the mechanism of action of the SRM as these are 
features of the threat itself. Symptom profile (including no. of relapses) is 
linked to illness identity beliefs (Moss-Morris et al., 2002) and may also reflect 
actual or perceived treatment efficacy (Horne and Weinman, 1999). An 
individual may perceive fewer relapses as evidence of treatment working and 
decide to continue taking it (Jopson and Moss-Morris, 2003). Conversely, they 
may perceive fewer relapses as evidence of an improvement in disease and 
decide that treatment is no longer required or choose to ‘experiment’ with 
dosage to see if it is still needed (Pound et al., 2005; Jopson and Moss-
Morris, 2003). When explored at this level, it is also possible to see why 
number of relapses garnered different results in different studies, in terms of 
direction of effect. As can be seen with just this example, there can be a range 
of individual, patient driven factors that change the ‘outcome’ behaviour 
following the same pre-curser clinical factor and it is the understanding of 
these that may be more conducive to focussing behaviour change 
interventions.   
 
The same ‘logic’ can be applied to demographic factors, such as gender and 
education level, which both showed mixed results. Being of ‘older’ age was a 
consistent finding across the studies. With a progressive condition such as 
MS, older age and a longer time since diagnosis will often be accompanied by 
a worsening of the condition (more relapses, greater disability), and as 
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described above, it can be posited that it is how the individual represents 
these changes cognitively that drives health related behaviours, including 
adherence to treatment. Of note is that there was no common definition of 
what age constituted ‘older’ – it was often reported as the direction of the 
range of age on a continuum. Where age categories were used, these varied 
across studies, restricting alignment. Therefore, the data in terms of who is at 
greater risk of non-adherence based on age is also not clear and it can be 
proposed, that it is also certain factors associated with older age, rather than 
age per se which is causing the ‘relationship’ to be found. An example is the 
risk of unintentional non-adherence through forgetting may become a greater 
risk when there is more disease progression, related to time with disease, 
having a negative impact on cognitive function.  
Relationships between factors  
As described above, in the context of adherence, COM-B is proposed to be a 
useful behavioural framework as it allows for consideration of both intentional 
drivers of non-adherence (e.g. illness and treatment perceptions as outlined in 
the SRM) and unintentional barriers, such as cognitive limitations or physical 
access to treatment. As well as allowing for both ‘types’ of behavioural 
facilitators / barriers to be considered, it also hypothesises the potential 
relationships between categories (Capability, Motivation, Opportunity), thereby 
recognising the dynamic nature of adherence behaviours, not only between 
individuals, but ‘within’ individuals as their experiences change over time. 
Whilst COM-B is designed to be theory agnostic (Michie, Atkins and West, 
2014), in relation to adherence, it is possible to see how the framework 
supports the ‘extrapolation’ of the different levels of perceptual, cognitive and 
behavioural processes proposed to be influencing health self-regulation as 
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described by Leventhal and colleagues (2016) and, crucially, further aid our 
understanding of the ‘why’ of non-adherence . For example, perceptions of 
treatment efficacy may directly influence motivation to adhere, but for one 
individual they may be best addressed through increasing psychological 
capability (i.e. knowledge and understanding) rather than directly trying to 
influence motivation by encouraging objective monitoring of treatment 
outcomes.  
Factors modified through intervention    
  
As described above, there were significantly fewer studies identified which 
focussed on adherence interventions, and even less that demonstrated a 
positive impact through the targeting of factors, identified in the first part of the 
review.   
  
Three of the interventions proposed to target psychosocial as well as 
treatment variables (Turner et al., 2014; Berger, Liang and Hudmon, 2005; 
Mohr et al., 2000) and all of the interventions examined at least one 
psychosocial outcome alongside adherence. All of those that stated an explicit 
focus on psychosocial variables used ‘therapy’ style interventions, drawing on 
either CBT or MI principles. The interesting thing to note about this style of 
intervention is that it is very individualised. Whilst they work within a 
framework, they can be flexible to the situation and reactions of the person 
receiving the intervention (Miller and Rose, 2009; White, 2001). Therefore, 
they are likely to be able to explore the incidental and mediating 
considerations to identify the why behind certain behaviours (Rothman, 2004) 
as well as eliciting personal values and offering practical support to boost 
motivation, confidence and ability, leading to the successful outcomes 
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demonstrated. These interventions also seek to promote the learning of a set 
of skills, which will support not only adherence behaviours but other self-
management requirements too.   
  
Whilst building on the same framework, the two MI based interventions were 
very different and it could be argued that the intervention by Turner and 
colleagues (2014) demonstrated the positive impact of reminders and follow-
up, rather than MI due to its design. In addition to initial MI sessions, 
participants were provided with a home monitoring device to record their 
adherence with. Whilst the reminder function was optional, if notification of 
treatment compliance was not received, participants received a follow-up call.  
It could be argued that this is still working as a reminder, simply after the fact.  
The follow-up calls were delivered by a study therapist trained in MI, however, 
there was no significant impact on the psychosocial factors posited to be 
influencing adherence, in particular self-efficacy, which is a key tenet of MI. In 
addition, there was no follow-up to explore the maintenance of adherence 
behaviour once the intervention was complete. This is in comparison to a 
study conducted looking at the impact of illness representations on adherence 
in asthma. They were able to demonstrate a positive impact on both beliefs 
and adherence through a tailored intervention targeting illness representations 
(Petrie et al., 2012). Both outcomes were maintained once the explicit 
intervention had stopped, suggesting that the targeting of underlying belief 
drivers can promote better self-management. This is in comparison to 
‘reminder’ style interventions that may help reduce forgetting whilst in place 
but fail to account for the interplay between forgetting and motivation (Gadkari 
and McHorney, 2012) and therefore demonstrate limited success in 
maintaining positive behaviours.   
	 101	  
  
In comparison, Berger and colleagues (2005) describe a more ‘traditional’ MI 
intervention that did not include reminders or monitoring and were able to 
demonstrate a positive impact on stage of readiness to stop treatment, 
treatment importance (necessity) and self-efficacy2, as well as the primary 
outcome of persistence. However, they did not examine persistence rates 
beyond the timeframe of the intervention either, so it is not possible to 
determine if these changes would persist post-intervention. An interesting 
finding from this study was that through a focus on individual pros and cons of 
treatment, they were able to demonstrate a significant increase in pros, but 
this was not matched by a significant decrease in cons. As stated earlier, this 
is an important observation because often the cons of treatment cannot be 
removed (e.g. injection site pain, side effects) or changing treatment is seen 
as a ‘quick fix’ but does not address alternative, ‘underlying’ issues.   
  
The CBT based intervention was the only one that measured, and therefore 
demonstrated, impact post-intervention (Mohr et al., 2000). It primarily sought 
to improve levels of depression, for which there is strong evidence for the use 
of CBT (Butler et al., 2006) and had demonstrated this at the end of the eight 
weeks of support. At four months, they were also able to demonstrate greater 
levels of persistence in the intervention group, compared to the wait control 
group. Whilst the relationship between the two outcomes was not explored 
statistically, the apparent impact on treatment behaviours from the reduction 
of emotional negative affect supports the findings not only of this review but 
                                            
2 The self-efficacy scores were not available in the publication, though the 
discussion states a positive impact on this factor.   
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also of previous research in this area (DiMatteo et al. 2000). However, as 
proposed above, it could also represent the benefit of providing individuals 
with the appropriate skills to manage the multiple demands of living with a 
chronic condition, allowing for positive outcomes in relation to a number of 
behaviours and outcomes.   
  
The single intervention that did not use a therapy style intervention 
demonstrated a moderate impact on dosing adherence with the use of a PDA 
plus reminder, compared to PDA without reminders.  However, these numbers 
were within the range of ‘comparable’ adherence data for people with MS, 
rather than demonstrating exceptional results (Zettl, et al., 2016). This 
intervention aimed to target treatment variables, such as injection site rotation, 
signposting to information on side effects, as well as providing reminders to 
one intervention group. There was no focus on psychosocial factors, and it 
demonstrated no impact on psychosocial outcomes, such as depression and 
quality of life. Neither did improved adherence translate into a reduced 
number of relapses.   
  
BCW and theoretical underpinning   
Behaviour change theories and models  
In line with recommendations regarding the development of complex 
interventions (Craig et al., 2008), three of these interventions referenced a 
behavioural model or theory. It is proposed that this is important to aid 
intervention design as it allows for the iterative development of them from prior 
theory and evidence synthesis, thus building on knowledge as opposed to 
simply doing what ‘seemed like a good idea at the time. Additionally, it starts 
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to take us towards an understanding of what the mechanisms of action may 
be within these theories and models that influence behaviour, as well being a 
way to empirically ‘test’ these theories (Michie, Atkins and West, 2014). In this 
review, only one study cited building on a previous ‘exploration’ of the model 
specifically for their population and behaviour (Berger, Liang and Hardmon, 
2005), whilst the other two relied on the weight of evidence relating to the 
intervention techniques themselves (CBT and MI), (Turner et al., 2014; Mohr 
et al., 2000).Whilst some of the studies from the first review utilised a theory 
base for their exploration of drivers of adherence (e.g. Fraser, Hadjimichael 
and Vollmer, 2003) many did not, and this may go some way to explain the 
wide range of factors found across the studies and the relative incongruence 
between the two parts of this review.      
Policy categories 
As these interventions were developed in the context of research, as opposed 
to broad intervention implementation (e.g. developing standards of care within 
an NHS setting), the policy mapping exercise had to be fairly broad and high 
level as, whilst studies referred to the potential applications of their findings, 
none went specifically into details of what would be needed to implement them 
further.   
Behaviour change techniques 
Across the four interventions, there were sixteen BCTs identified, though none 
of the studies explicitly referenced the taxonomy (however, due to publication 
dates, only Zettl et al. (2016) could have reasonably done so). Many of the 
BCTs were repeated across the studies and overwhelmingly the intervention 
descriptions were clear and detailed enough to be able to determine which 
BCTs were being applied. This was further enhanced by the fact that three of 
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the studies used a recognised intervention framework and theoretical basis 
from which standard techniques could be elicited, as discussed above. The 
prevalent BCT categories for the therapeutic interventions were: goals and 
planning, feedback and monitoring, natural consequences, comparison of 
outcomes and identity (Abraham and Michie, 2008). As described above, Zettl 
and colleagues (2016) did not attempt to address psychosocial factors, other 
than forgetting, and therefore the BCTs used were limited to feedback and 
monitoring and associations. All interventions included ‘additional’ features 
which intended to shape knowledge and, whilst increasing social support was 
only an explicit aim in one of the interventions (Mohr et al., 2000) by their 
nature all three of the therapeutic based ones may have had a positive impact 
on support perceptions through the use of call centre staff / therapists who 
regularly interacted with participants. 
   
Reliability, rigour and trustworthiness of the data  
 
Review 1 – Factors impacting adherence in people with MS  
Overwhelmingly, data was collected using structured surveys or via clinical / 
treatment databases. This meant that the majority of data collected was 
restricted to clinical, demographic and treatment factors that are available 
through such databases or that survey responses were limited to components 
determined by the a-priori aims and assumptions of the research, again often 
treatment or clinical in nature. As described above, these studies can be 
useful in determining certain ‘risk factors’ for non-adherence but are often 
restricted in the number of modifiable factors they produce (Allemann et al., 
2016) due to their restrictive nature in terms of what is available. These 
methods also restrict the likelihood of generating novel findings as, to some 
	 105	  
degree, it is data of convenience in terms of being relatively easy to access 
and analyse, compared to trying to collect data on a broader, perhaps more 
complex, range of factors.   
In addition, whilst clinical and prescription databases can be considered fairly 
robust sources of data, the use of secondary sources of data, as opposed to 
the collection of primary data specific to the study aims will generally carry 
more risk of non-reliability.  
The time span of the search meant that there were a number of studies that 
looked specifically at the impact, or potential impact, of the development of 
new oral therapies in a market that was previously restricted to injection and 
infusion delivery methods. Therefore, there is potentially a bias in the results 
towards treatment related factors, which were the most prolific category in the 
initial data extraction. Whilst undoubtedly a salient consideration in relation to 
adherence, the prevalence of a wider range of factors that appeared in studies 
that had ‘broader’ investigations demonstrates the risk of missing other 
considerations with such a narrow research focus. For example, Hupperts and 
colleagues (2014) demonstrated that even with a fairly limited number of 
survey response options about treatment, there were 5 variants that came out 
as important (injection anxiety, pain, side effects, fatigue, efficacy). This not 
only speaks to a level of complexity beyond the dichotomous proposition of 
‘oral versus injection’ but also shows the potential for variance between 
patients, based on their own experiences and treatment trajectories.   
The variations across the studies in terms of methodologies and what 
constitutes appropriate adherence, suggest that there is an opportunity to 
conduct a full systematic review and, if possible, a meta-analysis to help 
determine the relative ‘weight’ of the varied findings. This may help to narrow 
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down the findings, which as discussed above, are currently disparate and 
adding little value in terms of the focus for adherence-based interventions. 
Furthermore, as a number of the findings were inconsistent, it would be useful 
to follow the methods of similar review (Johnston et al., 2016) which explored 
the number of times factors had been studied and how often it showed both a 
positive and a negative correlation (e.g. non-findings) as this may help to 
mitigate the bias towards factors that appear more frequently due being 
measured more frequently.   
 
A lack of consistent terminology was evident across the studies, as was a lack 
of consistent definitions (e.g. what constitutes ‘older’ age) and there was hardly 
any evidence of the use of categories to help group different factors, beyond 
clinical and demographic. The implication of this finding is that current research 
into adherence in MS is not helping us to narrow down the potential factors for 
consideration because it is very difficult to draw confident comparisons across 
studies. This also supports the ‘aspirations’ of initiatives such as the BCW to 
provide a common language that can be applied to behavioural research so 
that findings can be compared and built upon (Michie, Atkins and West, 2014).   
Review 2 – MS adherence factors successfully targeted though intervention  
With exception of Zettl (2016) the interventions were tested against standard 
care, so this makes it difficult to narrow down which of the intervention 
elements were having an impact. This is particularly relevant for Turner and 
colleagues (2014) as whilst it used an MI methodology, as described above, 
this was supplemented by an intensive reminder intervention; following up 
each time adherence was not recorded. This design, plus the lack of impact 
on psychosocial outcomes, makes it unclear as to whether it was MI per se 
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that was having an impact, or the reminding, follow-up and general social 
support. As noted by the authors themselves, research that looks at the role of 
MI with and without home monitoring could help us to understand the ‘why’ of 
the successful intervention. Additionally, whilst it was possible to map the 
BCTs that featured in an intervention ‘as a whole’ there was no mapping 
process within the descriptions to state what different parts of an intervention 
were targeting in particular.  
  
As with the first part of the review, despite the relative small number of 
successful intervention studies identified, there was still a lack of consistency 
between them. Timeframes were different, making it difficult to understand 
temporal implications and only one study sought to understand the impact of 
the intervention post completion. As seen in the first part of the review, 
definitions of adherence varied between studies and were measured 
differently.   
  
Only one study described their adherence findings in the context of population 
level data. So, it was possible to determine the effect between their sample 
groups but not if these findings were comparable or ‘better’ than adherence 
rates in the general MS population. The one study that did do this, found their 
data to be comparable to population adherence, as opposed to better than.   
  
The use of a theoretical and intervention framework base was evident in the 
majority of the studies, making categorising the interventions with the BCT 
taxonomy possible. However, only one study attempted to explicitly describe 
how their intervention mapped to the theoretical approach. As a proposed 
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advantage of using a theoretical framework within an intervention is to ‘test’ 
the hypotheses of the framework, providing a more detailed link between the 
two components and presenting results in the context of what it means in 
terms of its theoretical basis could help to increase our understanding of the 
applicability of these theories and refine them in light of ‘real world’ 
experiences.    
 
It was not within the scope of this review to interrogate the rigour or validity of 
the research designs and / or fidelity of intervention delivery. To this end, 
caution must be applied in terms of the overall validity of these findings, 
particularly if considering the two parts of the review independently of each 
other (e.g. this thesis is not intended to provide a definitive answer on what 
drives adherence in MS, or how adherence in MS should be addressed, it is 
intended to understand the level of congruence between the two areas of 
research and what is already known about this phenomenon). To this end, as 
described above, there is definitely scope to conduct a systematic review and / 
or meta-analysis to try to reach a more concrete understanding of adherence 
drivers in MS.      
Review of methods and models applied  
 
Scoping review  
The purpose of a scoping review, as described earlier, is to allow for the rapid 
mapping of key concepts from a particular research area of interest. It can be 
useful as a starting point to understand gaps in knowledge that may then 
warrant more robust investigation, as opposed to a systematic interrogation of 
an issue, even though the methods themselves are still systematic in nature 
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(Arksey and O’Malley, 2005). To this end, the review methodology applied 
would still seem to be valid in the context of this research question and has 
helped to demonstrate the relative incongruence between the two areas 
studied. However, the amount of data from the first review was unexpected 
and with more data, comes a greater risk of error and misinterpretation, 
particularly as this review was conducted independently. As described above, 
this area in particular (drivers of non-adherence in people with MS) would 
benefit from a more rigorous examination of the data, in particular applying 
more restrictions to the type of studies included and the application of quality 
criteria to the studies. This would not only increase the trustworthiness of the 
findings of the first review in relation to its specific question but may also 
reduce the number of variables that are found.  
With regards to the second part of the review, factors modified through 
behavioural intervention, similar limitations apply, though the significantly 
reduced amount of data, not just in terms of number of studies but also in 
terms of what was reported, reduces the likelihood of data errors in terms of 
reported results.  
Additionally, non-impactful interventions were excluded due to the specific 
objectives of this review, but the size of the final sample of included 
interventions suggests that it would advance our understanding to know what 
is being targeted, how it is being targeted and what is NOT working, as these 
insights may also help inform design considerations for adherence 
interventions.  
This review did not explore the different settings of the interventions or 
consider the practical application in usual care. This is important, as ideally, 
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potential interventions should be able to be implemented alongside standard 
care to help ensure uptake and dissemination as widely as possible.    
Use of the BCW to synthesise findings  
The broad range of factors found in the first part of the review necessitated the 
grouping of these factors to aid description, even before they were 
operationalised through the COM-B model for adherence. Overall, I felt that 
utilising the COM-B categories made it possible to gain even further clarity on 
the findings, though this may have been helped by my familiarity with the 
model and the fact that I use it regularly to synthesise adherence research 
and guide behavioural intervention design. Therefore, whether the process 
would have been as ‘clarifying’ for someone not as familiar with the model, I 
cannot say.   
As I worked on this review independently, there was only a single analysis and 
labelling of the factors and intervention components which, whilst the 
descriptions were, overall, clear and reasonably detailed, this still required an 
element of interpretation to determine the exact BCTs employed, (e.g. which 
aspects of goal setting, which aspects of ‘mindfulness’) and to try to align 
factors from the review to categories and features already within the 
adherence COM-B. I have been trained to undertake intervention coding with 
the BCT taxonomy, but the lack of interrater reliability and the fact that the 
studies themselves did not use this terminology means that the mapping may 
not be wholly accurate – though I am confident that the methods employed 
were rigorous enough to be able to stand behind the overall ‘story’ of this 
review. In addition, the ‘pre-defined’ nature of the COM-B for adherence may 
have meant that associations were made due to an element of priming, that 
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may not have occurred if labelling was done independently from the model 
(e.g. only using category descriptions).  
The discrepancy between the factors found in this review and those proposed 
in the ‘original’ COM-B for adherence suggest that trying to define specific 
models for specific behaviours may be a challenge, particularly in areas 
subject to as many heterogenous population types as adherence. However, 
the categories within the COM-B do appear to have served their purpose in 
allowing for the consolidation and consideration of the different ‘types’ of 
factors to consider. For example, through the process of creating a COM-B 
specifically for adherence in MS, it was evident that all three areas (capability, 
motivation and opportunity) were having an influence and it also allowed for 
hypotheses to be drawn on the potential relationships between factors. 
Furthermore, it helped to define where the findings supported the use of the 
extended SRM as a model for understanding adherence behaviour and where 
they did not.   
As stated earlier, COM-B is designed to be theory agnostic, and even though 
the adherence version from Jackson and colleagues (2014) incorporated 
illness and treatment representations, by using it as a way to categorise and 
explore congruence, findings were able to be described ‘beyond the models’ 
but still in a meaningful way. For example, I feel that aligning novel factors 
such as hope and travelling to their relevant categories means that this 
research is building on previous insights – these factors don’t just become 
another thing on a ‘list’, they are contributing to the development of an MS 
specific version of a model that has been built on decades of behavioural 
research.    
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The inability to map ‘non-modifiable’ determinants of adherence, such as 
demographic factors, does potentially reduce its utilisation as a method of 
distilling a body of adherence research as a whole. Whilst it could be argued 
that if something cannot be changed it does not need to feature in a 
behavioural model, the fact remains, as evidenced by this review, that a lot of 
adherence research currently explores these categories of non-adherence. 
Furthermore, whilst we may not be able to modify them, they are still ‘telling 
us’ something about the population we are trying to understand and potentially 
support. As described by Allemann and colleagues (2016), at a time where 
healthcare resources are increasingly under pressure and the incidence of 
chronic conditions continues to rise, being able to determine which population 
‘types’ are more at risk may aid prioritisation of intervention focus and 
delivery, with behavioural factors then being utilised to understand what needs 
to be targeted within these populations.   
In this review, I feel that the policy and intervention function components of the 
BCW did not contribute in terms of helping to understand or categorise the 
interventions or assessing their potential effectiveness. In relation to policies, 
it seems that these elements are more for consideration for deployment of 
interventions, as opposed to being a way to categorise them, particularly 
when looking at interventions that have been delivered as ‘research’ rather 
than at the system level. With regards to intervention functions, it was not 
clear to me what insight these added over and above the BCTs themselves, 
particularly as the some of the mappings proposed in the guidance did not 
make ‘common sense’ to me. For example, providing a reminder service as 
per the PDA intervention (Zettl et al., 2016) constitutes ‘environmental 
restructure’ (changing the physical context) and yet it is not aligned in the 
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guidance to psychological capability, whereby prompts such as these may 
help to mitigate cognitive challenges. The BCW does not claim to be a fixed 
blueprint, so to this end, it may be reasonable to expect differences to be 
found, but as with trying to determine a specific COM-B for adherence ‘overall’ 
perhaps it is enough to have the common names and descriptions of 
intervention functions available to facilitate description, rather than becoming 
too reductive and trying to pre-determine all the relationships.  
However, I did feel that being able to describe the interventions utilising the 
BCT Taxonomy aided the review, as it facilitated exploration and description 
of the specific components being used within each one. For example, the 
intervention that defined their intervention as MI based (Berger, Liang and 
Hardmon, 2005) but, when looking at the specific pieces of the intervention, it 
was possible to determine that a large part of the intervention was actually 
utilising the BCT ‘prompts and cues’ by calling people when non-adherence 
was detected. This in no way undermines the intervention, but I feel that this 
process of trying to define each of the discreet components does help to 
minimise ‘assumptions’ being made about what is being delivered. Similarly, 
being able to group BCTs by categories allowed for distillation of findings into 
more generalisable hypothesis. Such as the prevalence of ‘goals and 
planning’ techniques across studies addressing treatment beliefs or the 
application of ‘shaping knowledge’ techniques to support reduction in injection 
site pain. As described above, being able to map specific BCTs to specific 
targets 1:1 was not possible due to the way the interventions were reported, 
they had to be considered as a whole. To this end it is also possible to see the 
value of utilising the BCT taxonomy to describe interventions, not only to aid 
transparency and the aggregation of knowledge across research, but also to 
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prompt more ‘thinking’ about how the intervention is hypothesised to work at 
this component level.        
Self-regulatory model  
The findings from this review went someway to supporting the SRM, though a 
key component of the model, namely illness representations were not evident 
from the factors review, in terms of determinants of adherence behaviours. 
Treatment representations, specifically concerns and efficacy beliefs, were 
included in the revised COM-B for adherence in MS and therefore support 
Leventhal and colleagues (2016) proposal that, for adherence behaviours, the 
model can be extended to include specific representations about treatment. It 
may also suggest that, for adherence, treatment representations play a 
greater role in determining behaviour. However, the limitations of the factors 
review in terms of the type of data that was explored, as described above, 
could also suggest that illness representations did not appear in the review as 
this data was not explored, either through relevant surveys, such as the Illness 
Perception Questionnaire (Moss-Morris et al., 2002) or qualitatively. Other 
factors that are proposed to support self-regulation, such as self-efficacy and 
social influences were also evident from the review. The application of self-
regulation theory to more general self-management behaviours in MS (Jopson 
and Moss-Morris, 2002) and the fact that it was not explicitly explored in the 
research that was reviewed would suggest that further, explicit, exploration of 
the theory, particularly illness representations warrants further investigation.   
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Congruence between the two areas of research  
In line with other reviews that have tried to match adherence determinants and 
intervention targets (Allemann et al., 2016; Johnston et al., 2016) the findings 
from this review suggest that there is currently a lack of cohesion between 
these two areas of research. Research seeking to understand the correlates 
between patient features and adherence behaviours is producing many 
insights that are unmodifiable and inconsistent. Whilst these can help us 
understand who may benefit more from an intervention, they do not add to our 
knowledge of how to support change, or our understanding of the reasons 
behind these findings. In contrast, the majority of the successful behaviour 
change interventions provided one to one, exploratory and skills-based 
interventions, with some demonstrating an impact on both behavioural 
outcomes and proposed modifiable drivers of behaviour.   
  
The paucity of data looking seeking to understand the patient perspective ‘in 
their own words’ has likely compounded the inconsistency of findings and 
limited the progression of our understanding. As proposed by Vermeire and 
colleagues (2001) and demonstrated by Pound et al., (2005) much is to be 
gained in terms of our understanding if we seek to gather insights into 
medicine taking behaviour from the perspective of those prescribed the 
treatment in a qualitative way. Adherence is just a single, albeit important, 
aspect of chronic disease self-management and occurs as part of a fluctuating 
and individual experience of the condition. Data that tells us ‘if someone is 
older they are more likely to be non-adherent’ does little to shed any light on 
the complex, and individual, perceptual, cognitive and behavioural factors that 
are leading to a decision or ability to adhere.   
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Summary and implications for future research   
  
This findings from this review suggest that our understanding of why people 
with MS are non-adherent requires a deeper and more complex exploration 
than has be attained by the work to date which has been largely reductive, 
quantitative and built on data that is pre-populated or convenient. The 
incongruence between research that explored the drivers of non-adherence 
and research that successfully targeted adherence related factors and 
positively influenced them, demonstrates that there is more to be understood 
about how these factors are working ‘behaviourally’ and their mechanisms of 
action.  
   
The large range of factors found in the first part of the scoping review also 
suggests that this area of research in particular could benefit from a 
systematic review and / or meta-analysis of factors to help reduce the number 
of variables and prioritise future research.  
 
The relative lack of qualitative study methods to explore adherence in MS to 
date, and the paucity of research building on theoretical models of behaviour 
in the first part of the review has likely contributed to the disconnect. It is 
proposed that a qualitative exploration will enhance our understanding, not 
only of the ‘why’ of correlations that have been previously found, but also help 
to elicit which aspects are susceptible to modification, thereby enhancing our 
ability to appropriately target interventions and, hopefully, increase their 
effectiveness.   
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Finally, the lack of findings relating to illness representations in particular 
suggest that this is also an area that has been underexplored and warrants 
further investigation.      
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Qualitative Research Study - Adherence in people with Multiple Sclerosis: 
perspectives of patients from Germany, Spain and the United Kingdom 
Introduction  
It was evident from the literature review conducted that there is a lack of 
qualitative research that has been conducted looking at the potential barriers 
to adherence in people with MS (PwMS). The majority of qualitative research 
in MS has explored other self-management behaviours, such exercise (Plow 
and Finlayson, 2014) and undertaking physiotherapy (Paul et al., 2014); or it 
has been used to better understand the impact of living with the condition 
(Galushko et al., 2014; Dennison et al., 2011; Johnson et al., 2004; Mohr et 
al., 1999). Lowden and colleagues (2014) conducted a phenomenological 
study to better understand the patient experience of making a treatment 
decision, but this was focussed on initial choice, rather than adherence 
behaviours per se (Lowden, Lee and Ritchie, 2014).   
Whilst the review conducted in the first part of this thesis provided some 
insight into potential drivers of nonadherence, as discussed, the design of the 
studies included meant that the majority of insights were generated from a-
priori assumptions or limited to the extent of retrospective data available. Even 
the minority of studies that sought direct feedback from the patients did so 
through pre-defined survey responses. Some of the findings are supported 
further through their mapping onto the COM-B model of adherence, which in 
turn is supported by work relating to illness perceptions and treatment beliefs 
(motivational components) discussed in the review, however, the relationship 
between change to these factors and adherence outcomes was not 
statistically explored to determine the extent to which changing these factors 
mediated adherence outcomes. Furthermore, there were a large number of 
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factors that only appeared once or produced conflicting responses. A 
quantitative methodology will, to some extent, ‘dismiss’ these findings. 
However, as the frequency of response was often related to how often it was 
examined, it is possible that some of these factors are of greater importance 
than the research suggests.  
The review also demonstrated that the majority of successful behaviour 
change interventions (albeit from a small sample) provided ‘skills based’ 
interventions, intended to support psychosocial as well as treatment factors 
that were modifiable. As per my review and the models utilised (SRM, COM-
B, BCW), I wanted to further explore the idea that adherence is a part of an 
individual’s overall coping strategy in terms of disease management 
(Leventhal et al., 2016; Brandes and Mullan, 2014) and that, due to its multi-
level nature, self-regulation will place adherence in the context of living with 
MS overall, rather than it being a discreet action. I also wanted to see the 
range of strategies and skills employed by people with MS to ‘manage well’ 
day to day and see how these aligned with behaviour change techniques 
identified from the review and / or suggested the value of additional support 
and intervention considerations.  
 
I felt that this offered an opportunity to build on insights generated from the 
review, explore further the applicability of the identified models for this 
population and to expand on the body of research that has already explored 
self-management challenges in people with MS.   
  
To this end I designed a qualitative study to explore the impact of perceptions 
and experiences on adherence in people with MS, within the context of 
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managing the condition overall. It is proposed that a qualitative exploration will 
help identify salient findings from the current body of research and allow for 
novel findings to be generated. In addition, the nature of exploratory research 
should allow for a greater understanding of the relationships and / or 
mechanisms of action between factors and behaviours through the provision 
of insights into the ‘logic’ of the participants.   
Sponsorship 
As well as contributing towards my Professional Doctorate, this piece of 
qualitative research was also used to support the design of a patient support 
programme for people prescribed two specific DMTs which would be 
sponsored by a pharmaceutical company. Therefore, this research was also 
sponsored by the company and they provided independent approval of the 
protocol and materials in line with European Healthcare Market Research 
Regulations (see ethical considerations and approvals section). This provided 
an opportunity to include participants from more than one country and utilise 
native speaking health psychology specialists in Germany and Spain. As well 
as embracing a broad sampling strategy it provided the opportunity to explore 
potential differences between / across cultures, which had also been lacking 
from the research found to date in my review.     
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Aims   
 
The aims of this research were to:  
• Understand the lived experience of MS and how it influences 
adherence.  
• Explore illness and treatment perceptions of people with MS in line with 
key tenets of the self-regulatory model  
• Investigate the drivers of and barriers to adherence and operationalise 
these utilising COM-B to compare to factors determined from the 
scoping review   
• Explore potential differences between countries (Germany, Spain, & 
the UK)  
 
Methodology   
 
Design   
Due to the exploratory nature of the research, a qualitative approach was 
chosen as opposed to a quantitative methodology. A qualitative approach 
allows the key issues to be explored in greater depth and offers a more flexible 
methodology, allowing for the research to adapt to findings and outcomes 
through the course of the study (Braun and Clarke, 2013). Whilst the research 
was ‘top down’ in that it was guided by an existing theoretical framework, 
namely the Self-Regulatory Model (SRM)  (Leventhal et al., 2016; Brandes and 
Mullan, 2014; Leventhal, Meyer and Nerenz, 1980) the relative paucity of 
qualitative data examining drivers of adherence in MS, means that there was 
justification in also seeking an opportunity to generate novel data, which would 
not be forthcoming from a purely quantitative data set (Braun and Clarke, 2013; 
Tolich and Davidson, 1999).   
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The aim of the qualitative research in this context was to gain detailed insights 
into the lived experience of healthcare and illness (Bishop and Yardley, 2007) 
and also the processes involved in health-related behaviours, in particular 
adherence to treatment. Therefore, a cross-sectional, semi-structured interview 
methodology was employed. This was to allow the research to be focussed on 
its primary aims without being too restrictive, giving the researcher an 
opportunity to explore and follow-up salient points. This meant that valuable 
new insights could be generated and the iterative development of the interview 
schedules to occur if applicable. This ‘sequential analysis’ allows for the 
exploration of ‘interesting’ data that are generated which are not included in the 
original research framework, thus increasing the potential richness of the data 
(Charmaz, 2002; Pope, Ziebland and Mays, 2000).   
One-to-one interviews were chosen to allow for the detailed insights into 
individual perspectives and experiences to be obtained. In addition, as the topic 
of their illness is potentially sensitive and previous research indicated very 
individualised trajectories and experiences, it was believed that one-to-one 
interviews would encourage more open responses and allow for ‘minority 
responses’ that may not come out in a patient focus group (Bishop and Yardley, 
2007).   
Framework Analysis was selected to explore and analyse the data (Ritchie et 
al., 2013). Framework analysis is a form of thematic analysis, lending itself to 
the exploration of experiences and factors influencing behaviour (Braun and 
Clarke, 2013). It is drawn from sociological research processes (Bloor, 1978) 
and has been widely used in an applied healthcare setting (Taylor-Robinson 
et al., 2008; Ritchie and Spencer, 2002). Its ‘systematic’ nature lends itself to 
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answering questions related to healthcare system design and allows the 
analysis and findings to be viewed by audiences outside of academia (Ritchie 
and Spencer, 2002). Increasingly it has been used within health psychology to 
help understand experiences, illness representations and explore theoretical 
hypotheses (Bower et al., 2012; Elliott, Fischer and Rennie, 1999) making it 
particularly relevant for this research. The method has also been used to 
explore reasons for non-adherence to medication in other patient groups   
(Thorneloe et al., 2016; Lacey, Cate and Broadway, 2009). It was selected as, 
in line with the semi-structured interview approach to collect the data, it is both 
inductive and deductive in its approach, allowing analysis to be guided by 
explicit a priori aims (i.e., the SRM) as well as permitting concepts to be 
derived independently from the data (Pope, Ziebland and Mays, 2000). This is 
in contrast to methods such as Grounded Theory, or Interpretive 
Phenomenological Analysis (IPA) that are overwhelmingly inductive (Braun 
and Clarke, 2013). Neither was Discourse Analysis (DA) deemed appropriate 
as this would have provided insights into the language used by participants 
and how this shapes their reality but was unlikely to yield ‘practical’ insights 
relating to the overarching aims of the research (Braun and Clarke, 2013; 
Ritchie et al., 2013). Finally, it was felt that this method was particularly useful 
for working across a data set that had been generated by a team of 
interviewers as the use of a matrix (participants in rows, themes / concepts in 
columns) helps to keep the data in context whilst still allowing for cross case 
and cross theme analysis (Ritchie et al., 2013).  
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Participants   
Purposeful sampling (Patton, 2014) was used to identify and recruit from across 
the three countries people with a diagnosis of MS, prescribed a DMT, who had 
a range of demographic and clinical characteristics (e.g. age, gender, levels of 
disability) and varied experiences relating to the objectives of the research (e.g. 
time since diagnosis, symptom experience) to help make the research as 
inclusive as possible and to explore potential temporal effects of both disease 
and treatment.     
This sample size was selected in line with recommendations relating to the 
type of research question (experience / influencing factors), the data collection 
method (interviews) and analysis method (thematic analysis; framework).  In 
relation to this combination of factors it is recommended that a sample size of 
6-10 is sufficient to be able to capture a range of perspectives (Braun and 
Clarke, 2013). Eight participants were sought for each country. This was to 
allow for both country specific data to be compared as discrete sets whilst still 
having a ‘manageable’ whole data set (n=24).    
Methods 
 
Recruitment strategy and procedure   
Patients were recruited through specialised market research agencies in each 
country utilising their MS research panel members. I provided multiple 
agencies with the sample criteria and a top-level overview of the research 
protocol to enable them to furnish me with quotes and timeframes for 
recruitment. Three agencies were selected (1 per country) based on cost and 
time to recruit.   
I created the necessary recruitment documentation in English (screening 
questionnaire, patient confirmation email / letter, research information sheet 
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and consent form – see appendix iii) and these were then translated into 
German and Spanish by the German and Spanish health psychologists 
working on the project. These documents were supplied to the chosen 
recruitment agencies in each country.   
Agencies performed the initial screening, utilising existing research panel 
members and performing pro-active recruitment where required to meet 
sample requirements. Once suitable participants were identified, the agency 
was tasked with sending the patient a confirmation email or letter which also 
included a copy of the research information sheet and consent form. The 
agency was tasked with collecting initial consent to take part. Once the 
participants returned the consent forms, the agency liaised with them, myself 
and the other two interviewers to determine suitable times for the interview to 
take place. Contact details were provided to me and the German and Spanish 
interviewers which included the participant's name and telephone number. As 
project lead, I was forwarded all the consent forms for audit purposes.    
The other interviewers and I called participants at the agreed time. If the 
participant responded, we would check that it was still an appropriate time and 
either proceed, rearrange or terminate as appropriate. If proceeding, the 
interviewer would check understanding of the research and reiterate the 
components of the consent, namely sponsorship, data privacy and the right to 
withdraw at any point. Verbal consent was also taken to record the 
conversation. If there was no response, the interviewer would try a maximum 
of three times in the 15-minute period directly following the arranged time of 
the call. If there was still no response, the interviewer would notify the market 
research agency for them to manage the rearrangement of the interview.      
	 126	  
Participants were remunerated £50 / €50 dependent on country in line with 
European Healthcare Market Research regulations and this was handled by 
the recruitment agency.     
Ethical considerations and approval   
 
Within the pharmaceutical industry, patient qualitative research falls under the 
auspices of the European Pharmaceutical Marketing Research  
Association (EphMRA) in relation to the appropriateness of the research itself 
and the European Medicines Agency (EMA) with regards to the reporting of 
adverse events. Pharmaceutical companies will use the guidance from these 
regulatory bodies to inform their own approval processes. The procedure 
undertaken for this study is outline below.  
Study and materials review and approval  
The research protocol and interview guide were all approved via a system 
called ‘Zinc Maps’. Zinc Maps is a web-based application designed to 
accommodate materials requiring multi-stakeholder approval. It is used 
comprehensively in the pharmaceutical industry and provides a repository for 
any materials that require approval and a chain of evidence of who has 
approved what, when. For the purpose of this research the sponsoring 
company are the owners of the Zinc process and all the materials within. I was 
the person who had overall responsibility for the origination of all the English 
versions of the documents, research design etc. and ensuring that the 
research project was conducted in line with the approved protocol.  
In this instance the research protocol and interview guide were reviewed and 
approved firstly at a regional level, to ensure consistency and applicability with 
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European Healthcare Market Research regulations. Materials (e.g. interview 
guide, consent forms etc.) were then approved at a local level where 
required to ensure consistency and applicability with UK / German / Spanish 
pharmaceutical market research regulations as appropriate. This differed 
between countries as the regional approval was sufficient to cover the 
research in all countries, but some markets required / chose to go through a 
process of local approval as well. 
Roles that would have been involved in review and approval include; legal, 
regulatory, medical and pharmacovigilance teams – these teams operate 
separately to the patient services team who sponsored the research. In this 
way the Zinc process can been seen as the equivalent of an ‘independent’ 
review panel within the pharmaceutical company, as you would have within a 
University structure.  
The following is a list of the approved documents by country. Approved 
versions are in the appendices and the approval stamp is either on the first 
page of the document and / or in the footer.   
Research protocol  
This was reviewed and approved at a regional level (as evidenced by the 
EMEA (Europe, Middle East and Asia) stamp) because the regional patient 
services team were the primary sponsors of the research overall. This is 
available for review in appendix iv.  
Research interview guides  
• Spanish and German versions were informally reviewed at a local level 
but these markets chose to cascade from the EMEA level formal 
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approval (EMEA MS Research Interview Guide, appendix v) as there 
were no significant changes made.    
• The UK did an additional formal local approval of the regional version 
(UK MS Research Interview Guide, appendix vi), as evidenced by the 
additional footer with a UK reference, this was because they used a 
different (local) SOP (standard operating procedure) for adverse event 
reporting 
Supporting research materials 
• Only the UK opted for formal Zinc approval of the additional research 
materials (UK MS Research Supporting Materials appendix iii) – this is 
evidenced by the footer with a UK reference. 
 
Minor amends were made based on specific regulations (e.g. Spain could not 
collect data on medicine history, only current treatments, whereas England 
and Germany could) but it was felt that none of these amends changed the 
study conditions such that they would have a detrimental impact on the study 
or unduly influence the findings.   
University of the West of England (UWE) ethics approval  
Evidence of the independent approval of this research (as outlined above) was 
supplied to the UWE ethics board as they did not review a proposal for this 
research before it was undertaken. This was following a request from the 
examiners during the viva for this thesis submission, and to ensure that the 
review board were satisfied with the approval process that had occurred and 
that the research was suitable for inclusion in the UWE research repository. 
The Chair of HAS Faculty Research Ethics committee (FREC) reviewed the 
process and the supporting materials (appendices iii – vi). She stated that they 
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were not able to provide retrospective approval as it should have gone through 
the formal FREC system but that there was clear evidence of review and that 
ethical principles had been adhered to. A copy of this email is included as 
appendix vii. Under advisement of the graduate school and my supervisor I 
proceeded with this submission on the basis of this feedback.  
Informed consent  
As described in the procedures above, participants were required to give 
informed consent prior to taking part in this research; it was obtained in writing 
prior to the interview and confirmed again verbally over the telephone before 
commencing the interview questions. Participants received a consent form 
and information sheet alongside their formal research invitation (email or hard 
copy letter). The information sheet outlined the aims and procedures of the 
research, the type of information to be collected and to outline confidentiality 
and data protection procedures. They were informed that participation was 
completely voluntary and that they had the right to withdraw at any time 
without giving a reason or justification. They were also provided contact 
details (of the recruitment agency) in the event of any questions prior to or 
after the research interviews.  
Calls were not scheduled until a signed consent was received (either by post, 
fax, or email scanned copy). At the start of each telephone call the researcher 
reiterated the important, salient information as described above, including 
specific examples, and gave the participant opportunity to ask questions.  
The ability to give informed consent requires a sufficient level of mental and 
cognitive ability in order to understand what is involved in the research. Whilst 
MS can impair cognitive functioning, as a whole, the population are not 
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considered mentally impaired by proxy of having MS. The recruitment agency, 
who are specialists in recruiting patients with chronic illness for the purposes 
of research, had the initial responsibility to screen out individuals who had 
impairments in understanding or communication that might affect their ability 
to give informed consent or sufficiently engage with the research process (e.g. 
patients with severe or profound intellectual disability or some people 
experiencing mental illness). However, each interviewer was also responsible 
for checking an individual’s ability to give informed consent at the start of each 
interview.     
It is worth noting at this stage that, within the remit of the guidance, research 
such as this can be blinded to participants and this is often preferable to 
reduce the likelihood of research being seen as promotion of the company or 
inducement to seek out a particular treatment. Guidance states that it should 
be made clear that research is being supported by a pharmaceutical company 
but not which one. However, if a participant asks to know the identity of the 
company then it must be disclosed and if an adverse event is reported then 
the company will also be declared as this information will need to be shared 
directly with them (EphMRA, 2016). To this end, this research was blinded in 
this way and the company only revealed during adverse event data capture or 
if asked directly by a participant.      
Participant confidentiality and data protection  
Different parties involved had knowledge of the identity of the participants 
commensurate but limited to what was required to perform their roles within 
the research. The recruitment agency held the most personal identifiable data 
as they were responsible for contacting and sharing materials and 
reimbursement with participants, to this end they had email / telephone / 
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address details as well as names. The Spanish and German interviewers and 
I were provided with first names and contact telephone numbers only in order 
to be able to conduct the interviews. I received copies of all the signed 
consent forms which contained participants full names and signatures.  
During the data collection, each participant was allocated a unique participant 
ID number which correspond to computer files, audio recordings and 
transcripts. This coding system was used when sending audio files for 
transcription and translation meaning that the transcription company only had 
names as per the audio recording. As part of the transcription service participant 
names were then removed from the transcripts themselves as they were not 
required to perform analysis.  
 
Electronic interview transcripts were all sent to the relevant local Atlantis 
Healthcare offices for initial quality review by the relevant person who 
conducted the interviews. Translated transcripts (into English from German and 
Spanish) were then electronically shared with myself for analysis. Any hard 
copy materials were kept in a locked cupboard in a lockable room accessible 
by the research team only. Electronic data and audio recordings were kept on 
a secure server in password protected files. All data will be kept for 10 years in 
accordance with the Data Protection Act (1998) and is subject to regulatory 
audit.  
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In the case of adverse event reporting (see separate section), participants were 
specifically asked if they would like to waive their anonymity. 
 
Data has been reported in an aggregated form to protect anonymity and 
confidentiality. Where direct quotes are used, information that could be deemed 
identifiable (e.g. names, specific locations) has been removed.   
 
Potential risk to participants  
The overall risk to people participating in this research study was considered to 
be low. The likelihood of physical risk was very low as there were no tasks or 
physical requirements to the research. Participants were however asked for 
demographic information (age, gender) and self-reported social and emotional 
wellbeing with particular reference to their condition. These questions may be 
perceived as sensitive to some people and could evoke an emotional reaction. 
For this reason, there was a small likelihood of psychological risk as a result of 
reflecting on their condition and overall well-being. To this end, participants 
were advised at the end of each interview that, if they were experiencing any 
‘adverse’ feelings following the interview that they may want to consider talking 
to someone appropriate. The guidance included in the interview scripts was as 
follows:   
Just before we go, I wanted to say that we understand it can be quite tiring to 
talk about these types of things in depth, so don’t be surprised if you feel a 
little tired, or you find yourself thinking about some of the things that we have 
talked about. If you do feel as if you would like to talk about anything that we 
have discussed more, it can be a good idea to talk to someone with some 
expertise in this area – perhaps your GP or a member of the team at your 
hospital / clinic  
 
	 133	  
No one reported any adverse psychological effects from the interviews to the 
interviewers or recruitment teams.    
 
Adverse event training and reporting  
Pharmacovigilance refers to the science and activities that support detection, 
understanding, assessment and prevention of adverse effects or any other 
medicine related problem. The European Medicines Agency (EMA) 
coordinates the European Union (EU) pharmacovigilance system and 
supporting services and processes to support this system. As evidence for 
medicines safety is limited to clinical trial populations prior to authorisation, it 
is deemed essential that the safety of all medicines continues to be monitored 
throughout its use in healthcare practice (EMA, 2016). To this end, as this 
research was sponsored by a pharmaceutical agency and it was possible that 
people involved were currently or previously prescribed medicines produced 
by the sponsoring company, it was necessary for the research team to 
undertake adverse event training provided by the pharmaceutical company 
and to record and report any adverse events in accordance with the 
company’s adverse event reporting adverse event reporting standard 
operating procedure (SOP). A copy of the SOP is not available as the 
sponsoring company would not agree for this to be shared but the text used in 
the event of needing to report an adverse event is included in the approved 
protocol (appendix iv).     
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Materials and equipment  
Interview schedule   
The interview schedule was based on the key aims of the research outlined 
above, drawing on the SRM framework. As with the recruitment material, I 
created the master interview schedule in English for subsequent translation. 
To meet the research objectives, I felt it was important to get the balance 
between deductive and inductive questioning. As seen in the review I 
undertook and as posited by other researchers (Pound et al., 2005; Vermeire 
et al., 2001) deductive methods have done little to enhance our understanding 
in terms of the most salient and modifiable drivers of adherence behaviour. 
However, this does not mean previous research is not of value, and that 
theories and models which have shown relevance in other areas will not apply 
to people with MS. Therefore, I designed the research questions and prompts 
to help gain both a deeper understanding of what is already hypothesised and 
what ‘holds true’ as well as giving opportunity for people with MS to provide 
novel insights and perspectives. The Illness Perception Questionnaire is a 
common method of operationalising the mental representations of the self- 
regulatory model  (Jopson and Moss-Morris, 2003; Moss-Morris et al., 2002) 
and I used this as a basis for creating the questions and prompts to explore 
beliefs related to the cause of the illness, its nature or identity, its duration, the 
personal consequences of suffering from it and the extent to which the illness 
can be controlled or cured  (Broadbent et al., 2006; Leventhal, Meyer and 
Nerenz, 1980). In addition, as a recent review has demonstrated the utlity of 
the Necessity-Concerns framework to determine adherence behaviours 
across condition and its ‘natural’ extension of the SRM, questions were 
included to explore beliefs related to treatment necessity and concerns, as 
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outlined by in the Beliefs about Medicines Questionnaire (Horne, Weinman 
and Hankins, 1999).   
 
As previously indicated, I wanted to ensure that there was also opportunity for 
novel data to be put forward by the participants, this necessitated the use of 
open questions and prompts, rather than closed, survey-based interviews 
which are the key features of much of the research done previously in this 
area. This meant that the structure and aims became a starting point for 
discussion, rather than a restriction. The structure of the schedule followed a 
pattern of broad starting questions (sometimes referred to as “leading-in” 
(Arthur and Nazroo, 2003)) to put the interviewee at ease and to start to focus 
attention towards their experiences of MS, followed by narrower, more specific 
topics to help meet the research objectives and completing with a broad 
“leading-out” question to provide an opportunity for the participant to talk 
about any related issues not yet covered or remembered after the fact (Kvale 
and Brinkman, 2009; Arthur and Nazroo, 2003).  
 
The key topics of the schedule and a brief rationale for their inclusion are 
listed below; a copy of the full schedule is available (see appendix v).  
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Broad - Leading in   
• Experience with MS   
o Diagnosis, day to day impact, symptoms, future, control, 
understanding [draws on key questions and domains of the IPQ]  
• Experience with treatment 
o Understanding, efficacy, control, necessity, concerns, side 
effects, types [draws on key questions and domains of the IPQ 
and the BMQ, as well as exploring potential differences between 
treatment types as was found in the review]  
Specific  
• Levels of adherence and persistence (current, prior) [to compare and 
understand perceptions and general self-management strategies 
between people with differing levels of adherence and to try to get to 
the ‘why’ of the differences in behavioural outcomes]    
• Medicine management / regimen [to investigate the findings from the 
review regarding treatment type and the impact on adherence]   
• Self-efficacy to manage treatment [to investigate the findings from the 
review that self-efficacy is an important driver to adherence and to 
understand what helps people with MS to feel confident about 
managing their condition and treatment]   
• Reasons for adherence / non-adherence / treatment changes [to build 
on the current research by providing an opportunity to patients to 
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describe in their own words the ‘logic’ behind their treatment-based 
decisions]   
• Self-management strategies - living day to day with MS [to investigate 
how adherence fits in with general coping strategies].   
• Therapeutic relationship with HCP [Many of the interventions did offer 
a form of therapeutic relationship, so I wanted to see how important 
this was for people with MS and how it impacted their behaviours] 
• Social support [To explore the relevance of this to self-management in 
line with COM-B]  
Broad - Leading out  
• Thinking about the things we have discussed, is there anything else 
that you think is important to consider?  
Suitability and evolution of the interview guide 
Guidance for qualitative research suggests that, where possible, interview 
guides are piloted to test its suitability and efficacy (e.g. is it garnering the type 
of data you expect, do people seem able / willing to answer the questions) 
(Braun and Clarke, 2013). However, it is acknowledged that in many cases, 
formal piloting is not practical or possible, which was the case with this 
research. To this end, they recommend reviewing the guide after the first few 
interviews to determine if any changes do need to be made (Braun and 
Clarke, 2013).  
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I arranged for the interview guide to be reviewed after one interview had been 
conducted in each country to assess the suitability of the schedule in terms of 
content, relevance, clarity, tone and length and to uncover any country 
specific considerations or general amends that were needed. Following this 
discussion it was evident that there were no country specific differences 
required and the overall schedule was fit for purpose. However, it was 
apparent that some of the prompts required a more positive framing to try to 
elicit good experiences as well as struggles. For example, we decided that 
prompts such as “What was your experience of being told you had multiple 
sclerosis?” and “Tell me about your treatment experience with MS?” would 
benefit from having an associated follow-on prompt of “Can you describe if 
there was anything positive that came from these experiences” where 
responses were felt to be negatively focused. Similarly, for the question 
“Would you feel comfortable talking to your HCP about problems or concerns 
you had relating to your treatment?” we felt it was important to consider a 
follow-on prompt relating to discussing positive treatment experiences with 
their HCP. These additional prompts did not change the overall structure of 
the guide or impact any of the leading questions, therefore formal 
amendments to, and re-approval of the guide were not required.   
Furthermore, as the schedule was intended to be a guide, rather than to be 
completed verbatim, all interviewers were able to make minor additions and 
amends throughout the process of interviews to reflect growing understand of 
the population and to ‘test’ novel data that was being generated, in line with 
the tenets of an iterative, qualitative research process (Charmaz, 2002). For 
example, as I began to notice people talking about how guilty they felt in 
relation to needing the support of friends and family, or having to prioritise 
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their needs over others, I would then explore in subsequent interviews how 
people felt about asking for or receiving support when they stated that this 
was something which happened. Again, these did not result in formal 
amendments to the guides but were considered a ‘natural’ part of the process 
to be acknowledged. Figure 6 shows the timeline for the data collection phase 
of this research.  
Figure 6 – Timeline for data collection and review of interview guide  
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Recording, transcription and translation   
All interviews were conducted via an in-house telephone system that 
automatically records all calls. The recordings were extracted as individual 
audio files, based on time of call and phone extension used. Each interview 
lasted between 40 and 60 minutes. Direct transcriptions of each audio file were 
made by an external transcription service based in the US, with the German 
and Spanish transcripts also being translated into English by the same agency. 
All transcripts were returned to the respective interviewers (German and 
Spanish interviewers were also fluent in English) to check a sample for 
consistency against recordings.  They were then all sent to me as the research 
lead for analysis.  
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NVivo   
Data were analysed using NVivo 10 Pro for Windows (QSR International).   
Analysis   
Framework Analysis   
Framework analysis is built around the tenet of what Bloor describes as 
‘Analytic Induction’ (Bloor, 1978). This is whereby hypotheses are derived 
from a set of cases and further cases are then used to continue to test this as 
appropriate.    
Process of analysis   
Ritchie and colleagues (2013) describe 5 stages to Framework analysis: 
familiarisation; identification / creation of a framework; indexing; charting 
summaries; and mapping / interpretation. These, as well as general 
recommendations for thematic analysis (Braun and Clarke, 2013; Braun and 
Clarke, 2006) were used as guidance for the data analysis.  
Familiarisation  
The aim of this first stage, familiarisation, is to get to know the data, both in 
terms of the individual interviews themselves and also the overall ‘sense’ from 
the data, often referred to as immersion and is a key starting point for many 
types of qualitative research (Braun and Clarke, 2013; Ritchie et al., 2013). To 
do this, I read all the transcripts on average between 3-5 times at this stage 
(depending on the depth of detail within the scripts and my prior level of 
familiarisation, for example interviews I had conducted myself versus German 
and Spanish ones). I made notes on key observations, in terms of things that 
were ‘interesting’, both from individual transcripts but also across the data set. 
Braun and Clarke (2013) refer to these observations as ‘noticings’. Some 
initial noticings included an apparent dichotomy between people who had 
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adjusted reasonably well and those who were struggling (or had struggled in 
the past), and the differences between the attitudes and experiences. For 
example, level of focus on the condition, support network and social 
experiences. The different manifestations of guilt, which remained a discreet 
theme until the end of the analysis, were particularly apparent at this stage as 
well, though not the extent to which it could be mechanism for action.       
Framework development, indexing / coding and summaries of cases  
As this was a qualitative study that was based on a theoretical underpinning, 
the starting framework was based on the key sections of interview schedule, as 
these represented key tenets of the theoretical models and findings from the 
review that were being explored further. Potential additional categories from the 
familiarisation phase were also added initially. On the whole these were sub-
components of interview schedule categories, for example splitting MS 
Experiences into diagnosis / early stages and current / on-going. It was then an 
iterative process between indexing and coding the transcripts into NVivo as 
participant cases according to the framework but also allowing for any additional 
categories that did not have a ‘home’.  
The final overarching categories were:  
• MS Experience – Diagnosis / Early Stages  
• MS Experience – Current / On-going  
• MS Experience – Future  
• Illness Perceptions  
• Treatment Experience – Past  
• Treatment Experience – Current  
• Treatment Beliefs and Comprehension  
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• Adherence – Extent of  
• Adherence – Drivers of  
• Self-efficacy  
• Self-management  
• Experiences with healthcare system / teams  
• Social support – managing disease / treatment   
• Social experiences (e.g. stigma, work)  
There was also a placeholder of ‘other’ for sections of the script that did not fit, 
primarily consisting of interactions between the interviewer and the interviewee 
that were ‘outside’ of the core topics. However, this category was still reviewed 
during the coding phase to ensure there were no topics / themes or influencing 
factors that would not have been included in the main framework categories.  
At this stage, some transcript sections would appear in multiple categories, in 
particular where sections highlighted the links between categories – such as 
drivers of adherence and illness perceptions, or self-management and level 
social support.  
During the indexing process, data were coded both semantically (e.g. the 
explicit content of the data) and then latent codes were applied (e.g. the implicit 
meaning from the data derived from a theoretical concept, such as illness 
identity, and / or my own concept of the data). This allowed for knowledge to be 
gained from the explicit data to help understand the overt relationships between 
beliefs, experiences and behaviours and also for the data to be synthesised and 
interpreted as a total dataset to test and produce population level hypotheses. 
Indexing at this stage also included the creation of supporting descriptions of 
how the data informed a category or case level summary. Data coding 
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examples (extracted from NVivo into Excel) from the overarching framework 
are in appendix viii.     
Once this coding had been completed, I explored the data again according to 
the framework structure and by individual codes. This part of the process helped 
me to create the ‘story’ of each element by looking at these sections as cases 
in their own right and testing the concepts across the data. Two examples of 
this are in appendix ix.  
 
Interpretation  
This stage represented the opportunity to take the ‘top down’ data as provided 
by the framework, and to move beyond managing it to understanding it as a 
whole data set (Ritchie et al., 2013). At this stage, latent coding in particular 
proved to be a key reference point to ‘bringing’ out the key themes that 
underpinned a number of the semantic categories. Alignment between 
categories and subsequent coding supporting the identification of relationships 
between people’s experiences / perceptions and their behaviours. For example, 
guilt (which had been a ‘noticing’ from the familiarisation stage) was woven 
through a number of categories, including: MS Experience – Future; Adherence 
– Drivers of; Self-Management and Social Support. When reviewing 
independent codes of guilt, it was possible to see that not only was this 
something that people felt, but that it was also a source a conflict. Between what 
people wanted now versus implications for the future or needing support from 
family but not wanting to be a burden. In this way, although the research had 
been built on a priori assumptions, novel themes were identified. These were 
finally built into a model with overarching themes, themes and sub-themes 
(Braun and Clarke, 2013) and how they appear to link into each other.  
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Quality of the analysis   
There is much discussion relating to the applicability of quantitative quality 
criteria to qualitative research (Braun and Clarke, 2013; Yardley, 2008). For 
example, the tenet of data reliability and its ability to be generalised 
irrespective of the ‘researcher’ and the specific members of a participant 
group speaks to a hypothesis that there is one version of the truth and that the 
researcher and research process should have a minimal impact on that truth. 
This is at odds with principles of qualitative research which fully acknowledge 
the role of the researcher in the process, from their skills at eliciting data from 
people through interview and focus group techniques to how their own 
standpoint and experience influences the interpretation and categorisation of 
the data. Furthermore, qualitative approaches acknowledge the ‘context 
bound nature of reality’ (Braun and Clarke, 2013, pg. 279) and that therefore 
there is no single perspective that can apply to all.   
In this research study, data were collected by three different researchers but 
analysed only by me. Whilst the clarification and input of the other 
interviewers was sought, this was principally to ensure that their own 
experiences from the research process were not literally ‘lost in translation’ 
and to seek their understanding, or clarification of the data they collected. This 
was not an attempt at inter-rater reliability whereby the test is “do all 
researchers reach an objective agreement” as it was felt that this was neither 
necessary nor valuable. As described in an empirical study conducted by a 
group of researchers looking at the role of inter-rater reliability in qualitative 
research, separate analysis of the same data produced close agreement on 
the basic themes, but they were all ‘packaged’ differently, dependent on the 
different researchers own experiences and points of view (Armstrong et al., 
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1997). To this end, it can be posited that the ‘reliability’ comes from the 
following and description of a dependable set of methods to collect and 
analyse the data, whilst being open, and to some extent even embracing, the 
context the researcher themselves brings (Braun and Clarke, 2013; Yardley, 
2003).    
This leads into the concept of transparency, which is highlighted by a number 
of guidelines as an indicator of good practice (Malterud, 2001; Yardley, 2000). 
As well as a clear description of the methods, quotations from the original text 
have been used as exemplars to support the integrity of interpretations and to 
help demonstrate the link between the raw data and the findings (Elliott, 
Fischer and Rennie, 1999).    
It is acknowledged that there is an increased risk of misinterpretation of the 
data with the translated manuscripts, particularly as I had not conducted this 
set of interviews but did undertake the analysis. However, as described 
above, processes were put in place to try to mitigate this risk as much as 
possible. This included a review of translated transcripts by the relevant 
interviewers to check translation quality and the check in and clarification 
actions that I undertook throughout the analysis process.       
During different stages of this analysis process I sought clarification and 
feedback from the other interviewers involved in the research. This took place 
after the initial framework creation, following the indexing and restructuring of 
the data and at the end of the process. Individual clarification was also sought 
as and when required in relation to parts of transcripts that had been conducted 
in Germany and Spain.      
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Results   
 
Sample   
A total of twenty-four eligible PwMS were recruited and interviewed across three 
countries; UK, Germany and Spain, with eight participants from each country. 
A total of twelve males and twelve females participated.  All participants were 
diagnosed with Relapse-Remitting MS (RRMS), all had been diagnosed more 
than two years prior to taking part in the research with the exception of one 
participant in the UK, who had been diagnosed less than two years prior and all 
were currently prescribed a treatment for MS. Disability was assessed through 
patient self-report at screening using criteria based on levels of symptoms and 
disability impact, adapted from the Expanded Disability Status Scale (EDSS, 
Kurtzke, 1983). Further details of the sample are available in Table 9.      
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Table 9 – Demographic details of participants by country   
Country   Gender   Age  
Range   
Current  
Treatment   
No. of previous 
treatments  
Level of MS  
Related Disability  
Germany  
(n=8)  
Female 
n=4  
30–59  
yrs  
Avonex n=1   
Betaferon n=3  
Copaxone n=1  
Gilenya n=2  
Tysabri n=1   
0 n=4  
1 n=2  
3 n=1  
4 n=1  
Mild Disability n=4  
Moderate 
 Disability 
n=3  
Severe Disability n=1  
  
Spain   
(n=8)  
Female 
n=2  
25–54  
yrs  
Avonex n=1   
Betaferon n=3  
Copaxone n=1   
Gilenya n=2  
Rebif n=2  
0 n=3  
1 n=2  
2 n=2  
5 n=1  
No symptoms n=1 
Some symptoms, no  
disability n=4  
Mild Disability n=2  
Severe n=1  
UK  
(n=8)  
Female 
n=6   
30–50  
yrs   
Alemtuzumab 
n=1   
Betaferon n=1  
Copaxone n=4  
Tysabri n=2  
0 n=2  
1 n=5  
2 n=1  
  
Some symptoms, no  
disability n=2  
Mild Disability n=2  
Moderate 
 Disability 
n=4  
  
    
 Themes  
Initially, results are presented as per the thematic structure that was created 
through the framework analysis process, to support the aim to allow for novel 
ideas to be presented.  
Subsequently, to build on the work done through the scoping review and to 
establish how these findings support / enhance or refute hypothesised models, 
findings will then be discussed as in relation to the aims of the research and 
operationalised using the COM-B framework.  
Themes were consistent across the 3 countries and are therefore presented 
with supporting evidence from all 3 sets of interviews. Quotes are coded by 
country.   
In line with recommended methods for organising themes in data (Braun and 
Clarke, 2013) they are presented as follows:  
Overarching Themes – These are themes which encapsulate a common 
idea presented in the main themes from the data, but do not contain discrete 
examples.   
Themes – These are the key patterns of data, related to the key objectives of 
the research, which inform our understanding of the data and provide the 
evidence for the overarching themes.    
Subthemes – These represent, where relevant, specific concepts that may 
make up part of a broader theme.   
Themes are visually represented in Figure  7.    
 	 Figure 7: Model of Thematic Relationships  
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Overarching Theme: Control  
 
Control was an overarching theme that had a bi-directional feed with many of 
the themes that were derived from the data set, including the second 
overarching theme, conflict. The need to feel in control was often a positive 
driver of self-management behaviours, including adherence, as a way of 
coping. These coping strategies were employed in order to gain a sense of 
control over their MS, though for some there was a degree of fatalistic 
acceptance that MS was in control of them; they simply had to manage as 
best they could with whatever MS decided to ‘give them’. The ‘battle’ 
between whether it was them or the condition that was in control linked into 
the conflict theme. In addition, whilst people realised MS was something that 
was largely genetic, many people still used language to refer to it as ‘other’, 
reinforcing the notion of conflict between what they could do and what the 
disease had power (control) over. Using coping strategies to reduce the 
impact of MS was a key way to feel in control. This was not just in response 
to symptom experience but also as a preventative measure, whereby not 
feeling or being in control was detrimental to their condition. For example, not 
controlling or minimising stress was seen as a key risk for relapses. To this 
end, control appeared to be an overarching theme as not only does it drive 
self-management behaviours, but the reciprocal nature of the relationship 
means that feeling in control is an important state for many people, which can 
be felt through the execution of coping strategies and / or through changes to 
the perceived impact of MS.             
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Theme: Impact of MS - “I am at the mercy of it”   
The impact of living with MS was different for different people, driven by a 
number of factors that could be categorised into four key sub-themes; 
physical (e.g. symptom experience, disability), psychological (e.g. stress, 
anger), social (e.g. reduced ability to work, isolation) and treatment (e.g. 
injection burden, side effects). Whilst all could independently influence 
perceptions of impact, they were interrelated with each other as well. For 
example, physical symptoms limiting social activities, social limitations having 
negative psychological consequences and psychological burden reducing 
ability to self-manage. As described above, the interplay between the impact 
of the condition and the success of coping strategies was both driven by and 
influential on people’s sense of control.  
Sub-theme: Physical Impact  
“Today we’ll pick on her, today we’ll give her a pain here, we’ll give her a pain there.” 
(UK) 
Across the sample, people experienced different levels of physical and 
cognitive symptoms as a result of their MS.   
 “Right now, the truth is that I do not notice symptoms as such…. you’re 
more tired and such but I’ve always been clumsy” (ESP)  
  
“All of a sudden my eyesight has gone funny and I have these blind spots 
all of a sudden and it is completely out of control. I have no say in it and 
I am at the mercy of it, really.” (UK)  
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Physical symptoms were catalysts for diagnosis, acknowledgement of the 
disease and self-management behaviours, including taking treatment.  
“Through the medication I can [control MS], I would say, because the 
medication I am currently taking, since I use this medicine, I must say, 
it's so good to me, how I was with still no other medication.” (DE) 
“…it (being diagnosed with MS) didn’t really mean, it didn’t mean 
anything to me until it really started affecting how I felt.” (UK)  
Conversely, whilst the absence or relative mildness of symptoms could cause 
people to doubt the need for treatment or even the validity of their illness, in 
this sample people still largely persisted with treatment regardless, due to fear 
about what ‘might’ happen in the future (see Anticipated Regret) but also to 
help maintain a sense of control in the here and now.  
“Sometimes I feel like I am on this medicine and I don’t know why I am 
on it…obviously I understand that, you know, I have got these changes 
in my MRI but because I am well, in myself, sometimes I feel like a bit of 
a fraud” (UK)   
“It never goes away, it is a worry and it affects everything, whereas 
when you are taking medication it pushes it more to the back of your 
mind. It is there but it is not taking over your mind” (UK)  
Though there was also evidence of symptoms being a physical prompt for 
medicine taking behaviour, not just a motivational driver.  
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“Possibly it’s been a good day and (I) forgot about it” (taking treatment) 
(UK)  
Cognitive and physical symptoms could also be barriers to people executing 
self-management behaviours, such as making it difficult to remember to 
take medicine or actually administer injections.   
 “I’m one of these anyway with short memory loss so I have to write 
everything down… so it’s not something I should forget but I have 
forgotten it in the past…” (UK)  
“…. because one day, then logically you forget because you're doing - 
you've come home late, you forgot because you get very tired…” (ESP)  
“And also if my hands aren’t working very well…someone else had to do 
the injection.” (UK) 
People would mitigate these challenges through asking for support from 
others and trying to incorporate taking treatment with daily routines.  
“…three times when I’ve missed it in the last six years or whatever it is, 
and that’s when I haven’t had the routine” (UK) 
“Because I have lots of medication that I take during the day, so he is 
always texting and things, saying have you taken your tablets and 
stuff.” (UK)  
As well as impacting self-management, the experience of physical symptoms 
could also influence psychological wellbeing and social factors, such as ability 
to work or go places.  
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“Now I'm just low, precisely because, by reason of the pain and the view 
that working in front of a computer I get a lot of trouble and pain 
naturally.” (ESP)  
 
“…it was my bladder and I found that a nightmare because it would 
cause me a lot of anxiety about leaving the house” (UK)   
 
Sub-theme: Social Impact  
 “People get a little frightened” (UK)   
 
As described in the section on physical symptoms, many people were 
significantly impacted socially by MS, often congruent with symptom experience 
and level of disability.  Reduced ability to work and take part in social activities 
were prolific examples.  
”I am not going back to teaching. I would like to do something, but my 
husband said the stress, he couldn’t cope with the worry, as if I get 
stressed I will need the wheelchair again.” (UK)  
 
“So I think that is why, when I see friends going off and doing, you 
know, horse riding at the weekend or, you know, going for walks and 
things and I think I used to do all long walks and I can’t do that 
anymore.” (UK)  
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In addition to the ‘physical’ restrictions, people would feel socially isolated from 
friends and family when they felt that their condition or experiences were not 
understood.  
 
“…because you lose a lot of friends if you have MS.  People get a little 
frightened” (UK)  
“…people with multiple sclerosis, at a time when they run out of friends. 
Typically, they are, those who are married, then usually end up 
separating. I mean this, this breaks your life…I think it is by laying, fear, 
ignorance of those around you” (ESP) 
However, where support was positive from friends, family and healthcare 
professionals this could be beneficial, such as practical support with managing 
treatment as described above, but also emotionally (see theme ‘Support and 
Understanding’).  A desire to maintain social and familial relationships was a 
driver of self-management.  
“Basically, I’ve got a five-year-old girl so it’s something I just have to get 
on and live with. I rest as much as I can”. (UK)    
Social experiences in terms of exposure to others with MS was sometimes 
beneficial and sometimes not. For example, two participants both had family 
members who had MS, for one this was reassuring as the impact on their lives 
(to date) had been minimal, for another the experience of her mother’s disease 
course caused her to try to avoid fully acknowledging what was happening and 
impacted her initial reaction when she finally received her ‘formal’ diagnosis.  
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“Yeah, because my mum had MS but she had it really badly. She was 
quite severely affected by it. I started getting symptoms in the last year 
of her life. She had MS for years and years and I just couldn't bear to tell 
my family so I just buried it and kept it to myself for about four years but 
I knew what these symptoms were…when I was diagnosed I almost 
went into shock and for the first year I felt like I was just floating around” 
(UK) 
 “I was kind of put at ease when I was explained more about it and looked 
it up a wee bit and, I think by talking to people and keeping a positive 
attitude…my Dad’s two - brother and sister they are - his first cousins 
have got it as well, and they’ve had it over 25 years and they’re still - 
touch wood - alive and kicking and well. So, I’ve known through them” 
(UK)  
Sub-theme: Psychological Impact 
 “I felt very sad ... very very sad” (ESP)  
 
Most people experienced a degree of psychological impact as a result of their 
MS. The extent to which this impacted people was variable across the group.  
For example, some people experienced quite severe psychological problems 
that required treatment.   
  
“I went to the doctor, a neurologist, which asked him to send me to a 
psychologist because I felt very sad ... very very sad and actually, I was 
diagnosed that I have a small depression” (ESP)  
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 “I got severe problems with my psyche, because I couldn’t cope with the 
disease and with the associated problems… I searched for psychological 
support, because I couldn’t stand the situation anymore...”  
Some people also felt that the relationship was two-way and that their 
psychological state could have an impact on their MS, with a perception that 
the ability to control their emotions, in particular stress, could lead to greater 
control over the condition.   
“And when you are first diagnosed, because of the psychological impact 
of the diagnosis you start thinking: maybe that is why I am having these 
relapses.” (UK)  
  
“I do not think that I have really control, however I do believe that I still, if 
I pay attention to me, I'm doing something good, try to avoid stress…can 
exert influence on it” (DE) 
  
For many, the psychological impact varied over the course of their condition.  
For some diagnosis was a particularly difficult time.   
“And then, then, in principle, therefore, is one, one, a big, a big hit, right? 
For you and your family, and those around you. Then, then, assuming 
you go a little, and then have a period of uncertainty, not knowing what 
it really is.” (ESP)  
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However, increasing disease and treatment burden over time would also 
negatively impact how people felt and their motivation to self-manage.  
 
 “I stopped with the medication…already almost one year… Because I 
was annoyed to administer an injection that often.” (DE) 
 
“…sometimes I just don't feel like doing it.  I would think: Oh I can't be 
doing with doing it today…. I feel like it is sticking this needle into me and 
it is doing God knows what to my fat and my skin.  Sometimes I think: I 
will just give it a break today.” (UK)  
 
“I am okay some days, but I cry a lot, if I am by myself, because I think 
oh, I can’t cope, I can’t do this, you know, like, sometimes, even going to 
the supermarket, because my legs are so painful, that then, when I go to 
the supermarket, I will be in floods of tears about having to go, because 
I think how am I going to cope with a  trolley and things.” (UK) 
 
Sub-theme: Treatment Impact  
“Injecting day in, day out doesn’t allow you to forget the illness” (ESP)  
 
Across the sample, treatment was shown to have both a positive and negative 
impact on people. For some, taking treatment went beyond just being 
something to manage the illness but was also a way to feel in control.  
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“Through the medicine I can [control MS]...because the medication I 
am currently taking, since I use this medicine…it’s so good to me now” 
(DE) 
“My perspective is that if you don’t do everything that you can and 
something goes wrong, then you are going to regret it for the rest of 
your life” (UK) 
Using treatment as a way to exert control held true for some people even 
when the immediate impact was not evident (see theme Anticipated Regret on 
this).  
Conversely, some people talked about the negative impact that following 
treatment regimens had on them.  For some, having to follow a treatment 
regimen was impactful psychologically as it served as a reminder that they 
were unwell or added to what already seemed a burdensome disease.   
“Injecting is depressing. It makes you feel like a sick person. Injecting 
day in, day out doesn’t allow you to forget the illness.” (ESP)  
 
“So you had to keep a diary of when you were doing it and stuff.  It was 
quite hard work…it was just a bit of a pain…it got to be like schoolwork 
in the end.  I was kind of filling it in and then kind of making it up…I was 
filling it in and then thinking well I must have done it there then and that 
makes that, it wasn’t a true reflection of it…I would’ve preferred not to 
have to do it.” (UK)  
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Equally, the physical burden of treatment, in particular injection treatments, 
could have a negative impact on people and their desire to stay on treatment.  
“It was difficult for me to inject oneself with the medication…however 
taking every day an oral medication.... this is really easy…” (DE) 
“Yes. I can’t use the automatic thing, because I couldn’t stand the noise 
of the click, so I do it manually. It is not that it hurts, because I put 
cream on that is fine, it is just every time I come to do it, I think oh God, 
I really don’t want to do it again… so I am seeing the hospital in 
January to discuss what other things I could do.” (UK) 
For some this was then compounded by perceptions of treatment efficacy.  
“I always think what is the point, because if you are diabetic and you 
take your injection, it is to stop you getting really ill that day. Whereas I 
think I don’t know whether it is doing anything for me or not.” (UK) 
“Because I find it hard when it is not a cure, it is not a thing that makes 
you feel better, it just makes you feel rubbish” (UK)  
The experience of side effects was also cited as a reason for discontinuation 
or non-adherence with treatment.   
 “If the side effects are extremely, then you should stop taking the 
drug...but I would always look for an alternative medication...” (ESP)  
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However, some people did find ways to try to actively reduce their side effects 
so that they could persist with treatment.  
  
“I always took it last thing at night, so the side effects would hopefully be 
during the night.” (UK)  
“I have to inject three times a week and usually I do at night because you 
have some effects, as very cold, so I am in bed” (ESP)  
 
Theme: Coping   
As described above, people would put coping mechanisms in place to try to 
mitigate the impact of MS across a number of dimensions (e.g. 
psychological, treatment). This was a form of direct control (e.g. where 
treatment obviously reduced relapses or learning pacing techniques to 
reduce fatigue) but it was also evident for some people that simply feeling in 
control was an important psychological ‘state’ – often driving or helping to 
maintain coping behaviours even in the absence of an overt physical effect. 
When looking at the types of coping mechanisms people put in place, it was 
evident from across the sample that there were two ‘types’; adaptive and 
avoidance behaviours. Adaptive behaviours were linked to acceptance of the 
condition and were, on the whole, positive. Avoidance behaviours were still a 
way of coping, but on the whole were more ‘negative’ or short sighted, these 
seem particularly prevalent at diagnosis and early stages of MS, as people 
took time to accept and adjust to the changes, or where the physical impact 
was still relatively ‘mild’. However, for some there was a balance to be struck 
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– acceptance and actively doing what they could to manage, but with a 
degree of trying to minimise the impact through not focussing on it more than 
needed or ‘taking each day as it comes’.    
Sub-theme: Adaptive 
 “Learning your limits…it’s about listening to your body you’re your needs” (UK)  
Many individuals found that their MS and treatment regimens were easier to 
cope with once they had made some necessary adjustments to their day-to- 
day living.   
“yeah you have to adjust your lifestyle.  You have to do it.  You 
can’t…because you end up basically making yourself a lot worse…not 
necessarily in a permanent way but certainly, now I know the warning 
signs and I know when to stop.” (UK)  
 “I think, that I'm excluded from many activities that I could have done 
before I got my disease. But I am looking for other activities which are 
feasible.” (DE) 
“Well, then, in every way, right? At work, at home, in the family, friends, 
everything…you cut your lifestyle, right? Now you have to adapt.” (ESP)  
Decisions to make conscious adaptations were often linked to acceptance of 
their condition and the circumstances around it, such as this participant talking 
about working with their psychologist to help them come to terms with using 
their walking stick.   
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“She gets me to see it [MS]….in a different way. So she got me to realise 
that I needed that walking stick and it makes more sense to use that and 
overcome the emotional side of it…so instead of letting it get me down, 
I kind of look at it in a more positive way as in, actually, that gets me out. 
Without that, I would just be in the house and I wouldn’t be able to get 
anywhere, so it is almost like you have to befriend that because that is, 
you know, what is going to, kind of, give you your lease of life, really.” 
(UK)  
This was also linked to more positive psychological outcomes for some.   
“…right, okay, hang on, slow down a wee bit, do this, do it that way, do 
it this way and just kind of plan it out a wee bit.  But definitely as well, I 
think keeping a positive attitude - that definitely, definitely helps… and 
speaking to people where needed.” (UK)  
However, for some, acceptance and compliance appeared to be tinged with a 
degree of fatalism, as if the individuals had surrendered themselves to the 
fate that MS had in store for them or had even relinquished their own sense of 
control.     
“I mean it’s not so much about control, it’s dealing with it basically… 
basically, I’ve got a five-year-old girl so it’s something I just have to get 
on and live with.  I rest as much as I can…other than that you just have 
to basically put up with it, you’ve got it.” (UK)  
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 “I do not know specifically how it serves well. I do not know; I would not 
know what to tell you. But they say there is this medicine and you do it.” 
(ESP)  
Sub-theme: Avoidance 
 “I am stubborn, and I don’t want to accept I have got MS” (UK)  
Comparatively, there were some individuals who appeared to be more 
avoidant in their coping style – or who referenced stages in their disease, 
particularly early on, that they had tried to deal with MS by ignoring what was 
happening.   
“It changed everything and it just took me a long time to come to terms 
with it, even though I had known I had had it for that long.  I think I must 
have been in some sort of denial and part of me was hoping it was 
something else for all those four years that I had kept it to myself.” (UK)  
  
For some, it was important to try and get a balance between managing the 
condition but not letting it ‘rule’ their lives, therefore they adopted behaviours 
that allowed them to avoid having to focus on their MS too much, including 
taking their medication.     
“It never goes away, it is a worry and it affects everything, whereas when 
you are taking medication it pushes it more to the back of your mind.  It 
is there but it is not taking over your mind.  You are not taken over 
psychologically or physically.” (UK)  
 
	 165 
“I personally believe MS has 100% control over you but what you can do 
is live your life without knowing…well knowing you have MS but not 
letting it affect your day to day life as much as possible” (UK) 
 
“I have learned with the MS to just live every day as it comes so, right 
now, that is firmly at the back of my mind and I just enjoy each day of my 
life as it is.  And when that day finally arrives I will deal with it then so, 
right now, I don't give it a second thought.” (UK) 
  
Avoidance of difficult and stressful situations was also a common way to try to 
manage their MS, though over the long term this could have a negative 
impact socially.    
“I think you try and stay away from stress but you know I just think a lot 
of my friends have gone on exclusion diets and kind of trying to control 
it, it is controlling their lives.” (DE)  
Overarching Theme: Conflict  
  
People seemed to experience a number of different conflicts in their 
experience of living with and managing of MS. There were social conflicts, 
such as a desire to maintain independence versus the practical need to seek 
help from others, or the need to reduce activities versus wanting to play an 
active role in work / family. The use of treatment could often be a source of 
conflict too, with people sometimes not seeing ‘the point’ or doubting its 
efficacy but being too worried about what might happen if they stopped to 
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respond to these doubts. These conflicts could sometimes manifest into 
feelings of guilt, particularly where friends and family were impacted, but also 
trying to prevent themselves feeling guilty in the future by taking action now. 
As described in the theme control, there was also a direct link between 
conflict and control, with control coming from the resolution of conflict but also 
a desire for control helping to resolve conflicts, or at least still prompt action, 
even if the underlying conflict was still there, such as in the medicine efficacy 
example above.   
Theme: Anticipated Regret  
 “If you don’t do everything that you can and something goes wrong, then you are 
going to regret it the rest of your life” (UK)  
 
A driver of many self-management behaviours, including adherence to 
treatment, was anticipated regret.  People spoke about their fears for the 
future in relation to their MS, particularly in terms of greater disability, and it 
was this that led them to look after themselves now.    
 “Especially because I don´t want to feel worse. Now I have a normal life, 
more or less. I don´t want to feel worse and end up in a wheelchair.” 
(ESP)  
“The most important thing is to stop me from getting worse.  If I was 
disabled, I could live a normal life but because of the progressive nature 
of MS and I know what happens at the later stages of MS I just think 
anything to stop it from getting worse” (UK)  
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For some people this was an internal driver, in that they felt it was their 
responsibility and talked about the impact in terms of the direct effect on them.  
Others turned to or were persuaded by people in their support network to 
undertake positive behaviours, and they too used thoughts about potential 
future outcomes to try and persuade adherence or other self-management 
behaviours.   
“It will be in the evening, when I am going there is no point, there is no 
point in taking an injection, what good is it, I am not going to feel any 
better tomorrow. And then my husband is like but you could feel worse 
tomorrow, we don’t know, if you stop, it might be worse” (UK)  
  
This anticipation seemed to provide a ‘buffer’ against negative beliefs relating 
to treatment.  For example, people would question the efficacy of the 
treatment, or express concerns, but still continue with treatment as they felt 
the potential risk of getting worse was too high.     
  
I do just sometimes think I wonder what would happen if I didn’t take it? 
But I don’t think I would like to take the risk and see what would 
happen.” (DE) 
  
“I am not sure if I would have the same course of the disease, without 
taking the medication…I am not sure if my medication has any effect.”  
(ESP)  
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Theme: Guilt  
“…that’s one of the things I was really keen on doing from the start is, making 
sure I do everything possible to make sure it’s never my fault,” (UK) 
 
Guilt manifested itself in a number ways across the research population, often 
driving ‘action’ in terms of self-management behaviours but also having a 
detrimental effect on psychological wellbeing for many. Having to ask for, or 
reply on the support of others, in particular friends and family, was 
troublesome for some.  
 
“My dad would take me to every appointment, but I don't think it's fair on 
him.” (DE)  
 
“My family, my boyfriend and such but I have faced this a rather strange 
way because… I have always tried not have to depend on anyone. 
Perhaps not aware at some point in my life later have to rely on 
someone.” (ESP)  
As seen in the previous theme, anticipated regret, guilt (or at least, anticipation 
of it) drove people to undertake self-management behaviours now, even if they 
were doubtful of their efficacy.  
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“I think I would feel guilty if I did start relapsing and I hadn’t gone on 
any medication.” (UK) 
Interestingly, a number of people felt guilty that their condition was not as bad 
as other people with MS, particularly if their symptoms were not as overt as 
other’s.   
“Obviously I understand that, you know, I have got these changes in my 
MRI but because I am well, in myself, sometimes I feel like a bit of a 
fraud.” (UK)  
  
“I feel guilty because a lot of people my age are a lot worse off.” (DE) 
Guilt about the impact of MS on others, in particular close family, was also 
evident and could be a source of conflict trying to balance their needs against 
those of others and also the short versus long-term implications of action / 
inaction.  
 “So at Christmas we are not doing swimming anymore. Which I felt 
extreme guilt about, but I know I just can’t carry on like that and do 
those sort of things. I am starting to know what my limits are.” (UK)  
 
“Now my MS is really…I’m really struggling with it…my children are 
struggling a little bit with it, because why is mummy not coming out with 
us today” (UK)  
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Theme: Support and Understanding  
“Talking has definitely, definitely helped – definitely” (UK)  
  		 
Participants talked about the impact that the reaction and support of other 
people had on them, in particular with relation to how supported and / or 
understood they felt.  Where empathy and understanding were shown this 
would tend to lead to more positive feelings. This could come from existing 
social sources or was provided through MS specific support groups or new 
social circles.    
“…it helps it because then you don’t feel, you know someone else is 
probably going through the same thing. And where they are mums, you 
know they are not these intelligent doctors that think you are just being 
paranoid.” (UK)  
  
 “I can suggest everyone. To attend a self-help group…I am positively 
impressed from a self-help group…it makes a lot of sense to attend this 
group because you receive immediately support...information sharing 
with peers is good” (DE)  
Conversely, where a lack of empathy was shown, this negatively impacted on 
people. For a number of people their experiences at diagnosis seemed to be 
particularly lacking in empathy, at a time when they felt it should have been 
forthcoming.   
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“I just needed someone to talk to.  I asked my MS nurse three times for 
a counsellor… I never heard anything so I never got to see a  
counsellor.  I felt that you need that sort of support, especially when you 
are first diagnosed.” (UK)  
“But, yes, at that time, I just didn’t like her approach; I just thought that is 
a bit hard, really. I think, you know, it is a bit, a lot to take in like that.” 
(DE) 
Some people had experienced problems at work following diagnosis, where a 
lack of adequate adjustment / provision was made, leading to them 
experiencing conflict between their personal needs and those of their 
workplace.   
“My work made it worse and worse for me, they were making me work 
upstairs and they were making it incredibly hard and in the end I just had 
a complete nervous breakdown, we had all the crisis team involved and 
got the mental health team.” (UK)  
  
As described in the ‘guilt’ theme, many participants felt a conflict between their 
own individual needs, and the needs of others in their lives.  
  
The level of support and degree of understanding exhibited by HCPs was also 
important. Conflicting beliefs between participants own perceptions of their 
condition and those of the HCPs appeared to have a negative impact.  
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 “My GPs don’t, they are scared of it…. reluctant.  They’re very hesitant 
about giving me any other medication because of the medication I’m 
on. If I had any new symptoms even if I think it’s unrelated to my MS 
they will be referring me back to the neurology team, because I don’t 
know whether it’s arse covering or they don’t know or they think that’s 
the best route…. they will say, yes, that’s down to your MS 
straightaway when sometimes it’s not. Actually it feels like you’ve been 
a bit brushed off…” (UK)  
  
However, participants had more positive feelings where there was a 
perception of understanding between participant and HCP  
  
“And I think I've been pretty lucky because both doctors and nurses are 
very involved and have been involved in that I'm pretty good in that it 
does not affect me too much, to let me know...disease as this options of 
treatments.” (ESP)  
  
For some, in addition to receiving support, participants felt that providing 
support to others, sharing their experiences and being empathetic was 
important.  
  
“I have helped me if I try to help, to newly diagnosed, because more 
than anything, as I understand … and as anyone, like me or someone 
who has been diagnosed with this, and has no support because… 
knows what you need at all times, right? And then, well, it is very 
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important that when someone tells you that you have multiple sclerosis, 
it therefore someone to explain that the world does not stop for that, 
and, and, and what will happen because you remove some of that 
uncertainty, I know I have.” (ESP)  
  
Many participants felt that other people did not understand the condition and 
its impact, which led to feeling of isolation from others in their lives.   
“My siblings are not very understanding. They don’t understand it. They 
just can’t understand that, I mean my sister, because my sister is a 
personal trainer, she is a bit like oh, come on, just use your legs, there is 
nothing wrong with you, you know, that sort of approach.” (UK)  
  
Some people had found that their support network had changed as a result of 
their MS.  There was evidence of previous friends distancing themselves and 
individuals simply not being able to interact with their social circle in the way 
that they used to.   
  
“It can’t be like this. I am only 34. So I think that is why, when I see 
friends going off and doing, you know, horse riding at the weekend or, 
you know, going for walks and things and I think I used to do all long 
walks and I can’t do that anymore.” (UK)  
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This was relevant with both direct and indirect support, with one individual 
referring to it as an invisible disease.    
“Because I don’t think there is a big, sort of, understanding of MS, really. 
It is like cancer, everybody has heard of cancer, haven’t they, whereas 
something like MS, unless it is close to you or within the family, I think a 
lot of people don’t really know or understand much about it at all.” (UK)  
  
There were some people who felt stigmatised by their condition, often linked 
to the impact that the symptoms had on their day to day activities and abilities, 
or with being referred to as disabled.     
“…because I was almost embarrassed, like, the first time I went out 
with the walking stick I was with my mum, and I had seen a couple of 
people that I knew, and I just threw my walking stick at my mum and I 
was, like, you hold it, I don’t want them to see me with a stick.” (UK)  
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Discussion  
This discussion comprises of the following sections: discussion of findings 
aligned to the research questions; review of methods and models applied; 
contribution to knowledge; conclusion and implications for practice.  
Discussion of findings  
 
The lived experience of MS and how it influences adherence  
 
This qualitative study provided insight into not only the lived experience of MS 
but also the impact of various factors driven by this experience on adherence 
behaviours. In this way it has helped to ‘extrapolate’ some of the mechanisms 
by which experiences, perceptions of these experiences and coping 
behaviours and appraisals of these influence behavioural outcomes.  
In this sample avoidant coping behaviours appeared to be more related to 
lower mood / unhappiness compared to adaptive coping, which was linked to 
a more positive outlook.  This is in line with psychological literature relating to 
unhelpful and helpful coping styles (Roth and Cohen, 2005). It was evident 
from across the sample that there was not a single effective way of coping 
with MS; participants employed different techniques and strategies as a 
response to their individual experiences with MS and these had a range of 
positive and negative implications. Most participants appeared to go through a 
process of adaptation, adapting to both their condition and to the changes in 
their lives as a result of their MS.  Acceptance was also important, and this 
too manifested itself in different ways. Acceptance where participants made 
adjustments in their everyday life to account for their MS had positive 
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implications for self-management and adherence. However, as described 
above, for some acceptance was linked to a degree of fatalism. In these 
cases, acceptance was less positive as individuals were resigned to the fact 
that MS ultimately is in control.  This may have negative implications for 
participant’s self-management behaviour and adherence if the perceive that 
they have no control over what is going to happen and therefore relinquish 
responsibility (Jopson and Moss-Morris, 2003; Moss-Morris et al., 2002).   
Equally, in this sample, avoidance was not definitively a positive or negative 
coping style. In some cases, avoidance was used to try not to think about the 
condition, this type of avoidant coping style can have detrimental implications, 
as avoiding and not accepting the condition can be a barrier to adherence 
(Moss-Morris et al., 2002).  This is similar to comments that some people 
made about how taking medicines or attending appointments serve as 
reminder of the condition. Conversely, avoidance was also used as a positive 
self-management coping strategy. This was seen when techniques were 
employed to avoid experiencing symptoms (in particular, adherence) so that 
they could put it to the back of their mind.    
Unsurprisingly, living with and managing treatment for MS had a significant 
impact on people in many areas of their lives including their physical, 
psychological and social wellbeing. There was a complex interplay between 
these factors that influenced the way people coped with their MS and 
ultimately how much control they felt they had over their condition, similar to 
the ‘hot cross bun’ model proposed in Cognitive Behavioural Therapy (Sage 
et al., 2013). This model highlights how emotions, sensations, thoughts and 
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behaviours all link into and influence each other, and how this is a 
multidirectional relationship. The accounts of the people in this research 
described this in different ways. For example, how physical limitations 
impacted their ability to do certain ‘social’ behaviours, which then led to 
negative emotions. Or how and emotional state of despondency, would lead 
to unhelpful self-management behaviours and a potential worsening of the 
condition. So, these factors can all influence self-management behaviours, in 
a very individualised way.  Overwhelmingly, those who had strategies to 
support these dimensions felt more in control of their MS and better equipped 
to self-manage.    
Similar to ways of coping, anticipated regret was neither definitively positive or 
negative. For some it was empowering and motivational, for others it was a 
source of conflict. Positive outcomes included better adherence and self-
management driven by a need to not feel that they hadn’t ‘done their best’ to 
reduce the future impact of MS.  For some people this held true even when 
they didn’t feel certain about the efficacy of the treatment; the potential risk of 
doing nothing was greater than following a treatment plan that may or may not 
have an impact.  This supports the necessity-concerns framework, whereby it 
is the appropriate balance of pros and cons of a treatment that can drive 
adherence behaviours, rather than the absence of negative beliefs per se 
(Horne and Weinman, 1999). Often this was linked to symptom experiences, 
with a desire to reduce the likelihood of relapses key, as well as prolonging 
overall wellbeing.  However, anticipated regret could also be a source of 
conflict, as people were not confident in the value of their treatment but 
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continued to use it anyway. In this case people were being driven by negative 
perceptions as opposed to positive ones, which over time may have a 
detrimental impact on emotional wellbeing and treatment satisfaction.  
Additionally, behaviours are likely to be more susceptible to change if people 
are not confident in the efficacy of the treatment, as they ‘pros buffer’ is not 
there.  
People felt guilty on a number of levels in relation to their MS. Some people 
felt guilty about the impact their MS was having on other people around them, 
such as restrictions on family activity or needing to get additional support.  
Interestingly, some people felt guilty about their MS experiences in 
comparison to other people with MS; feeling guilty if they perceived their 
symptoms and circumstances to be better than others. These feelings of guilt 
were a source of conflict for some people, particularly when they have to 
make the choice between effectively managing their MS or taking the time to 
do the ‘other’ things in their life.   
The people we interviewed varied in their needs for and perceptions of the 
support they received. The understanding of others about MS and their 
experiences was very important, this included understanding of friends and 
family, HCPs and other people with MS. Finding people who empathised and 
understood was reported as a positive thing and was also linked to positive 
behaviours in relation to self-management. Equally, other people not 
understanding and not being supportive lead to negative feelings, a changing 
social network and isolation. In addition, people appeared to feel in conflict 
about their support and needs. For example, conflict with regards to the 
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amount of support they received and their desire for independence, or their 
need to look after themselves and their obligations to others (e.g. family, 
friends). Many people found it difficult to find a balance in these conflicts, 
having a detrimental psychological impact and implications for their ability and 
desire to appropriately self-manage their condition.   
The apparent overarching relationship between conflict and control could be 
considered a manifestation of the process of regulation proposed by the SRM. 
Leventhal proposes that people seek to find balance and that this is the 
ultimate driver of regulation behaviours (Leventhal, Meyer and Nerenz, 1980). 
This has been supported in research exploring general self-management 
behaviours in people with MS (Jopson and Moss-Morris, 2003) and this 
research supports these findings in relation to specific adherence behaviours. 
Conflicts, such as feeling okay now compared to knowledge about previous 
relapses or the likelihood of future increased disability, would be mitigated or 
at least addressed through the application of coping mechanisms (such as 
medicine taking) to trying and regain a sense of control. Similarly, where ways 
of coping were not effective, or presented additional challenges, this could 
cause conflict. Such as where the burden of treatment led to people wishing 
they could ‘just try and see’ what life would be like without it, even when they 
couldn’t follow through on this for fear of the negative consequences of 
stopping.  
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Illness and treatment perceptions in the context of adherence in line with key tenets of 
the self-regulatory model  
Control  
Control was an overarching theme from the qualitative research and is one of 
the 5 key variables proposed by the SRM (Moss-Morris et al., 2002), 
operationalised thorough the illness perception questionnaire to include both 
level of personal control over illness and the extent to which illness can be 
controlled with treatment (Jopson and Moss-Morris, 2003; Moss-Morris et al., 
2002). In line with proposed SRM processes, perceived control was bi-
directional in that people attempted to put in place strategies to control MS 
and then, appraise how well these strategies, including adherence, worked. In 
turn this would influence perceptions of control and whether to maintain or 
adapt behaviours accordingly. For example, where medicine was deemed to 
be effective this would drive adherence, with some people even stating that 
this helped them to feel in control of MS, as opposed to MS controlling them. 
Similarly, some people were keen to try other treatments if they perceived 
them to be ineffective.  
When talking about their sense of personal control it was often in the context 
of ‘taking’ the control from MS itself. This could be posited to link with desiring 
regulation. Leventhal’s model is built on the premise that we respond to a 
health threat because it disrupts our ‘status quo’ and therefore we seek to, as 
much as possible, return to normal (Leventhal, Phillips and Burns, 2016; 
O’Connor, Jardine and Millar, 2008). Therefore, it is interesting to hear people 
describe this ‘battle’ between themselves and the condition and a desire to 
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wrestle control away from MS. It was this facet of control that led it to link into 
the other overarching theme of Conflict.   
Duration  
Overwhelmingly, people we interviewed had accepted that the course of their 
illness was uncertain, but that they could expect to get worse over time and 
that it could not be cured. Acceptance of these features of the condition, (i.e. 
overarching timeframe and decline over time) was synonymous with 
adaptation to manage and cope with the condition, supporting the role of 
these perceptions to influence coping procedures as outlined in the SRM 
(Leventhal, Phillips and Burns, 2016; O’Connor, Jardine and Millar, 2008). 
Some participants referred to periods where they had found it difficult to 
accept what was happening, particularly early on in the disease course / 
diagnosis, and that at this time they would ‘avoid’ doing things to manage it, 
as this would be tantamount to accepting what was happening. The role of 
acceptance is also cognizant with broader self-management literature in MS 
(Jopson and Moss-Morris, 2002).  
The theme of ‘Anticipated Regret’ appeared to be largely driven by 
perceptions of duration and worsening of disease over time. Adherence to 
treatment in particular was driven by ‘fear of the future’ and not wanting to get 
worse or feeling that they hadn’t tried everything possible to slow progression.  
Cause 
Causal beliefs did not feature strongly in the discourse of these patients. 
Where it did appear, it was in reference to the impact of their actions or 
psychological states, in particular stress, on relapses and symptoms, rather 
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than etiology. In this way, these beliefs seemed more aligned with the identity 
variable of illness perceptions. As there is not a known cause of MS then this 
is likely a contributing factor to people not talking about the root cause of the 
condition and referencing instead the uncertainty surrounding the disease.   
Identity   
As described within the causal variable, identity (symptom experience) of MS, 
linked to the theme ‘Impact of MS’ would influence coping behaviours and the 
success or failure of these behaviours could also be judged by changes in 
symptom experience. This aligns with the SRM in terms of both perceptions 
influencing coping procedures but also the process of appraisal of actions.  
Consequences 
Physical and cognitive symptoms had a substantial impact on day to day 
living and the consequences of this could both motivate and impair coping 
processes. A desire to reduce the impact of the condition, both short and long 
term was often a motivator for self-management behaviours. As seen in both 
the illness perception variable duration and the research theme ‘anticipated 
regret’ predicted potential consequences of not taking treatment led people to 
adhere, even if the immediate benefits were not always apparent.   
Cognitive and physical consequences were also a direct barrier in terms of 
impairing ability to physically administer treatment or through cognitive 
problems that cause people to forget or, as described earlier, may actually 
impede an individual’s ability to adequately self-regulate due to the reliance 
on cognitive processes.   
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Emotional response  
Within the theme of psychological impact, it was possible to see how 
emotional appraisal and response to MS could impact both ‘general’ ability to 
cope and specifically motivation to adhere to treatment. Interestingly, 
psychological factors, in particular stress, were also linked to individual’s 
causal perceptions, whereby people felt that if they could control their 
emotions ‘better’ this would have a positive impact on their MS symptoms.  
Treatment Necessity  
Perceptions of the need and importance of treatment was a definite driver of 
adherence behaviours, both when the ‘results’ of treatment were obvious (e.g. 
reduction in relapses) linked to relationship between the themes of treatment 
impact and coping but also as evidenced within the theme anticipated regret 
whereby people’s beliefs that the treatment was important in the long-term 
would promote adherence in the ‘here and now’. This relationship supports 
the hypothesis that treatment perceptions can be mediated by illness 
perceptions (Leventhal, Phillips and Burns, 2016).  
Treatment Concerns 
Concerns about treatment, in particular side effects, had directly caused 
people to stop taking treatment. It was also apparent that specific concerns 
relating to injections (e.g. site reactions, pain) negatively impacted 
perceptions of treatment and desire to adhere, with some people admitting to 
avoiding treatment on days when it seemed too overwhelming. However, 
similar to perceptions of treatment necessity / control, where it was felt 
treatment was important (necessary) people would put coping mechanisms in 
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place to try to mitigate the side effects, either actively (e.g. taking at night to 
reduce the impact of tiredness caused by treatment) or, to some extent, 
avoiding thinking about it ‘too much’ – this was often the conflict that was 
seen as part of anticipated regret and potential future guilt.    
Operationalisation to COM-B  
To allow for comparison of findings between the scoping review and the 
qualitative study, where possible findings have been operationalised to COM-
B to see the extent to which the findings from both parts of this research are 
congruent and also to determine what this qualitative study has added to our 
understanding of drivers of adherence behaviours in people with MS.  
Firstly, theme constructs were mapped to explicit factors from the revised 
COM-B for adherence to DMTs in people with MS. The mapping was based 
on my interpretation and understanding of the themes from the qualitative 
research and descriptions of the COM-B categories and factors. This mapping 
is listed in Table 9. 
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Table 9 - Mapping of COM-B for adherence in people with MS to qualitative 
themes 
Category  Factors from review  Evident in qualitative 
research as impacting 
adherence?  
Related themes  
Capability 
(psychological)  
Cognitive functioning 
Forgetting  
 
Yes  Physical impact  
Coping  
Adaptive  
Support and understanding 
Capability 
(physical)  
Increased disability  Yes  Physical impact  
Motivation 
(reflective)  
Beliefs about treatment  
Concerns / side effects  
Efficacy  
Yes  Treatment impact  
Coping  
Adaptive  
Conflict  
Anticipated regret  
Self-efficacy  Yes  Coping mechanisms  
Hope  No   
Quality of Life  Yes  Physical impact  
Treatment impact 
Coping   
Adaptive 
Motivation 
(automatic)  
Mood state / emotional 
disorder  
Yes  Psychological impact  
Coping  
Adaptive 
Avoiding  
Conflict  
Guilt  
Opportunity 
(physical)  
Cost  No   
Social support 
Caregiver help to 
administer injection 
Yes  Physical impact  
Coping  
Adaptive  
Avoidant  
Support and understanding  
Guilt  
Social support 
Caregiver ‘general’ support 
Yes  Physical impact  
Coping  
Adaptive  
Support and understanding  
Guilt  
Regimen complexity 
Dosing  
Yes  Treatment impact  
Coping  
Avoidant  
Adaptive  
Conflict  
Support and understanding  
Guilt 
Anticipated regret  
Packaging characteristics 
of medicine  
Oral preference  
Injection fatigue  
Injection site pain  
Injection anxiety  
Yes  Treatment impact  
Coping  
Avoidant  
Adaptive  
Conflict  
Support and understanding  
Guilt 
Anticipated regret 
HCP-patient 
relationship/communication  
Physician support of 
treatment  
Yes  Treatment impact  
Support and understanding  
Travelling  Yes  Physical impact  
Coping  
Adaptive  
Opportunity 
(social)  
n/a    
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Secondly, additional factors from the qualitative research were then, where 
relevant, mapped to factors from the original COM-B for adherence that had 
not been evident from the scoping review (Jackson et al., 2014). Finally, any 
additional factors from the qualitative research that mapped to categories but 
not original factors were added. This provided an updated COM-B for 
adherence to DMTs in people with MS (see Figure 8).  
As stated earlier in this thesis, whilst COM-B is designed to be theory 
agnostic, it is a method by which to operationalise theoretical constructs and 
within the model published for adherence (Jackson et al., 2014) there are key 
elements of SRM (illness perceptions, treatment beliefs, emotional response) 
already included, that have been discussed in this previous section.  
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Figure 8 - Revised COM-B for adherence to DMTs in people with MS – incorporating qualitative 
findings 
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Congruence of factors from the review and the qualitative research 
Some participants felt that their impaired cognitive functioning, due to MS, did 
impact their ability to remember treatment and, to ensure adherence, needed 
to put contingencies in place to mitigate this. These could be both practical 
and social, such as routine development or having someone else manage the 
scheduling of treatments. As described earlier, forgetting as a discreet factor 
was omitted from the COM-B for adherence published by Jackson and 
colleagues (2014) as it was deemed to have too many potential confounding 
influences, such as motivation or lack of understanding. In addition, there is a 
risk of social desirability leading to this factor being ‘overrepresented’ as it is 
perceived to be more acceptable than deliberate non-adherence (DiMatteo et 
al., 2002). However, it was a consistent factor from the review, was targeted 
and successfully addressed by intervention and was described in the 
qualitative interviews as something that could impact adherence if not 
mitigated through coping procedures. To this end, it seems important that this 
is included as a factor for consideration and that support should be offered for 
how to reduce likelihood of forgetting, particularly in conditions such as MS 
where cognitive function can be impaired.      
There was also support for the impact of increased disability on adherence, in 
particular related to ability to inject. In addition, increased disability also 
increased motivation to adhere / self-manage. People referred to the 
experiences of previous relapses and / or potential future functional decline as 
their reason for wanting to persist with treatment, as demonstrated by the 
qualitative themes of guilt and anticipated regret. Interestingly, these themes 
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align with behaviour change techniques such as comparative imaginings of 
future outcomes, threat and (unsurprisingly) anticipated regret (Michie, Atkins 
and West, 2014). This alignment between change in illness threat, perceived 
consequences of this change (or potential change) and their influence on 
coping procedures supports both the model of self-regulation and gives 
insight into the types of techniques that may be useful to promote through 
intervention, drawing on ‘natural’ occurring regulation methods (e.g. 
anticipated regret).    
Beliefs about treatment, specifically concerns / side effects and efficacy were 
also evident in the qualitative narratives and have been discussed above.  
The role of self-efficacy was evident in the qualitative research, in line with 
review findings and the COM-B model for adherence. Self-efficacy is defined 
as an individual’s belief that they have the capabilities to carry out a specific 
task or tasks to reach a desired outcome (Bandura, 1989). Self-efficacy has 
been shown to be predictive of a broad range of health behaviours, including 
adherence, across a range of chronic diseases (O’Leary, 1985). Whilst, on the 
whole, participants didn’t explicitly talk about their level of confidence to 
execute behaviours, it was evident through the coping procedures people 
adopted when they didn’t feel confident (e.g. where people struggled with 
medication regimens and therefore relied on social support) and also the way 
that people referred to times where they struggled to cope linked to not feeling 
able to do the necessary things to manage their MS.  
Hope was a specific factor from the scoping review but does not feature in the 
original COM-B for adherence and did not come through in the qualitative 
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research. As described earlier, hope is not a specific illness perception within 
the SRM but may tie into beliefs about future consequences and sense of 
personal control over the illness and has been shown to have a close 
association with both motivation and positive coping, underpinned by mental 
representations of health. Some people did talk about maintaining a positive 
outlook, but this was more in relation to how this helped them cope 
emotionally, rather than being a driver of adherence per se. Similar but more 
specific constructs, such as beliefs about future consequences and belief in 
the ability to control the condition appeared to  be more closely aligned to 
execution of adherence behaviours, in line with other research (Lloyd et al., 
2009; Maikranz et al., 2007).  
It is well accepted that MS has been shown to negatively impact health related 
quality of life (HRQoL) (Klevan et al., 2014; Mitchell et al., 2005). HRQoL 
considers the impact of health status on quality of life, with consideration of 
physical, mental, emotional and social implications (Bullinger, 1991). In this 
way, it is usually utilised as an outcome, rather than a predictive measure 
(Rabin and deCharro, 2001). However, when we consider how the aspects of 
QoL described here (e.g. physical, mental etc.) align with the impact of MS 
factors from the qualitative model of thematic relationships and, in turn, their 
impact on coping behaviours, it is possible to see how the relationship may be 
bi-directional. This supports the SRM in terms of disease management being 
an ongoing process of response, action, appraisal, adapted response; rather 
than a static ‘cause and effect’ relationship (Leventhal, Phillips and Burns, 
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2016) and demonstrates the potential mechanisms by which QoL predicts 
adherence behaviour.  
Research has demonstrated the impact of mood state / disorder on adherence 
(DiMatteo, Lepper and Croghan, 2000). It is proposed that it can impact 
behaviour through mechanisms such as reduction in motivation, impacting 
self-efficacy and through common comorbidities / symptoms such as fatigue 
impacting ability to execute desired behaviours. In addition, the SRM proposes 
the role of emotional response in influencing coping procedures alongside 
cognitive appraisals (Leventhal, Phillips and Burns, 2016). The impact of 
emotional states and response was evident from both the scoping review and 
the qualitative research. Furthermore, it was one of the factors that responded 
to behavioural intervention. It is important that the relationship between 
emotional distress / affect and behavioural outcomes is recognised as this 
reinforces the need for support to go beyond providing just practical tools and 
information to ‘directly’ facilitate behaviour. In addition, understanding and 
supporting psychological factors as well, will not only be of benefit to the 
individual themselves on an emotional level but likely have a positive influence 
on their ability and motivation to execute adherence behaviours.  
Cost was not something that was evident from qualitative review, though this is 
likely to do with the healthcare system set up in each of the countries involved 
– namely universal healthcare where the cost of medicine is not met by the 
patients.  
The role of social support, both practically to help with injections / medication 
management and also more holistically, in terms of reducing emotional impact 
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and providing motivation to manage was a core theme from the research, and 
was cognizant with findings from the review and the original COM-B. Social 
support in this context has been the subject of much review and has been 
demonstrated as a key influencing factor on health outcomes, including 
adherence (Shin and Kang, 2015; Tovar et al., 2013).  In addition, three of the 
interventions reviewed provided some form of social support, even if this 
wasn’t an explicit aim of the research. Whilst the premise of the SRM allows 
for consideration of social influences on appraisals and coping, it doesn’t 
explicitly examine them and the authors themselves recognise that there is an 
opportunity to explore these mechanisms further (Leventhal, Phillips and 
Burns, 2016). Considering how much friends and family featured in people’s 
discourse around the MS, both in terms of support given but also how people 
felt about the impact their condition had on those around them, and the guilt 
sometimes associated with that, it would seem that, when trying to understand 
not only the drivers of behaviour but also the mechanisms of action, explicitly 
reviewing social models alongside cognitive and emotional ones may be a 
useful addition to the tenets of the self-regulation model.        
The findings from the review highlighting the challenges people experienced in 
relation to treatment burden were replicated in the qualitative study. Injection 
treatments were perceived by many as difficult to manage and all the factors 
from the review (fatigue, pain, anxiety) were referenced in the discourse. In 
this sample, people were apparently, on the whole, fairly adherent and for 
those who persisted with injection-based treatments, the burden was 
‘accepted’ in relation to beliefs about the need for the medicine and fear about 
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the ‘what if’ of non-adherence, in line with the constructs of the necessity 
concerns framework (Horne and Weinman, 1999). Similarly, this finding also 
validates the inclusion of treatment perceptions as an extension of the SRM 
when looking specifically at adherence behaviours. Interestingly, some 
participants talked about their wish to ‘test’ the treatment; they felt that their 
belief in the value of persisting in the face of the challenges would be 
enhanced or reinforced if they could see that, without it, things were worse. 
This supports a finding from a qualitative synthesis of medicine taking 
behaviour whereby treatment holidays were a common way that people 
experimented with medicine to validate its effectiveness, referred to as lay 
testing (Pound et al., 2005). However, in this sample, people did not describe 
acting on this desire as anticipated regret appeared to provide a buffer against 
actually stopping treatment, likely influenced by the perceived seriousness of 
the consequences of the disease.  
In the review, HCP support of medication was a factor related to adherence 
behaviours. The COM-B for adherence includes this but with broader definition 
that encompasses not just treatment congruence but the quality of the 
overarching relationship and communication between patient and HCP. 
Research has explored the impact of the healthcare professional and patient 
relationship on adherence (Fuertes et al., 2015; Koudriavtseva et al., 2012) 
and found it to be an important driver of adherence behaviours. It is proposed 
to facilitate through a number of mechanisms, including trust, understanding, 
motivation and, in the case of shared decision making, helping to match 
clinical recommendations to the desires and the prioritised outcomes of the 
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patient (Fuertes et al., 2015; Koudriavtseva et al., 2012). The narratives of the 
people we spoke to demonstrated how ‘bad’ experiences with HCPs had 
negatively impacted them emotionally and, in some cases, led to avoidant 
coping behaviours or restricted acceptance and adaptation. Conversely, where 
people felt listened to and understood, their outlook on professional advice 
was more positive and the ‘additional’ social support appeared to increase 
confidence in their ability to control and cope with MS. This acceptance of the 
role of the patient in discussions and decision making has been proposed to 
facilitate the process of self-regulation in a positive way (Pollock and Grime, 
2000). Therefore, in the final proposed COM-B for adherence to DMTs in 
people with MS (Figure 8), it was felt that the original description of the factor 
was more relevant to cover all the aspects of this driver, rather than calling out 
one aspect as was relevant for the review findings.          
Travelling was a factor added from the review that did not feature in the 
original COM-B for adherence. In the context of these patients, travelling was a 
‘risk’ for non-adherence as it meant that normal routines and management 
strategies were disrupted, likely compounded by cognitive limitations and 
linked to the removal of their standard stimuli for action.        
Factors from the COM-B model of adherence supported by this research that did not 
feature in the scoping review  
When comparing the insights from the qualitative study to original factors in 
the COM-B model that did not feature in the scoping review, there were four 
that were supported and therefore were added back into the final proposed 
COM-B model for adherence to DMTs in people with MS.  
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The primary addition was the re-inclusion of illness perceptions within the 
category of reflective motivation, across the five key domains (duration, 
cause, identity, consequences and emotional response) (Leventhal et al., 
1980) plus coherence, which features in the Revised Illness Perception 
Questionnaire (Moss-Morris et al., 2002). These are discussed above. 
The role of comprehension of disease and treatment to facilitate adherence 
behaviours was evident through people’s descriptions of what motivated them 
to adhere to and persist with treatment. For example, knowledge of disease 
course and the function of treatment to reduce relapses, rather than cure MS 
or manage immediate symptoms was important as this helped to manage 
treatment and outcome expectancies and also informed perceptions of 
disease consequences. As described previously, whilst education alone is not 
enough to change behaviour, it is a core underpinning of behavioural change 
and, to this end, should be considered a core factor to review when exploring 
potential reasons for non-adherence (Haynes, 1996). In addition, three of the 
interventions included in the scoping review included educational materials 
and discussion topics, supporting the appropriate understanding of disease 
and treatment, as well as targeting other adherence factors (Zettl et al., 2016; 
Turner et al., 2014; Berger, Liang and Hudmon, 2005).  
In line with the findings related to the impact of increased disability and the 
challenges people faced with injection treatments, it was possible to re-
include dexterity from the original model within physical capability.  
Similarly, people talked about the stimuli and cues for action that prompted 
adherence behaviours, linked to routines (e.g. timing treatment use alongside 
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a morning cup of tea) or reminders (self-set or from others). In addition, 
congruent with identity illness representations, symptoms and disease 
experience were also a prompt, though this seemed to be more sub-
conscious than routines as an absence or reduction of symptoms (‘a good 
day’) could mean that people forgot their treatment, suggesting that their 
usual physical experiences were prompting action, rather than ‘overt’ 
cognitive decisions. 
 Additional themes or findings that could be mapped to COM-B categories  
There was one additional theme from the qualitative research that aligned 
with the category of reflective motivation that didn’t appear to be appropriately 
covered by the other included factors; anticipated regret. From the narratives 
it appeared to be not only a key driver of behaviours but also a ‘buffer’ against 
potentially unhelpful beliefs such as low treatment efficacy and negative 
experiences such as treatment burden. I felt that this was distinct from 
treatment necessity as it seemed to go beyond saying ‘I need this treatment’   
to describe the process of making a decision now to ‘protect’ your future self, 
not only from the condition but also from feeling that you, as the person in 
control, hadn’t done all you could, when you could.  
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Review of methods and models applied  
 
Qualitative methodology  
The previous limited qualitative exploration of the phenomenon of adherence 
in people with MS and the lack of behavioural insight this had generated 
suggested that taking a qualitative approach to try to enhance our 
understanding would contribute to knowledge in this area. However, as the 
work to date had garnered many potential variables, and in the spirit of trying 
to build on existing work, the research methods allowed for the inclusion of a 
theoretical ‘underpinning’ (namely the SRM and COM-b) to guide 
questionnaire development and analysis, whilst still allowing for novel data to 
be generated.  
On reflection I still feel that this was the right approach. Qualitative methods 
are seen as appropriate to answer questions where ‘pre-emptive reduction’ 
risks preventing discovery of insights (Atieno, 2009), something that had been 
apparent from the body of work so far. To this end, I feel this study did 
generate new insight, not only in terms of factors that could be added to or 
further validated in the MS specific adherence COM-B model, but also by 
generating a greater understanding of some of the potential mechanisms of 
action of these factors, as demonstrated in the model of thematic 
relationships that was produced from the research, prior to an application of 
the findings to pre-existing models.  
Underpinning the research with the same model that was used in the first part 
of the review (COM-B) and drawing out components of the self-regulatory 
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model, helped to anchor the findings to prior research and give structure to 
the research question as a whole. The self-regulatory model, which is a 
dynamic, multi-level model, particularly lends itself to qualitative exploration. 
Whilst the key variables of illness and treatment representations have been 
operationalised to self-report questionnaires (Broadbent et al., 2006; Horne, 
Weinman and Hankins, 1999) these can only tell us part of the story of self-
regulation. In an area where little qualitative research has been done, work to 
understand the prototypes people are referencing to influence their 
representations and how these in turn, manifest as coping procedures and 
appraisals needs a deeper level of investigation than can likely be conducted 
through just the use of questionnaires. 
There are limitations to the approach taken. By its nature, qualitative research 
does not seek to assign frequencies, weightings or statistical significance to 
its findings (Atieno, 2009). Similarly, it can be difficult to assign generalisability 
to the findings in qualitative research (Braun and Clarke, 2013).  In a research 
area where there is currently little consensus, as demonstrated by the large 
number of adherence factors identified in the first part of the scoping review, 
there is a risk that qualitative research will simply add to the ‘noise’ rather 
than help us identify areas for prioritisation, or provide insights that help the 
few, not the many. To this end, I do not propose that this qualitative research 
negates the need for systematic or meta-analytic review of this research area, 
as posited at the end of my scoping review. However, I think the use of a-
priori assumptions and models, and the combination of analysing the data 
‘raw’ AND operationalising to the SRM and COM-B, mitigated some of the risk 
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of just adding noise, as evidenced by the production of a further revised 
version of the COM-B, which built on existing knowledge.     
A particular limitation of this study, similar to the scoping review, is the fact 
that the analysis was conducted by one person only. Whilst guidance for the 
conducting of qualitative research does not negate the conducting of research 
and analysis independently per se (Braun and Clarke, 2013), I do feel the lack 
of in-depth discussion around the themes and again, as per the first review, 
further input and review of the operationalisation of the findings, not only 
made the process more difficult but reduces the reliability of the findings. 
Particularly as there were specific models being explored, which will influence 
the interpretation of the findings. Whist the role of the researcher is fully 
acknowledged in qualitative research (Bishop and Yardley, 2007), I feel that 
this is a potential weakness of this study and, if I were doing this again, I 
would seek to involve the other interviewers more formally in the analysis 
stage.     
COM-B Model    
Whilst the findings from the research supported many tenets of the SRM, I 
feel that reviewing the findings in line with a broader model (COM-B) 
prevented the research from becoming too restrictive and, in this way, it 
fulfilled its hypothesised function to reduce the likelihood of exploring 
behaviour within a single construct (e.g. motivation) and to consider the 
physical, cognitive and socially driven elements that may also be relevant, 
whilst still keeping them in the context of how they influence each other. 
Furthermore, as this had been used in the first part of the review it seemed 
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relevant to carry the process through the qualitative research. As discussed 
previously, the use of the model to operationalise findings carries a risk of 
factors being found because of a priming effect, but I believe that interpreting 
the data first without operationalisation (though the framework did obviously 
build on the underlying models of the research) helped to mitigate this in a 
least a small way.   
The addition of a new factor and the finding that not all of the factors from the 
‘original’ COM-B model for adherence were evident from this research, further 
supports my proposal in the first part of this thesis, that perhaps it is enough 
to have this model at a category level to aid research synthesis and 
considerations for intervention design (Jackson et al., 2014). As described by 
Ogden (2016), there is a potential risk that too much systemisation of health 
psychology, undermines the role and skills of psychologist themselves to 
make interpretations and recommendations based on their experience and 
ability to apply a human element to research, that is, at the end of the day, 
about how humans ‘work’.   
Self-regulatory model  
I feel that whilst this review supported many tenets of the SRM, I believe it 
also highlighted some areas for further consideration. The key premise of 
‘regulation’ was supported by the findings from the qualitative review and 
many of the illness representations that were not evident in the scoping 
review were supported also. The complex and dynamic nature of adherence 
behaviours, and how many different factors can influence not only beliefs but 
the planning processes involved in executing behaviours (both explicit and 
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implicit) were also evident from this research and support they hypothesised 
way that self-regulation works (Leventhal, Phillips and Burns, 2016).  
However, I feel that the SRM does not adequately account for the role of 
social support and considerations in the influencing of representations, coping 
procedures and appraisals. Both the factors review and this qualitative 
research demonstrated how much people with MS were ‘reliant’ on the 
support of others to help manage their condition and treatment, and also how 
considerations for the impact of their condition on others influenced their 
perceptions of the disease and motivated them to self-manage. The authors 
themselves acknowledge that there is more that could be done to understand 
the social influences (Leventhal, Phillips and Burns, 2016) and this research 
supports that assertion. I believe this reiterates the use of the COM-B 
framework to allow for extrapolation of these external factors alongside the 
cognitive appraisals, but I do wonder if there is an opportunity to map more 
formally social process either within or alongside the SRM. Figure 9 
represents an example of how social models could ‘fit in’ to help draw out in 
more detail the mechanisms of action of this particular area of adherence 
influence, in a similar way the SRM can sit within the motivation category of 
COM-B. Whilst the aim is not to pre-determine the particular factors within 
each category, perhaps a hybrid, where recommended models / theories are 
assigned to the categories to aid better understanding of the mechanisms 
within and across each category, would be beneficial. It also incorporates 
findings from the first review whereby impaired cognitive function may not just 
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‘unintentionally’ impede ability to execute behaviours but also the overall 
process of regulation.   
 
Figure 9 – Hypothesised mapping of models  
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Contribution to knowledge  
This scoping review and qualitative study has contributed to our knowledge 
by: 
• Highlighting the current incongruence between research investigating 
factors influencing adherence in people with MS and the interventions 
designed to address these factors 
• Increasing our understanding of the mechanisms of these factors in 
term of how they influence adherence through qualitative exploration  
• Proposing a COM-B model for adherence that is specific for this 
population, built on existing research (factors review) and further 
validated and refined through qualitative exploration  
• Identifying successful intervention techniques to address some of these 
factors in MS  
• Proposing how COM-B may be better used to operationalise findings 
through the application of specific models to categories, based on the 
behaviour being selected, as opposed to trying to ‘pre-map’ discreet 
factors.    
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Conclusion   
This research has highlighted the fact that, despite many years, and a relatively 
large volume, of research looking at drivers of adherence in people with MS, 
we do not yet have a core understanding of what should be prioritised in terms 
of trying to change that behaviour. This was borne out in the volume of discreet 
factors that were found, the incongruence of findings between the two scoping 
reviews and the additional insight that was gained from qualitative exploration.  
The first scoping review identified a broad range of potential relationships, but 
with little consistency and stratification being identified. In addition, the methods 
employed and, to some extent, the premise of the research has meant that 
many factors identified are un-modifiable and there is little consideration for the 
complex relationships between factors and behaviour. The qualitative research 
supported this as it demonstrated that the same treatment types and symptoms 
could be managed and perceived differently by different people, dependent on 
broader factors, such as levels of perceived control, support, emotional state 
and priority values.   
Secondly, this style of research is based on the ‘strength’ of findings – which is 
the most important factor, who is most likely to deviate from their treatment 
plan? As described above, this may help to identify those most ‘at risk’ of 
nonadherence (Allemann et al., 2016) but does enhance our understanding of 
how best to support people. The qualitative findings demonstrated that 
managing MS is multifaceted; adherence does not occur in an isolated vacuum. 
To this end, trying to find the statistically significant ‘silver bullet’ that will solve 
everything is untenable. As described by Vermeire and colleagues (2001) 
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adherence is a flexible and somewhat elusive goal, in this instance, one size of 
intervention will not fit all. The relative success of skills based, individualised 
therapeutic interventions in enhancing both adherence and psychosocial 
outcomes demonstrates this. If an intervention has been able to enhance 
someone’s overall ability to cope and feel in control, provide support and 
understanding and help people resolve conflicts, then as we have seen from 
people’s own experiences, this sets them up to be able to effectively manage 
and respond to all the demands that living with MS, including adherence, 
presents.   
This research has also supported the use of elements of the BCW to categorise 
and synthesise bodies of research, not only to aid understanding but also as a 
tool to build insights on the back of previous research, as demonstrated by the 
three variations of COM-B featuring in this work alone. It’s strength in helping 
to ‘unpick’ interventions, particularly with the mapping of BCTs, was also 
evident as this allowed for synthesis of a range of different interventions, albeit 
a small sample. However, as has been said by others, this research also 
demonstrated that caution should probably be applied to trying to predefine 
lower level tenets of the BCW, such as factors within COM-B categories and 
the linking of techniques to intervention functions, for risk of becoming too 
reductive and potentially undermining the skills of the psychologist themselves. 
However, it’s function to be able to draw out some of the relational 
considerations does lend itself to mappings at a more intermediate level, such 
as the Extended-SRM within motivation in the case of an overarching 
adherence model, as proposed in my mapped model.  
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 The applicability of the SRM to this population was also evident, in particular 
through the qualitative narratives. People talked about how their feelings and 
beliefs about MS influenced their coping behaviours, both practical and 
emotional, and how these could be influenced by features of the disease, as 
well as thoughts about the past and the future. The role of regulation was also 
seen, in particular between the themes of conflict and control.  
However, both the qualitative research and the operationalisation of factors 
through COM-B suggest that the SRM ‘alone’ is not enough to understand 
adherence behaviours and, if used in isolation, risks not accounting for 
potentially strong influencers, such as social drivers, and more discreet 
concepts such as guilt. 
Implications for practice  
This research has somewhat helped to better understand the phenomenon of 
adherence in people with MS, in particular through the revised COM-B 
specifically for people prescribed DMTs and the model of thematic 
relationships from the qualitative research. Whilst, due to the limitations 
already cited, these are not proposed as the final models for adherence in 
MS, I feel they provide a more synthesised version of the research to date 
from which future research can be built. In addition, the behavioural focus of 
this research means that these findings, including those from the second 
review, can hopefully better inform the design of future behavioural 
interventions for people with MS.  
I feel that this research is also a bit of a ‘call to action’ in terms of trying to 
align research that explores the drivers of behaviour and research that tries to 
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modify it. Particularly as I have found this disconnect in the area of acute 
coronary syndrome as well (Johnston et al., 2016). Continually generating 
data that we don’t build upon, that we cannot influence is going to do little to 
advance our ability to positively influence adherence behaviours. 
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 Appendix i: Study Selection Process Flow - Review 1 Factors impacting adherence in MS  
 
 
No. of records identified through 
database searching 
(n=4874) 
Titles screened 
(n=4874) 
Records excluded: not relevant  
(n=4804) 
Abstracts screened 
(n=70) 
Total records excluded (n=19): 
Adherence rates only (n=6)  
Adherence to other behaviour (n=3) 
Clinical outcomes (n=1)  
Intervention study (n=6) 
Questionnaire development (n=1) 
Review / commentary; no original data (n=2) 
 
 
Full texts assessed for eligibility 
(n=51) 
Total records excluded (n=20): 
Adherence impact only (n=2)  
Adherence rates only (n=4)  
Clinical drivers / physician decision only (n=8) 
Clinician role in adherence (n=1) 
Hypothetical treatment (n=1)  
Intervention study (n=1)  
Review / commentary; no original data (n=3) 
Full data extraction and reference list 
review  
(n=31) 
Additional texts identified and data 
extracted  
(n=2) 
Total studies included in current 
findings 
(n=33) 
 
Appendix ii: Study Selection Process Flow - Review 2 MS Adherence factors successfully 
modified through intervention  
 
 
 
 
No. of records identified 
through database searching 
(n=361) 
Titles screened 
(n=361) 
Records excluded: not relevant  
(n=315) 
Abstracts screened 
(n=46) 
Total records excluded (n=30): 
Basic education intervention (n=9)  
No significant impact on adherence (n=10) 
Only measured ‘other’ self-management behaviours 
(n=6)  
No control or comparison data (n=5) 
 
 
 
Full texts assessed for eligibility 
(n=16) 
Total records excluded (n=14): 
No significant impact on adherence (n=7)  
Intervention description not clear enough (n=2)  
Measured adherence to the intervention, not 
treatment (n=2) 
No control or comparison data (n=3) 
 
Full data extraction and reference 
list review  
(n=2) 
Additional texts identified and data 
extracted  
(n=2) 
Total studies included in current 
findings 
(n=4) 
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Screening Questionnaire 
 
Please select/complete as appropriate: 
1. Gender – inferred by interviewer 
Male  Female  
 
2. What age are you? 
Age (years)  If under 18, CLOSE 
 
3. Have you been diagnosed with multiple sclerosis? 
Yes  Go to Q4 
No  CLOSE 
 
4. When were you diagnosed with multiple sclerosis? 
DD/MM/YYYY  
 
5. Do you know what type of multiple sclerosis you are diagnosed with? 
Relapse-Remitting MS (RRMS)  Go to Q6 
Secondary Progressive MS (SPMS)  CLOSE 
Primary Progressive MS (PPMS)  CLOSE 
Progressive Relapsing MS (PRMS)  CLOSE 
Don’t Know  CLOSE 
 
6. Are you currently receiving treatment for multiple sclerosis? 
Yes  Go to Q7 
No  CLOSE 
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7. What treatment(s) are you currently using for your MS?  
 
Treatment Tick applicable 
Avonex (interferon Beta 1a)  
Betaferon (interferon Beta-
1b) 
 
Copaxone (glatiramer acetate)  
Extavia (interferon Beta- 1b)  
Gilenya (fingolimod)  
Rebif (subcutaneous 
interferon Beta -1a) 
 
Tysabri (natalizumab)  
Other (please state)  
 
8. Have you received any treatments for multiple sclerosis prior to your current treatment? 
Yes  Go to Q9 
No  Go to Q10 
 
9. If Yes, how many? 
 
 
10. What level of MS related disability do you currently have? 
No symptoms  
Some symptoms, No disability  
Mild Disability  
Moderate Disability  
Severe Disability  
No Response/Not sure  
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Patient Confirmation Email / Letter  
 
This email / letter will be sent to people who have been identified by the recruitment agency as 
eligible for the research and have expressed an interest in taking part.  
 
Dear [Recipient] 
 
RE:  Research exploring the experiences, perceptions and beliefs of people diagnosed with 
multiple sclerosis. 
 
Following your expression of interest to take part in this research on [insert date], I am pleased to 
confirm that we will be calling you on [insert date] at [insert time]. You will be called by one of our 
interviewers and it is anticipated that the call will take approximately 45-60 minutes. 
 
Before the interview we would like to share some further details of the research which are outlined 
in the Research Information Sheet that has been included with this correspondence.   
 
In addition, we are required to get signed consent from you before conducting the interview.  We 
have included a Consent Form with this correspondence.  Please can you sign and date this once you 
have read the Research Information Sheet and feel confident that you are happy to proceed with the 
interview. This signed form can either be returned to us by post, fax or scanned into an email.  The 
contact details to return this form are detailed below.  Please be aware that as we cannot conduct 
the interview without this consent, it may be necessary to change the date and time of the interview 
if it is not received before the date detailed at the start of this email / letter.     
 
We look forward to speaking with you, 
Yours sincerely, 
 
[Name] 
[Title] 
Include recruitment company contact details 
 MS-UK-10/13-4613a   
 
Research Information Sheet 
 
You have been invited to participate in this research, which is aiming to understand the experiences 
and perceptions of people diagnosed with multiple sclerosis and their experiences of treatment. In 
addition we would also like to understand your current experiences of healthcare support and 
identify any areas where additional support might be beneficial.   
 
This research is being conducted by Atlantis Healthcare in association with a pharmaceutical 
company that creates and makes medicines and other health products.   
 
Participating in this research involves being interviewed by a researcher over the telephone and it is 
anticipated that the interview will last approximately 45-50 minutes.  During this interview you will 
be asked questions that relate to your personal health experiences, medication use and experiences, 
symptoms of MS, the impact of MS on you day to day and your experiences with your healthcare 
team.   
 
During the research interview, it may also be necessary to collect additional safety information in 
relation to particular medicines / drug products, should you say something in the interview that 
indicates a safety risk with that product. This is known as ‘Adverse Event Reporting’.     
 
The interview will be recorded and subsequently transcribed to help us analyse the discussion. All 
the information collected will be kept completely confidential and will not be passed onto the 
healthcare professional overseeing your care for multiple sclerosis. Furthermore, comments you 
make during the interview will be made anonymous in our research report and you will remain 
completely anonymous to the pharmaceutical company who are conducting the research. 
 
Your participation in this research will be completely voluntary, you will have the right to withdraw 
your participation at any time and to withhold any information you do not wish to share. 
 
If you are interested in being involved in this research or would like to discuss it further with our 
team, please let us know by getting in touch by emailing or calling our central coordinator.  
- Third party recruitment agency details  
 
 MS-UK-10/13-4613a   
 
 
 
Consent Form 
 
Title of research: Qualitative research to explore the experiences, perceptions and beliefs of people 
diagnosed with multiple sclerosis. 
 
Name of researchers: Atlantis Healthcare in association with a pharmaceutical company. 
 
Please read the statements below and tick the box to confirm that you have read and understood 
the information provided. 
 
¨ I confirm that I have read and understand the information sheet provided for the above 
research and have had the opportunity to ask questions. 
 
¨ I understand that my participation in this research is voluntary and that I am free to 
withdraw at any time, without giving any reason. 
 
¨ I understand that the interviewer has an obligation to report any adverse events that are 
mentioned during the course of the interview. 
 
¨ I give my consent to participate in this research interview. 
 
 
 
________________________  ____________  ________________________ 
Name of Participant   Date   Signature 
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Research to explore the experiences, perceptions 
and beliefs of adult people with Multiple Sclerosis 
(MS) and their impact on adherence 
 
Research Sponsors 
Research will be sponsored by Genzyme and carried out in collaboration will Atlantis Healthcare 
(AH). 
 
Rationale 
This qualitative research is proposed to find out more about the experiences of people with multiple 
sclerosis (PwMS). This qualitative research will seek to validate findings from our literature review, 
from which the current programme design assumptions have been drawn (please see the ‘Clinical 
Framework’ for an outline of these factors).  
 
This research will aim to understand the drivers and barriers in adherence to treatment and self-
management behaviours in MS. Using a qualitative research technique, there will be exploration of 
the beliefs that are key in adherence and an investigation of current self-management processes. 
The outcome data will be used to inform a hypothesis of key factors that impact adherence and how 
these factors can inform a proposed support solution. 
 
In the following sections the qualitative research protocol will be described, including rationale, 
objectives, participant sample and procedure, followed by detailed research methods. 
 
Research objectives 
Primary 
• Explore the current and previous experiences of treatment for MS. 
• Investigate the practical drivers and barriers in adherence to treatment for MS. 
• Identify key beliefs that impact adherence to MS treatment. 
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Secondary 
• Determine the strategies employed by PwMS to help adhere to their current or previous 
treatment. 
• Gain insight into perceived support and informational needs of PwMS and perception of 
gaps in care and support. 
• Explore perceptions of ability to adhere to monitoring and self-checking requirements  
• Explore perceptions of proposed example screening questions.  
 
Recruitment Strategy and Procedure 
Participants 
A total of 24 PwMS will be interviewed across three countries. Participants will be recruited from the 
UK, Germany and Spain. Eight eligible participants will be recruited from each local market for one-
to-one telephone interviews. During recruitment researchers will endeavour to recruit a diverse 
sample of participants to reflect a range of different experiences.  
 
Inclusion criteria: 
• Diagnosed with Relapse Remitting MS (RRMS) 
• Fluent speakers of first language of country of interview, or English 
• Aged 18 years and over 
• Currently receiving a disease modifying treatment (DMT) for MS 
 
Desirable inclusion criteria: 
• Range of socio-demographic criteria 
- Gender: aim to reflect incidence rates across the condition 
- Age: aim to include broad range of age groups (>18 years old) 
- Regional variation within each country: aim to include PwMS from a number of 
different district or regional hospitals, as well as specialist centres in each 
country 
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• Multiple Sclerosis factors 
- Sample to have been prescribed a range of different disease modifying 
treatments (DMTs) 
- Participant sample to contain a range of time since diagnosis 
- Aim to include a range of abilities:  
1. No symptoms,  
2. Some symptoms, no disability,  
3. Mild disability,  
4. Moderate disability, 
5. Severe disability 
 
Exclusion criteria: 
• Patients with severe or profound intellectual disability 
• Patients who have a cognitive ability such that their level of impairment prevents them from 
fully understanding the research and research protocol 
 
Recruitment 
Third party market research recruitment agencies will be used to identify and recruit participants for 
each country. They will be contracted by Atlantis Healthcare with associated costs being passed 
through to Genzyme.  
 
Procedure 
PwMS meeting the inclusion criteria will be sent an invitation email or letter explaining the nature of 
the research, why they have been contacted and how their details were obtained. Interested 
participants will then be contacted to arrange an interview time that is convenient with them. 
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Research Methods 
Qualitative interviews 
The design of the current research will be a qualitative study based on semi-structured telephone 
interviews.  Interviews will be carried out by a Health Psychology Specialist with people who are 
diagnosed with multiple sclerosis (PwMS). Expected duration of interviews will be 45 to 60 minutes 
per interview.  
 
The interviewer will follow an interview guide stating general themes and questions to be explored, 
accompanied by suggested prompts and sub-questions. The interviewer will also have the flexibility 
to bring up new questions during the interview as a result of what the interviewee says. 
Each interview will be recorded and transcribed verbatim to allow for subsequent analysis. 
 
Rationale 
A qualitative approach allows the key issues to be explored in greater depth and detail. The aim of 
qualitative research in this context is to gain detailed insights into PwMS’s lived experience of 
healthcare and illness, and also the processes involved in health related behaviours (Bishop and 
Yardley, 2007).  
 
One-to-one interviews have been chosen as this will allow us to get detailed insights into individual 
perspectives and experiences. In addition, as the topic of their illness is potentially sensitive, it is 
hoped that one-to-one interviews will encourage more open responses and allow for ‘minority 
responses’ which may not come out in a patient focus group (Bishop and Yardley, 2007). 
 
Sampling strategy 
This research will use purposeful sampling in order to explore a range of perspectives of the PwMS. 
In the context of qualitative research, purposeful sampling involves seeking out participants with 
particular experiences relating to the objectives of the research. This evokes more in-depth 
understanding of the topic as a pose to making empirical generalizations (Patton, 2002). In the 
current research, researchers will endeavour to recruit a diverse sample of participants with a range 
of different socio-economic characteristics (e.g. age, gender, religion etc.). 
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Data analysis plan 
The interview content will initially be transcribed in preparation for data analysis. The qualitative 
data will then be analysed using a framework analysis approach as outlined by Ritchie and Spencer 
(1994). Framework analysis is used to elicit and identify commonly expressed patterns (themes) 
within qualitative data. This information can then be used to interpret aspects of the research topic 
and draw meaningful conclusions. 
 
Ethical Considerations 
Regulatory approvals 
This research will not commence before it has received approval from Genzyme for the research 
protocol and all research materials.  This includes approval of interview schedules, participant 
information sheets and patient screeners. 
 
The research will be conducted in accordance with the ethical guidelines for conducting research 
with human participants as outlined by the European Pharmaceutical Market Research Association 
(EphMRA) in the European Healthcare Market Research regulations.  
 
Informed consent and participant information 
Participants will be required to give informed consent prior to taking part in the research; this will be 
obtained in writing prior to the interview and will be confirmed again verbally over the telephone 
before the interview commences. Eligible participants will be sent via post or email a formal 
research invitation accompanied by a consent form and an information sheet outlining the aims and 
procedures of the research the type of information that will be collected (e.g. related to their 
personal health experiences, medication use, symptoms, impact of MS on daily living and 
experiences with their healthcare team) and to reassure them of the confidentiality of the research. 
Participants will be informed that their participation is completely voluntary and they have the right 
to withdraw at any time without giving a reason or justification.  They will also be provided with 
contact details should they have any questions prior to agreeing to take part in the research.   
The interview call will not be scheduled until a signed consent form has been received (either by 
post, fax or email scanned copy). At the start of the telephone call the researcher will reiterate the 
important salient information as described above, including specific examples, and give the 
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participant the opportunity to ask questions.  The researcher will ensure they are confident the 
information sheet has been read and understood. 
 
 
The ability to give informed consent requires a sufficient level of mental and cognitive ability in order 
to understand what is involved in the research.  Therefore, the recruitment agency will be asked to 
screen for any individuals who have impairments in understanding or communication that may 
affect their ability to give informed consent or sufficiently engage with the research process (e.g. 
patients with severe or profound intellectual disability or some people experiencing mental illness). 
However, if the researcher still has concerns over an individual’s ability to give informed consent, 
where possible the third party organisation will be consulted for further guidance or interview 
terminated. 
 
Participant confidentiality and data protection 
The identity of the participants in this research will be kept strictly confidential. Their identity will 
not be disclosed outside of the recruitment and research team.  In the case of Adverse Event 
reporting, participants will be specifically asked if they would like to waive their anonymity. Personal 
identifiable data of the participants will not be shared and data will be reported in an aggregated 
form to protect anonymity and confidentiality. When direct quotes are used, all identifiable 
information will be removed 
 
During the data collection, audio recordings, interview transcripts, patient information sheets and 
consent forms will all be sent to Atlantis Healthcare offices for review and analysis. Hard copies of all 
research materials will be kept in a locked cupboard in a lockable room and access given to the 
Atlantis Healthcare research team only. Electronic data and audio recordings will be kept on a secure 
server in password protected files. Each participant will be allocated a unique participant ID number 
which will correspond to computer files, recordings and transcripts. To maintain a high level of 
confidentiality this coding system will also be used when sending audio files for transcription. Only 
the recruitment agency and the AH research team will be able to associate any data with the identity 
of the participant.  All data will be kept for 10 years in accordance with the Data Protection Act 
(1998).   
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Potential risk to participants 
The overall risk to people participating in this research study is considered to be low. The likelihood 
of physical risk is very low as there are no tasks or physical requirements in this research. 
Participants will however be asked for demographic information (i.e. age, gender) and self-reported 
social and emotional wellbeing with particular reference to their condition. These questions may be 
perceived as sensitive to some people and could evoke an emotional reaction. For this reason there 
may be a small likelihood of psychological risk as a result of reflecting on their condition and overall 
well-being. As a part of standard practice with this type of research participants will be participants 
will be advised at the end of each interview that, if they are experiencing any ‘adverse’ feelings 
following the interview that they may want to consider talking to someone appropriate.  
 
Adverse events 
Adverse Events will be reported in accordance with AE reporting SOPs, please see appendices i and 
ii. 
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Appendix I: Text if a Patient Respondent Raises 
an Adverse Event  
[Safety Information is identified and the participant is on a Genzyme/Sanofi Product] 
What you [have just said] / [said earlier in the interview] is classified as safety information 
(NOTE: follow the definition of Safety Information as per SOP). The product manufacturer 
commissioning this programme (Genzyme) is required to collect this kind of information in 
order to continue identifying new side effects, and ways in which the risks of known side 
effects can be minimised. Every report they receive contains potentially useful information. I 
would like to spend a couple of minutes with you now to collect the necessary details of this 
safety information, so that the manufacturer can fulfil their obligations.  Are you willing to 
assist with the reporting of this? 
If NO:  Because I have become aware of this reportable safety information, I am obliged to 
report this to product manufacturer. I will file this report without identifying your personal 
details. I may use your initials, gender or age group in case follow-up is required and I need 
to contact you for this. I would also recommend that you speak to your doctor so that they 
are aware of what you have experienced, and if necessary, follow up with you. 
If YES: Thank you. The information you provide will be sent Genzyme’s Drug Safety 
department who, although unlikely, may wish to contact your doctor for further 
information. Would you like to provide the name of your doctor and allow permission to 
share your full name to enable them to identify yourself to your doctor?” 
 [Allow the patient to respond –Address any question they may have regarding the safety 
information report] 
If the patient agrees to their personal details being included in the report, their contact 
details and HCP details are sent with the report. 
If the patient prefers not to share their details, the report is sent de-identified and as agreed 
per the Safety Information Reporting SOP.   
“Thank you. The information you provide will be sent to Genzyme’s Drug Safety 
department. 
[Safety Information is identified and the participant is on a NON-Genzyme/Sanofi Product] 
What you [have just said] / [said earlier in the interview] is classified as safety information 
and we would therefore advise that you speak to your doctor so that they are aware of 
what you have experienced, and if necessary, follow up with you. [Allow the patient to 
respond –Address any question they may have regarding the reporting of the safety 
information] 
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Summary Rationale  
This qualitative research aims to explore and understand the beliefs and adherence 
behaviour of adult people with multiple sclerosis (PwMS) on disease modifying treatment 
(DMT). 
 
This research will explore: 
• The situations, beliefs, experiences and abilities that may drive people’s adherence 
to treatment and monitoring during MS treatment, 
• Current self-management processes, perspectives of support and perceived gaps in 
help and support. 
• Perceptions of proposed example screening questions.  
 
Interviews will be conducted with PwMS across three countries (UK, Germany and Spain). 
One-to-one interviews will be conducted by Atlantis Healthcare clinical researchers over the 
telephone, recorded and transcribed verbatim. The analysis will be done thematically to 
draw out the most important issues affecting patients’ adherence and quality of life, as well 
as explore their current self-management strategies. 
 
All adverse events (AEs) will be recorded and reported back to Genzyme, the client, 
according to their standard operating procedures and approved wording, please see 
appendices i and ii.  All researchers involved in interviewing patients will complete training 
in AE reporting according to Genzyme standards prior to data collection. 
 
 
 
 
 
    
 
 
 
 
Interview Schedule 
The following schedule is a guide for the interviewer. The questions are not required to be 
read verbatim to the patient, but can be used as prompts to refer to as and when needed 
throughout the natural flow of the conversation. The guide is designed to help ensure that 
the relevant topics are covered. The precise ‘course’ of the interview is dependent upon the 
interviewee and it is the role of the interviewer to facilitate rather than lead the discussion. 
This flexibility allows the researcher to dig deeper into relevant issues to fully understand 
the interviewee’s perspective to achieve the research objectives. 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
Introduction  
 
(To be read verbatim) 
“Thank you for agreeing to take part in this research today. My name is …… [state Name] 
and I work for a company called Atlantis Healthcare based in [state country: the 
UK/Germany/Spain]. We are looking to understand the experiences of people with multiple 
sclerosis, including what it is like to live with MS and your thoughts about different disease 
modifying treatment (DMT) options to help manage your condition. We are also looking to 
understand your experiences with healthcare professionals, of healthcare in general and to 
explore any additional support needs that you may have.  In this study you will be asked to 
talk about some subjects that are sensitive and personal.  For example, how you feel about 
having MS, the types of treatment you have had and how they have worked for you (or not), 
the reasons you may or not stayed with a treatment, support you may or may not have in 
relation to your MS and the possible emotional consequences of MS and treatment 
outcomes. The information from this telephone interview will be used to inform the 
development of a programme offering support to people with MS in living with MS and 
managing their treatment. 
 
There are no right/wrong answers; we just want to explore your experiences. 
Before we begin I just need to explain a few things about the study:  
 
• This research is sponsored by a pharmaceutical company and is being carried out 
within the Market Research codes of conduct  
• The aim of this research is to gain your views for market research purposes only and 
is not intended to be promotional.  
• Anything that you are told about during this research should be treated as 
confidential. Any information presented during the course of this research is done so solely 
    
 
to explore reactions to such information and should be assumed to represent hypotheses 
about what can be said about a product or disease area. It should not be used to influence 
decisions outside the research setting.  
• The identity of respondents is confidential and none of your details will be passed on 
to any 3rd party.  
• Outputs of this research may be used by the sponsoring pharmaceutical company in 
a promotional or external context at an aggregated level or using anonymised quotes.  
• This interview will be audio recorded for analysis and quality control purposes.  
• Any information you disclose will be treated in the strictest confidence and the 
results of the research aggregated to provide an overall picture of attitudes to the areas 
being covered in this survey. No answers will be attributable to you as an individual.  
• You have the right to withdraw from the research at any time and to withhold 
information as you see fit and to refuse to be audio recorded.  
 
Can you please confirm that you understand and accept the points that I have just read out 
and are happy to proceed with the interview on this basis?  
 
Interviewer to put cross in appropriate box  
¨ YES   
¨ NO  
 
[Text if a respondent says ‘Yes’] 
This interview will take approximately 45 minutes to an hour. Are you comfortable with 
that?  
Do you have any questions at this point?” 
[Text if a respondent says ‘No’] 
That’s absolutely fine, we will not continue with the interview.  
Do you have any questions before we finish this call?  
[Answer / record as appropriate] 
    
 
Thank you for your time.  
  
Interview 
 
Multiple Sclerosis 
 
1. I’d like to begin by understanding a little more about your experiences with multiple 
sclerosis. Can you tell me about your condition, how and when you were first 
diagnosed and how it may have impacted you and your day to day life? 
 
Aim: To understand the patient’s background, how they identify with MS and the 
interviewee’s experiences of living with their condition that may impact on their motivation 
to adhere. 
 
Prompts / sub questions  
Clinical 
Framework 
Topic Detail 
 Diagnosis / 
Timeframe 
When were you first diagnosed with multiple 
sclerosis?  
What was your experience of being told you had 
multiple sclerosis? 
Self-efficacy / 
Treatment 
Efficacy and 
Necessity / 
Patient related 
outcomes / 
Disability and 
Lifestyle 
Symptoms 
Personal Control of 
Condition 
What symptoms affect you in your everyday life? 
How much control do you feel you have over 
your symptoms? (explore how this impacts their 
self-management behaviours, including 
adherence) 
 
Self-efficacy  Personal Control of 
Condition  
Do you feel you are able to control or change 
your MS?  
 Future  What do you see happening in the future in 
relation to your multiple sclerosis? (explore their 
reasoning for what is likely to happen in the 
future) 
 
    
 
 
 
 
Treatment experiences/beliefs 
 
2. We have talked about your experiences of living with multiple sclerosis; I’d also like 
to understand your experiences of disease modifying treatment (DMT) options you 
receive or may have previously received [check if the patient understands DMT, 
otherwise explain]. Can you tell me more about this?  
 
Aim: to understand the patient’s treatment experience and their beliefs about treatment/ 
treatment options.  
 
Prompts / sub questions  
Clinical 
Framework 
Topic Detail 
 Previous/Current 
treatment 
Ascertain previous and current DMTs 
Motivation to 
adhere / 
Treatment 
Necessity and 
Efficacy 
Experience / Timeframe Tell me about your treatment experience 
with MS.  
How has this changed over time / with 
different treatments?  
Treatment 
Efficacy / 
Necessity 
Treatment efficacy How effective do you think your treatment is 
and what does ‘effective’ mean to you? 
What has worked/what hasn’t? 
Practical barrier: 
Comprehension 
Treatment 
understanding 
Do you feel you have a good understanding 
of your treatments?  
e.g. what they are, differences and how they 
work? 
Motivation to 
adhere 
Treatment control Do you feel treatment can control or change 
your condition?  Why?  
Treatment 
Necessity / 
Motivation to 
adhere 
Medication importance How important is your treatment? 
What is the most important thing about your 
treatment?   
What would be the impact on you if you 
didn’t have any treatment for your MS?  
Treatment Side effects Do you feel you have experienced side 
    
 
concerns effects or adverse experiences, 
Explore impact these have on the way the 
PwMS feels about a treatment and their 
adherence 
Treatment 
Concerns 
Concerns/Questions Do you have any concerns or unanswered 
questions about your medication?  (explore 
the impact this has on self-management and 
confidence) 
 
Adherence and Persistence  
 
3. Thinking about the treatment you have received, I want to explore how you follow or 
have followed you medication regimen. Many people have their own way of taking 
their medicines, which can be different from the instructions given by the doctors. 
What do you do / what is your routine?  
 
Aim: to understand adherence and persistence to DMT  
 
Prompts / sub questions 
Clinical 
Framework 
Topic Detail 
 Clarify What is your current medication regimen? 
Treatment 
Necessity / 
Treatment 
Efficacy / 
Motivation to 
Adhere 
Persistence Have you ever decided to stop using your 
medication? 
[If yes] - what made you do this / how long for? 
[If no] – what is it that makes / made you 
continue?  
Treatment 
Necessity / 
Treatment 
Efficacy / 
Motivation to 
Adhere 
Adherence Do you follow your medication regimen as 
advised by HCP? 
Have you followed previous treatment 
regimens? 
(explore reasons for adherence or non-
adherence as applicable) 
 Adherence  To what extent do you follow the regimen? 
Self-efficacy Self-efficacy Do you feel confident that you are able to follow 
the regimen? (explore reasons as applicable) 
Treatment 
Necessity / 
Non-adherence: 
reason 
When you haven’t followed the regimen as 
prescribed, what are the reasons for this? 
    
 
Treatment 
Efficacy / 
Motivation to 
Adhere 
 
Explore reason for non-adherence (current and 
previous) 
- Change depending on how you feel? (e.g. 
side effects, emotional reasons, no MS 
symptoms) 
- Change depending on what you are 
doing? (e.g. holiday) 
-  
 
 
Self-efficacy  
 
Clinical 
Framework 
Topic Detail 
Self-efficacy / 
Cognitive Decline 
& Forgetting 
Self-management 
strategies 
Do you have any strategies to help you 
remember? (i.e. planning, reminders) 
Self-efficacy / 
Cognitive Decline 
& Forgetting  
Ease of self-
management 
Do you find it relatively easy to rather difficult 
to self-manage your treatment regimen? 
(explore reasons) 
Self-efficacy / 
Cognitive Decline 
& Forgetting 
Support Do you have help with your treatment for MS? 
- From friends and family 
- Other support? 
 
Self-management 
 
Clinical 
Framework 
Topic Detail 
Practical 
Barriers:  
Cognitive 
Functioning 
 
Motivation: Self-
management 
Self-management 
strategies 
Would you develop any strategies to help you 
attend to your monitoring? (i.e. planning, 
reminders) 
Practical 
Barriers:  
Cognitive 
Functioning 
 
Ease of self-
management 
Would you find it relatively easy or rather 
difficult to self-manage compared to your 
current regimen? 
    
 
Motivation: Self-
management 
 
Practical 
Barriers:  
Cognitive 
Functioning 
 
Motivation: Self-
management 
 
Independent 
management / 
Support  
Do you think you would want help with your 
monitoring regimen or would you manage it 
yourself? 
If you were going to have help who would you 
ask?  
• Friends and family? 
• Healthcare team?  
• Other?  
 
HCP interaction 
 
4. I’d now like to talk to you about your experiences with healthcare professionals who 
are involved in the treatment and management of your multiple sclerosis. Can you 
tell me a bit about your interactions with your doctors and nurses?  
 
Aim: To explore the possible impact of HCP interactions and support on adherence  
 
Prompts / sub questions  
Clinical 
Framework 
Topic Detail 
 Who is the HCP? 
(Background) 
Without giving their personal names, which 
HCPs do you see in relation to your multiple 
sclerosis? (e.g. GP, specialist, nurse, pharmacist, 
other)?  
Treatment 
Necessity / 
Treatment 
Concerns 
HCP understanding Do you feel confident that your HCP 
understands your experiences with your 
Multiple Sclerosis and your treatment?  
Treatment 
Necessity / 
Treatment 
Concerns 
Confidence in HCP Would you feel comfortable talking to your HCP 
about problems or concerns you had relating to 
your treatment?  
 
Self-efficacy  Monitoring assistance Does your HCP tell or support you with how to 
follow the medication regimen?  
Would you feel confident / able to talk to your 
HCP about changes you had made to your 
treatment regime?  
    
 
 
 
Support 
 
5. We are trying to understand what type of support has been helpful for people with 
multiple sclerosis. Have you ever accessed a patient support programme to help with 
your MS? 
 
Aim: To explore current access to patients support and investigate what has been helpful, 
what has not and why? 
Prompts / sub questions  
Topic Detail 
Patient support Have you ever accessed a patient support programme to help 
with your MS or managing your treatment for MS? 
Yes: What treatment was it for? What did it involve?   Did you / 
do you find it helpful?  
Current support Do you currently access a support program or group? (e.g. web 
forum, advocacy group) 
Use/Best What kind of support have you found most useful/best? 
Not useful/Helpful What have you not found useful or helpful? 
Gaps Currently any gaps in the support you receive or have 
previously received? 
Would you use additional 
support? 
Is additional support something you would use/find appealing? 
- Yes: Why? 
- No: Why?  
 
Thank you and Conclude 
 
Thank you very much for talking with me today. The information you’ve given us will be very 
valuable. 
 
Thinking back to what we have discussed, is there anything else that you would like to add?  
 
    
 
Just before we go I wanted to say that we understand it can be quite tiring to talk about 
these types of things in depth, so don’t be surprised if you feel a little tired, or you find 
yourself thinking about some of the things that we have talked about. If you do feel as if you 
would like to talk about anything that we have discussed more, it can be a good idea to talk 
to someone with some expertise in this area – perhaps your GP or a member of the team at 
your hospital / clinic  
 
Once again, thank you very much for taking the time to speak with us. 
 
  
    
 
Appendix I Text if a Patient Respondent Raises an 
Adverse Event  
[Safety Information is identified and the participant is on a Genzyme/Sanofi Product] 
What you [have just said] / [said earlier in the interview] is classified as safety information 
(NOTE: follow the definition of Safety Information as per SOP). The product manufacturer 
commissioning this programme (Genzyme) is required to collect this kind of information in 
order to continue identifying new side effects, and ways in which the risks of known side 
effects can be minimised. Every report they receive contains potentially useful information. I 
would like to spend a couple of minutes with you now to collect the necessary details of this 
safety information, so that the manufacturer can fulfil their obligations.  Are you willing to 
assist with the reporting of this? 
If NO:  Because I have become aware of this reportable safety information, I am obliged to 
report this to product manufacturer. I will file this report without identifying your personal 
details. I may use your initials, gender or age group in case follow-up is required and I need 
to contact you for this. I would also recommend that you speak to your doctor so that they 
are aware of what you have experienced, and if necessary, follow up with you. 
If YES: Thank you. The information you provide will be sent Genzyme’s Drug Safety 
department who, although unlikely, may wish to contact your doctor for further 
information. Would you like to provide the name of your doctor and allow permission to 
share your full name to enable them to identify yourself to your doctor?” 
 [Allow the patient to respond –Address any question they may have regarding the safety 
information report] 
If the patient agrees to their personal details being included in the report, their contact 
details and HCP details are sent with the report. 
If the patient prefers not to share their details, the report is sent de-identified and as agreed 
per the Safety Information Reporting SOP.   
“Thank you. The information you provide will be sent to Genzyme’s Drug Safety 
department. 
[Safety Information is identified and the participant is on a NON-Genzyme/Sanofi Product] 
What you [have just said] / [said earlier in the interview] is classified as safety information 
and we would therefore advise that you speak to your doctor so that they are aware of 
what you have experienced, and if necessary, follow up with you. [Allow the patient to 
respond –Address any question they may have regarding the reporting of the safety 
information] 
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Market Research Guideline Statement 
 
This market research will be conducted in accordance with The UK Market Research Society, British 
Healthcare Business Intelligence Association guidelines, as well as European EphMRA guidelines.   
 
Adverse Event Statement to be added to UK Versions: 
 
You are about to enter a market research survey.  The independent market research agency has 
been asked to pass on to our client details of adverse events and / or product complaints that are 
raised during the course of market research interviews.  Your response will, of course, be treated in 
confidence, should you raise an adverse event and / or product complaint, the market research 
agency will need to report this, even if it has already been reported by you directly to the company 
or the regulatory authorities using the MHRA’s ‘Yellow Card’ system.  In such a situation you will be 
contacted to ask whether or not you are willing to waive the confidentiality given to you under the 
market research codes of conduct specifically in relation to that adverse event and / or product 
complaint.  Everything else you contribute during the course of the interview will continue to remain 
confidential.  
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Summary Rationale  
This qualitative research aims to explore and understand the beliefs and adherence 
behaviour of adult people with multiple sclerosis (PwMS) on disease modifying treatment 
(DMT). 
 
This research will explore: 
• The situations, beliefs, experiences and abilities that may drive people’s adherence 
to treatment and monitoring during MS treatment, 
• Current self-management processes, perspectives of support and perceived gaps in 
help and support. 
• Perceptions of proposed example screening questions.  
 
Interviews will be conducted with PwMS across three countries (UK, Germany and Spain). 
One-to-one interviews will be conducted by Atlantis Healthcare clinical researchers over the 
telephone, recorded and transcribed verbatim. The analysis will be done thematically to 
draw out the most important issues affecting patients’ adherence and quality of life, as well 
as explore their current self-management strategies. 
 
All adverse events (AEs) will be recorded and reported back to Genzyme, the client, 
according to their standard operating procedures and approved wording, please see 
appendices i and ii.  All researchers involved in interviewing patients will complete training 
in AE reporting according to Genzyme standards prior to data collection. 
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Interview Schedule 
The following schedule is a guide for the interviewer. The questions are not required to be 
read verbatim to the patient, but can be used as prompts to refer to as and when needed 
throughout the natural flow of the conversation. The guide is designed to help ensure that 
the relevant topics are covered. The precise ‘course’ of the interview is dependent upon the 
interviewee and it is the role of the interviewer to facilitate rather than lead the discussion. 
This flexibility allows the researcher to dig deeper into relevant issues to fully understand 
the interviewee’s perspective to achieve the research objectives. 
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Introduction  
 
(To be read verbatim) 
“Thank you for agreeing to take part in this research today. My name is …… [state Name] 
and I work for a company called Atlantis Healthcare based in [state country: the 
UK/Germany/Spain]. We are looking to understand the experiences of people with multiple 
sclerosis, including what it is like to live with MS and your thoughts about different disease 
modifying treatment (DMT) options to help manage your condition. We are also looking to 
understand your experiences with healthcare professionals, of healthcare in general and to 
explore any additional support needs that you may have.  In this study you will be asked to 
talk about some subjects that are sensitive and personal.  For example, how you feel about 
having MS, the types of treatment you have had and how they have worked for you (or not), 
the reasons you may or not stayed with a treatment, support you may or may not have in 
relation to your MS and the possible emotional consequences of MS and treatment 
outcomes. The information from this telephone interview will be used to inform the 
development of a programme offering support to people with MS in living with MS and 
managing their treatment. 
 
There are no right/wrong answers; we just want to explore your experiences. 
Before we begin I just need to explain a few things about the study:  
 
• This research is sponsored by a pharmaceutical company and is being carried out 
within the Market Research codes of conduct  
• The aim of this research is to gain your views for market research purposes only and 
is not intended to be promotional.  
• Anything that you are told about during this research should be treated as 
confidential. Any information presented during the course of this research is done so solely 
to explore reactions to such information and should be assumed to represent hypotheses 
about what can be said about a product or disease area. It should not be used to influence 
decisions outside the research setting.  
 MS-UK-10/13-4613   
 
• The identity of respondents is confidential and none of your details will be passed on 
to any 3rd party.  
• Outputs of this research may be used by the sponsoring pharmaceutical company in 
a promotional or external context at an aggregated level or using anonymised quotes.  
• This interview will be audio recorded for analysis and quality control purposes.  
• Any information you disclose will be treated in the strictest confidence and the 
results of the research aggregated to provide an overall picture of attitudes to the areas 
being covered in this survey. No answers will be attributable to you as an individual.  
• You have the right to withdraw from the research at any time and to withhold 
information as you see fit and to refuse to be audio recorded.  
 
Can you please confirm that you understand and accept the points that I have just read out 
and are happy to proceed with the interview on this basis?  
 
Interviewer to put cross in appropriate box  
¨ YES   
¨ NO  
 
[Text if a respondent says ‘Yes’] 
This interview will take approximately 45 minutes to an hour. Are you comfortable with 
that?  
Do you have any questions at this point?” 
[Text if a respondent says ‘No’] 
That’s absolutely fine, we will not continue with the interview.  
Do you have any questions before we finish this call?  
[Answer / record as appropriate] 
Thank you for your time.  
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Interview 
 
Multiple Sclerosis 
 
1. I’d like to begin by understanding a little more about your experiences with multiple 
sclerosis. Can you tell me about your condition, how and when you were first 
diagnosed and how it may have impacted you and your day to day life? 
 
Aim: To understand the patient’s background, how they identify with MS and the 
interviewee’s experiences of living with their condition that may impact on their motivation 
to adhere. 
 
Prompts / sub questions  
Clinical 
Framework 
Topic Detail 
 Diagnosis / 
Timeframe 
When were you first diagnosed with multiple 
sclerosis?  
What was your experience of being told you had 
multiple sclerosis? 
Self-efficacy / 
Treatment 
Efficacy and 
Necessity / 
Patient related 
outcomes / 
Disability and 
Lifestyle 
Symptoms 
Personal Control of 
Condition 
What symptoms affect you in your everyday life? 
How much control do you feel you have over 
your symptoms? (explore how this impacts their 
self-management behaviours, including 
adherence) 
 
Self-efficacy  Personal Control of 
Condition  
Do you feel you are able to control or change 
your MS?  
 Future  What do you see happening in the future in 
relation to your multiple sclerosis? (explore their 
reasoning for what is likely to happen in the 
future) 
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Treatment experiences/beliefs 
 
2. We have talked about your experiences of living with multiple sclerosis; I’d also like 
to understand your experiences of disease modifying treatment (DMT) options you 
receive or may have previously received [check if the patient understands DMT, 
otherwise explain]. Can you tell me more about this?  
 
Aim: to understand the patient’s treatment experience and their beliefs about treatment/ 
treatment options.  
 
Prompts / sub questions  
Clinical 
Framework 
Topic Detail 
 Previous/Current 
treatment 
Ascertain previous and current DMTs 
Motivation to 
adhere / 
Treatment 
Necessity and 
Efficacy 
Experience / Timeframe Tell me about your treatment experience 
with MS.  
How has this changed over time / with 
different treatments?  
Treatment 
Efficacy / 
Necessity 
Treatment efficacy How effective do you think your treatment is 
and what does ‘effective’ mean to you? 
What has worked/what hasn’t? 
Practical barrier: 
Comprehension 
Treatment 
understanding 
Do you feel you have a good understanding 
of your treatments?  
e.g. what they are, differences and how they 
work? 
Motivation to 
adhere 
Treatment control Do you feel treatment can control or change 
your condition?  Why?  
Treatment 
Necessity / 
Motivation to 
adhere 
Medication importance How important is your treatment? 
What is the most important thing about your 
treatment?   
What would be the impact on you if you 
didn’t have any treatment for your MS?  
Treatment 
concerns 
Side effects Do you feel you have experienced side 
effects or adverse experiences, 
Explore impact these have on the way the 
PwMS feels about a treatment and their 
adherence 
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Treatment 
Concerns 
Concerns/Questions Do you have any concerns or unanswered 
questions about your medication?  (explore 
the impact this has on self-management and 
confidence) 
 
Adherence and Persistence  
 
3. Thinking about the treatment you have received, I want to explore how you follow or 
have followed you medication regimen. Many people have their own way of taking 
their medicines, which can be different from the instructions given by the doctors. 
What do you do / what is your routine?  
 
Aim: to understand adherence and persistence to DMT  
 
Prompts / sub questions 
Clinical 
Framework 
Topic Detail 
 Clarify What is your current medication regimen? 
Treatment 
Necessity / 
Treatment 
Efficacy / 
Motivation to 
Adhere 
Persistence Have you ever decided to stop using your 
medication? 
[If yes] - what made you do this / how long for? 
[If no] – what is it that makes / made you 
continue?  
Treatment 
Necessity / 
Treatment 
Efficacy / 
Motivation to 
Adhere 
Adherence Do you follow your medication regimen as 
advised by HCP? 
Have you followed previous treatment 
regimens? 
(explore reasons for adherence or non-
adherence as applicable) 
 Adherence  To what extent do you follow the regimen? 
Self-efficacy Self-efficacy Do you feel confident that you are able to follow 
the regimen? (explore reasons as applicable) 
Treatment 
Necessity / 
Treatment 
Efficacy / 
Motivation to 
Adhere 
Non-adherence: 
reason 
When you haven’t followed the regimen as 
prescribed, what are the reasons for this? 
 
Explore reason for non-adherence (current and 
previous) 
- Change depending on how you feel? (e.g. 
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side effects, emotional reasons, no MS 
symptoms) 
- Change depending on what you are 
doing? (e.g. holiday) 
-  
 
 
Self-efficacy 
 
Clinical 
Framework 
Topic Detail 
Self-efficacy / 
Cognitive Decline 
& Forgetting 
Self-management 
strategies 
Do you have any strategies to help you 
remember? (i.e. planning, reminders) 
Self-efficacy / 
Cognitive Decline 
& Forgetting  
Ease of self-
management 
Do you find it relatively easy to rather difficult 
to self-manage your treatment regimen? 
(explore reasons) 
Self-efficacy / 
Cognitive Decline 
& Forgetting 
Support Do you have help with your treatment for MS? 
- From friends and family 
- Other support? 
 
Self-management 
 
Clinical 
Framework 
Topic Detail 
Practical 
Barriers:  
Cognitive 
Functioning 
 
Motivation: Self-
management 
Self-management 
strategies 
Would you develop any strategies to help you 
attend to your monitoring? (i.e. planning, 
reminders) 
Practical 
Barriers:  
Cognitive 
Functioning 
 
Motivation: Self-
management 
 
Ease of self-
management 
Would you find it relatively easy or rather 
difficult to self-manage compared to your 
current regimen? 
Practical Independent Do you think you would want help with your 
 MS-UK-10/13-4613   
 
Barriers:  
Cognitive 
Functioning 
 
Motivation: Self-
management 
 
management / 
Support  
monitoring regimen or would you manage it 
yourself? 
If you were going to have help who would you 
ask?  
• Friends and family? 
• Healthcare team?  
• Other?  
 
HCP interaction 
 
4. I’d now like to talk to you about your experiences with healthcare professionals who 
are involved in the treatment and management of your multiple sclerosis. Can you 
tell me a bit about your interactions with your doctors and nurses?  
 
Aim: To explore the possible impact of HCP interactions and support on adherence  
 
Prompts / sub questions  
Clinical 
Framework 
Topic Detail 
 Who is the HCP? 
(Background) 
Without giving their personal names, which 
HCPs do you see in relation to your multiple 
sclerosis? (e.g. GP, specialist, nurse, pharmacist, 
other)?  
Treatment 
Necessity / 
Treatment 
Concerns 
HCP understanding Do you feel confident that your HCP 
understands your experiences with your 
Multiple Sclerosis and your treatment?  
Treatment 
Necessity / 
Treatment 
Concerns 
Confidence in HCP Would you feel comfortable talking to your HCP 
about problems or concerns you had relating to 
your treatment?  
 
Self-efficacy  Monitoring assistance Does your HCP tell or support you with how to 
follow the medication regimen?  
Would you feel confident / able to talk to your 
HCP about changes you had made to your 
treatment regime?  
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Support 
 
5. We are trying to understand what type of support has been helpful for people with 
multiple sclerosis. Have you ever accessed a patient support programme to help with 
your MS? 
 
Aim: To explore current access to patients support and investigate what has been helpful, 
what has not and why? 
Prompts / sub questions  
Topic Detail 
Patient support Have you ever accessed a patient support programme to help 
with your MS or managing your treatment for MS? 
Yes: What treatment was it for? What did it involve?   Did you / 
do you find it helpful?  
Current support Do you currently access a support program or group? (e.g. web 
forum, advocacy group) 
Use/Best What kind of support have you found most useful/best? 
Not useful/Helpful What have you not found useful or helpful? 
Gaps Currently any gaps in the support you receive or have 
previously received? 
Would you use additional 
support? 
Is additional support something you would use/find appealing? 
- Yes: Why? 
- No: Why?  
 
Thank you and Conclude 
 
Thank you very much for talking with me today. The information you’ve given us will be very 
valuable. 
 
Thinking back to what we have discussed, is there anything else that you would like to add?  
 
Just before we go I wanted to say that we understand it can be quite tiring to talk about 
these types of things in depth, so don’t be surprised if you feel a little tired, or you find 
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yourself thinking about some of the things that we have talked about. If you do feel as if you 
would like to talk about anything that we have discussed more, it can be a good idea to talk 
to someone with some expertise in this area – perhaps your GP or a member of the team at 
your hospital / clinic  
 
Once again, thank you very much for taking the time to speak with us. 
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Appendix I Text if a Patient Respondent Raises an 
Adverse Event  
[Safety Information is identified and the participant is on a Genzyme/Sanofi Product] 
What you [have just said] / [said earlier in the interview] is classified as safety information 
(NOTE: follow the definition of Safety Information as per SOP). The product manufacturer 
commissioning this programme (Genzyme) is required to collect this kind of information in 
order to continue identifying new side effects, and ways in which the risks of known side 
effects can be minimised. Every report they receive contains potentially useful information. I 
would like to spend a couple of minutes with you now to collect the necessary details of this 
safety information, so that the manufacturer can fulfil their obligations.  Are you willing to 
assist with the reporting of this? 
If NO:  Because I have become aware of this reportable safety information, I am obliged to 
report this to product manufacturer. I will file this report without identifying your personal 
details. I may use your initials, gender or age group in case follow-up is required and I need 
to contact you for this. I would also recommend that you speak to your doctor so that they 
are aware of what you have experienced, and if necessary, follow up with you. 
If YES: Thank you. The information you provide will be sent Genzyme’s Drug Safety 
department who, although unlikely, may wish to contact your doctor for further 
information. Would you like to provide the name of your doctor and allow permission to 
share your full name to enable them to identify yourself to your doctor?” 
 [Allow the patient to respond –Address any question they may have regarding the safety 
information report] 
If the patient agrees to their personal details being included in the report, their contact 
details and HCP details are sent with the report. 
If the patient prefers not to share their details, the report is sent de-identified and as agreed 
per the Safety Information Reporting SOP.   
“Thank you. The information you provide will be sent to Genzyme’s Drug Safety 
department. 
[Safety Information is identified and the participant is on a NON-Genzyme/Sanofi Product] 
What you [have just said] / [said earlier in the interview] is classified as safety information 
and we would therefore advise that you speak to your doctor so that they are aware of 
what you have experienced, and if necessary, follow up with you. [Allow the patient to 
respond –Address any question they may have regarding the reporting of the safety 
information] 
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Appendix II  AE SOP 
[Genzyme SOP has been superseded by Sanofi’s SOP.  Copy in gallery for information] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix vii – Correspondence from the Chair of the HAS Faculty Research Ethics Committee 
 
From: Julie Woodley  
Sent: 30 April 2018 14:01 
To: Helen Jackson <Helen.Jackson@uwe.ac.uk> 
Subject: RE: Evidence of independent approval of MS research 
  
Hi Helen 
We have gone through our records as far back as 2010 and there is no record of Clare putting in an 
application. Don’t suppose she has changed her name has she? 
I have read through the protocol and I would have expected this type of study to have gone through 
FREC at the time. She could either have applied through FREC or the system she went through looks 
pretty robust so she could have submitted that evidence and we would have ratified the approval 
(This sometimes happens when people transfer and have approvals already in place.) 
  
There is clear evidence of review and also that ethical principles have been adhered to but it should 
have come to a FREC 
Hope that helps 
Julie 
  
Dr Julie Woodley 
Senior Lecturer -Allied Health 
Chair of HAS Faculty Research Ethics Committee 
Rm 2K01 Glenside campus UWE 
Faculty of Health and Applied Science 
Stapleton 
Bristol BS16 1DD 
+44 (0)117 3288528 
UREC Research Ethics Website   http://www1.uwe.ac.uk/research/researchethics 
  
  
 
 
 
 
 
 
Appendix viii – Data extraction framework example  
  
 
 
 
 
 
 
 
 
Appendix ix – examples of qualitative cases  
  
